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Abstract
This thesis outlines and provides direct evidence for transcription factor-mediated 
instructive regulation of the 11-10 gene in CD4 T cells. Firstly, I describe transcription 
factors that are differentially expressed in populations of IL-10-producing CD4 T cells. 
Genome-wide mRNA profiles (GeneChip) are used from six populations of CD4 T 
populations which represent both temporal and lineage-specific time-points within naive, 
effector and regulatory CD4 T cell populations. Secondly, validation experiments 
(qPCR) verified whether transcription factors isolated from the genome-wide profiling 
experiments (GeneChip) were quantitatively expressed in IL-10-producing populations. 
Thirdly, comparative genomics was used to analyze in silico the 11-10 locus for conserved 
putative transcription factor binding sites at potential regulatory regions. Selected 
transcription factors were retro-virally transduced into primary naive CD4 T cells and 
analyzed for their ability to induce IL-10 expression in a variety of differentiation 
conditions. Finally, the role of functionally validated transcription factors inducing IL-10 
production was investigated at the molecular level, via their presence at specific locations 
at the 11-10 locus in vivo and in chromatin modifications. One example, GATA-3, shown 
here to be differentially expressed in IL-10-producing CD4 T cell populations, instructing 
modifications at the 11-10 locus and inducing IL-10 production in CD4 T cells.
The second aim of this thesis was to investigate — at the transcription factor-level -- the 
comparison of two phenotypically different CD4 regulatory T cell populations 
(CD25+Treg and IL-10-Treg). On one hand, both CD4 T regulatory cell populations are 
similar in that they do not produce effector upon secondary stimuli, both are anergic, and
both suppress CD4 T cell proliferation in vitro and in vivo (as shown by their ability to 
abrogate multiple autoimmune and allergic disease animal models). On the other hand, 
CD25+Treg are phenotypically described by their expression of the lineage-specific 
transcription factor, FoxP3, and IL-10- Treg do not express FoxP3. Therefore, the 
molecular mechanisms as to how IL-10- Treg do not express effector cytokines, are anergic 
and suppress CD4 T cell proliferation in vitro and in vivo without the expression of 
FoxP3 is investigated in this thesis. This thesis concludes by providing strong evidence 
that IL-10-Treg down-regulate key NF-kB and AP-1 family transcripts and inhibit NFAT 
transcriptional activity, thereby compensating for FoxP3 expression, which is necessary 
in natural occurring CD25+Treg.
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INTRODUCTION
1. Perspective
The host immune response is competitively selected for mechanisms to protect the host 
from a variety of potential invading pathogens and intrinsic cellular defects. During 
evolution, as multi-cellular organisms developed from land-bome to migratory species 
the pressure from new pathogenic microorganisms increased, and therefore the host 
immune system played an increasing complex role in protecting species from new 
infectious threats. Today, the human immune system is a highly developed, complex mix 
of specialized cells, which serve multi-faceted functions in multi-cellular compartments 
throughout the host. As a continuously adapting organ, the immune system remains a 
vital driver for human survival in respect to eliminating or co-existing with an array of 
old and new infectious pathogens from a constantly changing natural environment.
Not surprisingly, evolution likely selected individuals that not only developed vigilant 
immune responses which aggressively protected the host, but also individuals who 
mounted balanced immune responses that reduced excessive or pathogenic self- 
destruction. Examples of extreme cases of these situations are immunodeficiency on the 
one hand (e.g., susceptibility to Mycobacterium tuberculosis (MTb)) or autoimmune and 
inflammatory pathologies on the other hand (e.g., inflammatory bowel disease (IBD), 
allergy or atopic reactions) (1). In order for the immune response to find the appropriate 
balance during an immunogenic challenge a system of negative feedback mechanisms are 
hardwired into the host immune response that co-coordinately lower the level of pro- 
inflammatory forces at the peak of immune activity. One key anti-inflammatory 
molecule that plays a central role in balancing the immune response is the
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immunosuppressive cytokine, IL-10. IL-10 acts to lower the sensitivity of the immune 
response directly at the interface between the innate and adaptive arms of the host 
immune response. The molecular mechanism in which this crucial immunomodulatory 
cytokine is regulated at the molecular level remains an important immunological question 
today and will be the focus of this thesis.
1.2 The immune response-an overview
The immune system defends the host against infection. The immune response is 
orchestrated by two main mechanisms: innate immunity and adaptive immunity (2). 
Innate immunity is the first line of defense against infectious pathogens where initiation 
of cellular and molecular mechanisms occurs within minutes of pathogen recognition (2). 
The innate response is initiated by antigen presenting cells (APCs), which distinguish 
infectious structures through germ-line encoded receptors, generally termed pattern 
recognition receptors (PRRs) (2). Upon activation, PRRs on APCs will undergo 
phagocytosis and/or signal via distinct intrinsic networks to trigger the production of pro- 
or anti-inflammatory cytokines and up-regulation of co-stimulatory molecules to activate 
and initiate the adaptive immune response (2). The adaptive immune response (> 96 
hours after initial antigen recognition) is dependent on the innate response to present 
specific signals that guide the differentiation of the subsequent antigen-specific adaptive 
response (2). A pool of naive T and B cells is located throughout the host, but mainly in 
primary and secondary lymph nodes that serve as the reservoir of cells which rapidly 
expand into the adaptive immune response. A CD4 T cell adaptive response can be 
achieved when antigen-specific naive CD4 T cells differentiate into antigen-specific CD4
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T helper (Th) cells (3), which assist or “help” other immune cells presenting similar 
antigen-specific motifs during the course of an immune response and secondly are able to 
secrete pro- or anti-inflammatory effector molecules (4). Molecules released by 
differentiated T cells act at local sites of secretion or systemically throughout the host to 
maintain the immune response (5).
1.2.1 Adaptive immune response: CD4 T cells
CD4 and CD8 T cells comprise the T cell mediated arm of the adaptive immune 
response. Naive T cells circulate throughout the body and can be “primed” to clonally 
expand and mount an adaptive immune response via presentation of specific antigen and 
co-stimulatory molecules from an APC. This antigen specific “priming” occurs when 
naive CD8 T cells recognize and clonally expand after APCs present specific antigen and 
major histocompatibility complex (MHC) class I molecules, while CD4 T cells are 
triggered via specific APCs (Dendritic Cell (DC)) expressing antigen and MHC class II 
molecules (6). Subsequent factors can further influence the expansion of recently primed 
naive CD4 T cells which include the cytokine microenvironment, the avidity for the 
initial antigen:T cell receptor (TCR) “triggering” and the strength of co-stimulatory 
molecules provided by the DC (6). The rapid expansion of clonally antigen-specific T 
cells provides a key mechanism in the adaptive immune response.
CD4 T cells have been shown to be required for the host response to an array of 
pathogens. For example, an antigen-specific CD4 T cell response is necessary for the 
control or clearance of various bacterial, viral and intra- and extra-cellular parasitic
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pathogens by the host. A CD4 T cell response is not only required for immediate cell- 
mediated immunity, but a small population of previously expanded CD4 T cells are long- 
lived in the host and necessary for immunological recall or a “memory” response 
witnessed during rapid re-activation of the immune response by subsequent exposure to a 
previous pathogen. The memory response is common to all adaptive arms of the immune 
response and commonly clinically targeted as a necessary feature in developing an 
effective therapeutic vaccine (7). In summary, the molecular mechanism in which naive 
CD4 T cells clonally expand from a common naive precursor cell to a phenotypic effector 
and/or memory population, distinguished by their ability to recognize specific antigens 
and produce large quantities of specific molecules, is essential to their dynamic ability 
within the immune response (8). Figure 1 illustrates a simplistic-view of an immune 
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Figure 1.1. Initiation, generation and effector mechanism achieved via two separate lineage of CD4 
Th cell during an immune response: Thl and Th2.
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An effective immune response is sometimes accompanied by host collateral damage 
elicited by the strong reaction to control infection. In order to minimize host damage, the 
activation of the anti-inflammatory networks within the course of an immune response is 
necessary. To accomplish this central role, the immune response must find the 
appropriate balance to coordinately fight infectious pathogens while preventing self­
induced immune pathology. Here in this essential “niche” is where the 
immunosuppressive cytokine IL-10, plays a key role in modulating immune homeostasis
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during an immune response, ensuring the immune response is able to eradicate pathogens 
while achieving minimum self-induced damage to the host.
1.3.1 Immune cells and conditions in which IL-10 is produced
To understand the role of IL-10 in the immune response, it is necessary to consider both 
the cell-types and biological conditions whereby IL-10 is produced. In immune cells, 
major producers of IL-10 are effector or regulatory CD4 T cells (discussed more later) (8, 
9). However, other immune cells produce IL-10 including: Natural Killer (NK) T cells, 
B cells, mast cells, DCs, and macrophages (however not to the quantitative level of IL- 
10-producing CD4 T cells) and collectively it seems necessary that multiple cell types are 
able to produce IL-10 in the course of an infection (9). This further illustrates the 
regulation of IL-10 within various immune cell-types and temporal layers within the 
course of an immune response. For example, under certain conditions B cell-derived IL- 
10 has been shown to inhibit pathology in the Thl-driven autoimmune disease, 
experimental autoimmune encephalomyelitis (EAE), demonstrating the non-redundant 
role of B cell-derived IL-10 (10). In contrast, CD4 T cell-derived IL-10 has been well- 
described to selectively protect the host against uncontrolled inflammatory responses, 
particularly with respect to the gastrointestinal tract (9) (discussed more below). 
Accordingly, IL-10 is produced in different quantitative levels by a variety of immune 
cells depending on multiple variables including: host area of infection, level of infection, 
and temporal stages during the immune response.
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Within CD4 T cell populations, IL-10 is produced by effector T helper and regulatory T 
(Treg) cells (8). Within effector populations, Th2 cells produce large amounts of IL-10, 
whereas a Thl cell can produce low amounts of IL-10 (9). In addition, CD4 Treg can 
produce IL-10 (8). Two types of CD4 Treg are defined to date, IL-10-producing CD4 Treg 
(IL-10-Treg) and natural occurring CD25+Treg. Both function to regulate immune 
responses and inflammatory pathology (discussed more below) (11). Importantly, both 
these CD4 Treg populations produce IL-10 and little to no effector cytokines, whereas the 
effector populations produce IL-10 in combination with other pro-inflammatory 
cytokines, which direct maintenance of the immune response (8). In summary, the CD4 
T cells compartment is a major producer of IL-10 and will serve as the cell-type for the 
study of 11-10 gene regulation in this thesis.
1.3.2 IL-10 mediated function
How does IL-10 regulate the immune response? IL-10 potently inhibits the innate 
immune response from activating a strong immune response via modulating the 
inflammatory signals produced by DCs (12), macrophages (13) and monocytes (9) 
(Figure 2). Specifically, IL-10 directly limits the innate immune response to promote 
killing upon antigen recognition, and further inhibits the adaptive immune response via 
down-regulation of: key co-stimulatory receptors CD80 and CD86, pro-inflammatory 
cytokines, MHC presentation directed by DCs, macrophages and monocytes (9). 
Intrinsically, IL-10 mediates signals within APCs to limit cytokine production and action 
(9). One mechanism is via IL-10 inhibition of the transcriptional activity of Nuclear 
Factor (NF)-kappaB (kB) complexes, which selectively activate target expression of key
Pro-inflammatory cytokines 
(IL-1P IL-6, TNF, IL-12)PRRs
CD 40L
CD40
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Figure 1.2. IL-10 inhibits the immune response.
This figure represents an adaptation on Figure 1.1, showing explicitly where IL-10 directly acts to inhibit 
the immune response.
pro-inflammatory cytokines (IL-1 (3, IL-6, IL-12, TNF) (14, 15). Furthermore, IL-10- 
mediated signaling in APCs directly effects STAT signaling, as IL-10 induces suppressor 
of cytokine synthesis SOCS-3, which act to attenuate pro-inflammatory cytokine 
signaling (16, 17). IL-10 directly down-regulates intrinsic networks within APCs and 
inhibits the release of inflammatory molecules with important consequences for their 
ability to activate and sustain the immune response.
Additional clues to the role of IL-10 in the balance of the immune response are seen with 
IL-10-deficient mice, IL-10(-/-), which were reported to spontaneously develop a severe 
Thl-driven pathology in the gut, chronic enterocolitis (IBD) (18, 19). Interestingly, the
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spontaneous inflammatory bowel phenotype was attenuated when IL-10(-/-) mice were 
housed under germ-free conditions (20). This suggested that the IL-10(-/-) IBD 
phenotype was dependent on the generation of an immune response to enteric bacteria 
and consequently with the loss of the immunosuppressive IL-10 a subsequent Thl- 
mediated uncontrolled immune response is elicited. This scenario was classically shown 
with protection of colitis in IL-10(-/-) animal models with administration at early time- 
points and continued treatment of recombinant IL-10 (rIL-10); however colitis developed 
after treatment stopped, suggesting that IL-10 down-regulates the activation and 
regulation of the immune response at the innate and adaptive interface (14, 21). Another 
key study demonstrated that IL-10 plays a non-redundant role in CD4 Treg suppressive 
ability to control colitis, as co-transfer of CD4 T cells and IL-10-deficient CD45RBlow, 
which contain CD25+Treg and other CD4 Treg and effector cells, or treatment of 
monoclonal IL-10 antibodies were unable to regulate intestinal inflammation in 
immunodeficient hosts; however co-transfer CD4 T cells and WT CD25+Treg were able 
to regulate pathology, independently of IL-10 (22). This group further demonstrated that 
in the IBD model, IL-10 was essential for CD25+Treg mediated suppression of “antigen- 
experienced” (effector or memory) CD4 T cells, but not required for CD25+Treg 
suppression of naive CD4 T cells (23). Finally, in a somewhat similar designed study, 
the adoptive transfer of CD25+Treg was shown to inhibit both the innate and T cell- 
mediated intestinal inflammation, and critically the innate immune mechanisms were 
suppressed in part due to T cell-derived IL-10 (discussed in greater detail below) (24). 
IL-10 has been shown to protect the host against pathology induced by strong pro- 
inflammatory responses with experimental group B streptococcal arthritis (25) and
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preventing lethal endotoxic shock (26). The experimental group B streptococcal arthritis 
study clearly described that the neutralization of endogenous IL-10 by administration of 
aIL-10 at the time of infection resulted in mortality associated with early sustained 
production of pro-inflammatory cytokines: IL-6, IL-lp and TNF (25). IL-10 has also 
been shown to limit pro-inflammatory collateral damage in other animal models 
including: pancreatitis, diabetes mellitus, allergy, asthma, and experimental endotoxemia 
(14,27).
1.3.3 Clinical perspective
IL-10 regulation (over and under production) with respect to clinical applications is 
currently of great interest (14, 27). Dysregulated expression levels of IL-10 are 
implicated in numerous diseases including: autoimmune disorders, AIDS progression, 
advanced alcoholic liver disease, Epstein-Barr virus infection, gastric cancer, cervical 
cancer, multiple myeloma, cutaneous malignant melanoma, and resistance to anti-viral 
therapy (14). Alternatively, activating the anti-inflammatory activities of IL-10 have 
been attempted by clinicians through administration of human rIL-10 to patients with 
Crohn’s disease, rheumatoid arthritis, psoriasis, hepatitis C infection, and patients 
undergoing organ transplantation (14). IL-10 administration has not been successful for 
IBD and autoimmune diseases, likely due to: short half-life, delivery to the wrong place, 
or treatment at the wrong time. A better approach is to find ways of activating 
production of IL-10, particularly from antigen-specific IL-10-producing T cells. For 
example, immunosuppressive drugs such as the glucocorticoid receptor agonist, 
dexamethosone, are known to induce IL-10 production from immune cells (28-30) and
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remain a widely prescribed drug for dampening pro-inflammatory immune responses. In 
summary, over-production of IL-10 can cause pathophysiological conditions seen 
primarily via a suppressed immune response and conversely a deficiency in IL-10 
production can cause a hyper-immune response inducing pathology or excessive 
collateral damage during infection. The neutralization or induction of IL-10 provides 
evidence that this cytokine could serve as a promising clinical target.
IL-10 administration or neutralization with respect to tumor therapy is another area of 
intense study (14). The results from this area of therapy are far from straight forward. 
Early cancer model studies described IL-10 to be a tumor-promoting molecule. Direct 
effects of IL-10 enhancement of tumor survival were shown through IL-10-induced 
down-regulation of MHC class I presentation on tumor cells, rendering them resistant to 
CD8 cytotoxic T cells (CTL)-mediated lysis (31). Transgenic mice expressing IL-10 
under control of the IL-2 promoter were described to be unable to limit the growth of 
immunogenic tumors and the administration of aIL-10 restored the ability for the 
immune response to control tumor growth (32). Finally, the use of aIL-10 in parallel 
with TCR ligation was shown to promote an anti-tumor response, probably by activation 
of tumor antigen-specific T cells (33). Alternatively several more recent studies have 
shown IL-10 to have a negative overall effect on tumor growth or survival, albeit a clear 
mechanism is not understood. Briefly, IL-10 tumor suppressing effect has been shown 
via at least three mechanisms (1) IL-10 directly inhibiting tumor-associated macrophages 
(TAMs) from angiogenesis via down-regulated expression of vascular endothelial growth 
factor (VEGF) (34, 35), (2) IL-10-mediated anti-metastatic activity via IL-10 activated
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NK cells (36) and (3) more generally from IL-10 anti-inflammatory effect on the immune 
response, specifically via its down-regulation of NF-kB transcriptional activity in APCs, 
which in turn, is considered to be tumor suppressing feature (15, 37). In conclusion, 
depending on the experimental model and probably the underlying differences between 
the models that are not fully appreciated, IL-10 effect seems to inhibit survival and 
growth of tumors, although certain conditions exist where it is considered a tumor- 
promoting cytokine as a result from its pleiotropic activities.
Taken together, IL-10 is a complex cytokine predominately inducing anti-inflammatory 
signals at different layers throughout the immune response and this effect can be 
dependent on multiple factors during the immune response. The role of IL-10 illustrates 
the challenge faced by the host immune system to respond to infectious pathogens while 
minimizing host collateral damage. From the clinical perspective the relevant questions 
for IL-10 being: (1) can specific IL-10-producing cell-types be targeted and (2) more 
globally, due to the multi-faceted role of IL-10 function in respect to specific cells, is it 
inherently too diverse a molecule to target therapeutically?
To address these questions we will review the functional and molecular mechanisms 
regulating various CD4 T cell populations (major IL-10 producer) and current studies 
reported with respect to 11-10 gene regulation.
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1.4 Function of CD4 T helper populations
CD4 Th populations are necessary in mediating the development of the host-protective 
response and are divided into at least two populations termed: Thl and Th2 (3, 5). 
Functionally, a Thl cell response is essential in the host cell-mediated protection to 
intracellular pathogens including viruses, parasites and bacteria; whereas a Th2 cell 
response (classified by high IgGi and IgE antibody isotypes) can instruct a humoral- 
mediated response to eradicate nematodes, helminthes and other extra-cellular pathogens 
(4, 5, 38, 39). Both Thl and Th2 responses can initiate the humoral immune response by 
activating naive B cells to produce IgM antibodies (4), and Thl cells can instruct the 
production of opsonizing antibodies IgG2a (4, 38). The effector action of a Thl response 
is primarily achieved through the activation of infected macrophages, whereas a Th2 
response is primarily responsible for activation and maintenance of mast cells, 
eosinophils and B cell growth factors (some of which is outlined in Figure 1) (4). The 
mechanisms by which Th populations achieve these describe effector actions are through 
the ligand/receptor interactions with APCs and short or long-range delivery of differential 
profiles of immunological proteins, of which, one key group is cytokines (Figure 1) (5). 
The molecular basis for the differentiation of a common naive precursor cell to distinct 
effector CD4 T cell populations able to produce distinct signatures of cytokines (which 
can be measured in serological samples) is the hallmark of the CD4 T cell-mediated 
adaptive immune response (40).
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1.4.1 Thl
Thl cells differentiate to produce high amounts of the type II interferon, IFN-y, upon 
secondary TCR stimulation (5). In the course of an infection, IFN-y is initially produced 
at high levels by NK cells and as the adaptive response develops IFN-y production also 
becomes a T cell effector-mediated cytokine (38). Thl cells, as well as CTLs, maintain 
IFN-y production that drive an activated immune response towards intracellular and some 
extra-cellular pathogens (5, 38). IFN-y is a key cytokine playing a central role in the 
induction of a cell-autonomous, microbicidal state in macrophages against intracellular 
pathogens and more generally for APCs to process antigen and co-currently present co­
stimulatory molecules (5, 41). Triggered CD4 T cells canonically consume IFN-y, which 
intrinsically signal and regulate Thl differentiation through directly up-regulating key 
Thl specific transcription factors and cross-regulating Th2 associated transcription 
factors (42) (discussed more below). Together, IFN-y producing Thl CD4 T cells ensure 
and stabilize an efficient cell-mediated immune response (5, 41). A lack of an efficient 
CD4-mediated response is seen in human patients with depleted CD4 T cells (for 
example: AIDS) where a common cause of death is caused by the opportunistic resident- 
microorganism Pneumocytis carinii and MTb which is a major reason they succumb to 
death; due in part to the lack of effector CD4 response in supporting macrophage 
activation (43, 44). It is important to note that if uncontrolled, a Thl-mediated immune 
response can also induce unnecessary host pathology and initiation of certain 
autoimmune diseases (41). For instance, IBD stems from the establishment of an 
uncontrolled CD4-driven immune response attacking host-resident microbial flora 
interactions and causing unwanted host-pathology (41, 45). In summary, a Thl-driven
15
immune response is essential for the clearance or control of various intracellular and 
extra-cellular pathogens; however if the Thl response is not properly regulated it can 
cause serious undue host pathology.
1.4.2 Th2
A Th2 response is required for control and or clearance of infection with certain extra­
cellular pathogens (nematodes and helminthes parasites) not generally recognized by 
known innate PRRs (5, 46). Th2 cells differentiate to produce high amounts of the 
signature cytokine IL-4 (as well as IL-5 and IL-13) upon secondary TCR triggering (5). 
IL-4 is a pleiotropic immunomodulatory cytokine produced by Th2 lymphocytes, mast 
cells and eosinophils (38). Functionally, IL-4-producing Th2 cells act to inhibit 
macrophages while activating B cells and mast cell growth (38). IL-4 instructs subsets of 
DCs to produce IL-12 (a key Thl-driving cytokine in early naive CD4 T cell 
differentiation) via IL-4-direct intrinsic ability to down-regulate IL-10 in DCs through a 
STAT6 mechanism (47). This may explain why paradoxically, IL-4 acts on DCs to 
prime CD4 T cells towards a Thl cell lineage (47). A Th2 response is defined by high 
IL-4, IL-5 and IL-13 cytokine levels and is necessary for eradication of certain extra­
cellular pathogens.
Th2 differentiation from a naive CD4 T cell is dependent on early IL-2 mediated intrinsic 
signaling initially stabilizing the 11-4 locus for low-level CD4 T cell IL-4 production 
which becomes under autocrine control via the IL-4R signaling network (48). In the 
initial stages of infection low-level IL-4 production by recently primed CD4 T cells and
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non-T cells, including eosinophils and basophils (38) (especially seen in the absence of 
IFN-y and IL-12/IL-18) can allow Th2 development. Similar to the CD4 Thl-mediated 
intrinsic signaling the IL-4R triggered network cross-regulates recently triggered CD4 
cells to inhibit Thl-associated receptors and transcription factors (4, 5, 49). Several in 
vivo mouse models have shown the essential and non-redundant role of IL-4-producing 
Th2 cells in the host protection against extra-cellular intestinal parasites (specifically: 
nematode and helminthes) (46). The inability of the host immune system to recognize 
and control extra-cellular parasites (especially nematode varieties) is suggested to have 
led to the evolution of a necessary effector mechanism (Th2 response) to protect against 
most intestinal nematode parasites (46). However, uncontrolled Th2-associated cytokine 
production (IL-4, IL-5, IL-13) can drive allergic inflammation and atopic reactions in the 
host (50, 51). If uncontrolled Th2-associated cytokines cause undue pathology via 
mechanisms including: IL-4 activates allergen-specific Th2-lineage cell differentiation, 
IL-5 promotes eosinophil infiltration, and IL-13 plays a central role hyper-secretion of 
mucus and regulation of AHR (51). Therefore, the combination or individual 
dysregulation of either of these potent cytokines within CD4 T cells can trigger long-term 
disease (allergic rhinitis, asthma, and atopic dermatitis) or death (anaphylaxis). It is 
likely that the host needs a combination of a Thl and Th2 response for a balanced 
immune response.
1.5 Molecular mechanisms in effector cytokine gene regulation
Cytokine gene regulation with respect to IFN-y and IL-4 expression has been extensively 
studied to determine the molecular mechanism behind the ability of common naive CD4
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T cell precursors to differentially produce these key molecules in either Thl or Th2 cells, 
respectively. The early moments after naive CD4 T cell “triggering” in the periphery are 
critical to initiating early intrinsic Thl versus Th2 differentiation (52). The avidity of the 
TCR to the antigen/MHC class II complex, the nature of co-stimulatory molecules, and 
the cytokine microenvironment all play a key role in subsequent differentiation of a naive 
CD4 T cells into a proficient effector population (3, 5). Extrinsically, the presence of IL- 
12 and IL-18 on recently primed naive CD4 T cells drives differentiation towards a Thl 
population, whereas early IL-2 and subsequent IL-4 will drive Th2 differentiation (5,41). 
After, the initial ubiquitous burst of IFN-y and IL-4 expression in recently primed naive 
CD4 T cells, the balance of Ifn-y and 11-4 gene regulation becomes highly cross-regulated 
at the level of chromatin, transcription factor milieu and cytokine receptor networks (52). 
This is not surprising considering their divergent effects of these powerful cytokines in 
the context of the host immune response.
Effector cytokine locus control can be conveniently divided into two mechanisms: 
epigenetic chromatin re-modeling and the up-regulation of specific transcription factors - 
or ubiquitous transcription factors - that bind to DNA regulatory regions of the re­
modeled locus to enhance or repress transcription (53). Naive CD4 T cells exhibit 
heterochromatic or condensed chromatin structure at both effector cytokine, IJn-y and II- 
4, loci and therefore are inaccessible to nuclear factors (54) in these cells. “Triggering” 
naive CD4 T cells, can induce epigenetic, chromatin re-modeling (54) and induction of 
cycling covalent modifications of histone tails (suggested to indicate “active” or 
“silenced” regulatory regions), which are best currently described through acetylation,
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methylation, and phosphorlylation at the targeted locus region (55, 56). Chromatin re­
modeling is directly induced by the presence of transcription factors at specific DNA- 
binding regions near or at long-range sites from the target gene locus (52, 54). The 
location of these potential regulatory regions can be observed via assays involving the 
study of DNase I Hypersensitive Sites (HSS) within the targeted (probed) genomic region 
(53). DNase I HSS studies were used to identify both IJh-ym d 11-4 gene regulatory 
regions for further study (53, 57, 58). Secondly, a specific group of transcription factors 
can home to the exposed or re-modeled locus to enhance or repress gene expression (54). 
These transcription factors can themselves be up-regulated through similar epigenetic 
differentiation through extra-cellular signals and further reinforced through autocrine or 
paracrine signaling (54). Key transcription factors act to further stabilize cytokine gene 
euchromatic architecture and consequently further exposing regulatory DNA binding 
regions for the rapid gene expression upon sequestration of nuclear factors after 
secondary TCR stimulus (54). Other key types of CD4 transcription factors are present 
in the cytosol and activated via TCR-mediated activation thereby translocating or 
shuttling to the nucleus to act at exposed or euchromatic DNA regulatory regions (59). 
The specific signature epigenetic transcription factors for Th populations will be 
discussed below, followed by a review of three key families of transcription factors that 
form important combinatorial complexes after TCR-mediated activation: NF-kB, NFAT 
(Nuclear factor of activated T cells) and AP-1 (Activator protein-1).
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1.5.1 Thl
Thl cells differentiate to produce high amounts of the signature cytokine IFN-y upon 
secondary TCR stimulation (5). Priming of naive T cells in the presence of the cytokines, 
IL-12 and IL-18, can drive Thl differentiation through intrinsic CD4 T cells IL- 
12Rp(l/2)/STAT4 and IL-18R/IL-1 receptor-associated kinase (IRAK)/NF-kB network 
mediated signaling (41, 60-62). Secondly, initial CD4 T cell production of IFN-y 
canonically acts, via the IFN-yR/STATl signaling network, to specifically target T-bet 
transcription, a T-box family transcription factor (variant of the Tbx21 gene) (63). 
Finally, T-bet, serves as the terminal, master regulator for the Thl population (63).
The transcription factor, T-bet, acts via three mechanism: (1) it drives Thl differentiation 
via re-modeling and /rans-activating the Ifh-y  gene and inducing IL-12RP2 (62) 
expression which leads to increased Thl driven signaling (64), (2) intrinsic cross­
regulation of Th2 signaling (64, 65), and (3) repression of 11-2 gene activation (66). The 
initial Ifn-y\ocm  re-modeling features induced by T-bet and subsequent /raws-activation 
of the Ifn-y  gene is via T-bet binding to a conserved (mouse and human) putative binding 
site located at a distant -2.0 kbp 5’ location from the IFN-y start site (64). Further 
studies, demonstrated that T-bet potently frans-activates the IFN-y promoter in at least 
one other region described as the “Brachiury site” at the proximal -66 bp position relative 
to the Ifn-ygQnQ start site for transcription (67). Secondly, T-bet physically interacts with 
GATA-3 (discussed more below) via interaction of tyrosine phosphorylated T-bet and 
GATA-3 (65) and thereby down-regulating Th2 signaling. Thirdly, T-bet interacts with 
RelA to form non-functional nuclear heterodimers and regulate the binding of RelA to
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the IL-2 promoter, and hence, /r<ms-activation of the 11-2 gene (66). Finally, T-bet gene- 
deficient mice, exhibit impaired Thl development, increased Th2-associated cytokine 
production, and up-regulated IL-2 production in CD4 and CD8 cells (64, 68). In terms of 
an immune response, T-bet(-/-) mice succumb to Salmonella infection (69) and increased 
host-susceptibility to infection with MTb (70).
At least two other transcription factors act to enhance IFN-y expression after the locus is 
made accessible: Hlx (71) and Ets-1 (72). Ets-1, E26 transformation-specific-1, has 
recently been shown to be an essential co-factor in IFN-y production via its binding to the 
proximal IFN-y promoter and cooperation with T-bet at the “Brachiury site” (72). 
Furthermore, Ets-1 is necessary for mounting certain Thl responses in vivo (72). Hlx, a 
homeobox 2.0 gene member, is an early transcriptional target gene of T-bet and acts 
synergistically with T-bet to increase IFN-y production in Thl cells, shown to be 
especially critical in the early establishment of a Thl response (71). Together, T-bet, Ets- 
1, and Hlx gene expression provide a firm marker in resting Thl cells and their 
subsequent ability to produce a Thl cytokine profile upon secondary stimulation.
1.5.2 Th2
Th2 cells produce high amounts of signature cytokines IL-4, IL-5, and IL-13 upon 
secondary TCR triggering. Priming of naive CD4 T cells in the presence of early IL- 
2/STAT5 signaling has been shown to be necessary in the early re-enforcement of IL-4 
production (48). The early IL-2-mediated signaling effect has been shown through the 
binding of STAT5a to an intronic region of the 11-4 locus and thereby allowing for early
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re-enforced IL-4 production (48). At the molecular level, the expression of IL-4 is 
subsequently, strongly controlled by the transcription factor GATA-3 (73-78). GATA-3, 
a zinc finger transcription factor, acts indirectly to repress the Thl cytokine, IFN-y, via 
direct down-regulation of STAT4 expression (75, 77, 79). The up-regulation of basal 
GATA-3 expression in recently primed CD4 T cells is controlled largely by the IL- 
4R(a/b)/STAT6 (80) signaling network (73); however other networks as yet undefined 
may induce independent IL-4R-mediated GATA-3 induction (74). During Th2 
differentiation, GATA-3 induces changes in the chromatin structure at the 11-4 locus (74, 
78) by binding to two sites: (1) the proximal 5’ region of the 11-4 locus and (2) the II-4/II- 
13 intergenic region (58, 76, 81). Furthermore, GATA-3 binds and strongly trans- 
activates the IL-5 (78, 82, 83) and IL-13 promoters (84). Since GATA-3(-/-) mice are 
embryonic lethal other knock-down approaches to inhibit GATA-3 have demonstrated its 
effect of Th2-associated cytokines. Inhibition by antisense transfection (73) or 
conditional deletion (85, 86) of GATA-3 in vitro and in vivo have further demonstrated 
the instructive role of GATA-3 in initiating (naive CD4 T cells) and maintaining (effector 
CD4 T cells) the expression of the cytokines: IL-4, IL-5, and IL-13.
GATA-3 weakly /r<ms-activates the IL-4 promoter (73, 76, 81) and an additional 
transcription factor, c-Maf (basic region-leucine zipper family member) (78, 87), is 
required to strongly /ra«s-activate the IL-4 promoter. Additionally, Growth Factor 
Independent (GFI)-1, a zinc finger transcription factor, is induced rapidly via the IL- 
4R/STAT6 signaling network (88) and promotes proliferation and co-activates with 
GATA-3, especially seen at early time-points to terminally differentiate CD4 T cells
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towards a Th2 phenotype (86). GFI-1 transcriptional up-regulation provides an early 
expression marker indicating STAT6 dependent signaling after initial TCR triggering has 
been initiated (88). Taken together, the GATA-3/c-Maf transcription factor combination 
provide a firm marker for the 11-4, 11-13, 11-5 gene regulation and GFI-1 expression 
provides a clear marker for IL-4 driven CD4 T cell differentiation.
Further action of TCR-activated transcription factors is necessary for optimal Thl-and 
Th2-associated cytokine production. These factors are not generally considered to be 
epigenetic, lineage specific transcription factors (in terms of differential up-regulated 
expression during Th cell differentiation) but instead are regulated after TCR activation 
via mechanisms such as protein-protein interactions (59). The dimerization of these TCR 
activation specific factors can regulate cytokine gene regulation (59). Of these nuclear 
factors, various distinct NFAT:AP-1 dimers have been shown in TCR-mediated 
secondary “triggering” to be necessary for optimal Thl and Th2 cytokine production 
(discussed more below) (59, 89).
1.5.3 NF-kB family
Nuclear factor(NF)-kappaB(icB) transcription factors form functionally active nuclear 
proteins that individually or synergistically bind and activate gene transcription necessary 
for activation, proliferation, and apoptosis in CD4 T cells. The NF-kB family is 
comprised of NF-KBl(pl05), NF-KB2(pl00), c-Rel, RelA(p65), and RelB (90). 
Together, the IKK-p (inhibitor of NF-kB (IkB) kinase-p) - dependent NF-kB activation 
pathway - is closely associated with targeting pro-inflammatory immune response genes
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after receiving external stimuli (90). There are at least two distinct NF-kB activation 
pathways: the classical and alternative pathway (90). We will focus and outline the 
classical pathway below. Briefly, the IKK complex is composed of two catalytic 
components IkBoc and IkB(3 and a regulatory subunit, IxBy (NEMO) (90). Classically, 
the IKK complex phosphorylates NF-KB-bound IkBs, where IkBs are channeled for 
proteasomal degradation thereby activating NF-kB dimers (p65/RelA, c-Rel, p50) to 
target gene transcription (90) (Fig. 1.3).
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Figure 1.3. NF-kB activation in CD4 T cells.
Represents a simplified cartoon o f the classical NF-kB pathway in CD4 T cells. A TCR stimulus activates 
the classical IKK pathway in CD4 T cells and induces the phosphorylation (P) (and subsequent 
polyubiquitination (not shown)) o f IkBs, which are then targeted for degradation by the proteasome. NF- 
kB dimers are released and translocate to the nucleus, binding to DNA regulatory regions and initiating 
target gene expression. New gene transcription is initiated and translation o f new IkB s shuttling nuclear 
NF-kB dimers back to the cytosol for further induction.
In T cells, IkB a  degrading signals are rapidly initiated via the triggering of the TCR to 
activate p65/RelA activation and rapid target gene activation (91, 92). IkB(3 degradation 
is initiated only after TCR-mediated gene expression and protein translation by a pathway 
that can be suppressed by calcineurin inhibiting drugs (cyclosporin A) which, in turn
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leads to the release of bound IkB P complexes for activation and target gene expression 
(93). Consequently, Ik B  p-dependent gene expression is slower than IicBa-dependent 
new gene transcription (91, 92). In unstimulated naive CD4 T cells, c-Rel binds 
primarily to IkBP (91, 92); however a body of literature now exists demonstrating how 
the innate immune system may pre-activate naive CD4 T cells with cytokines (IL-lp and 
TNF) to generate rapid TCR-triggered expression of high-abundance IL-2 and low- 
abundance IFN-y (94). The mechanism for this lies in pre-activated naive CD4 T cells 
ability to shuttle c-Rel from cytoplasmic-bound IkB P to nuclear IkBoc that in turn can 
more rapidly initiate cytokine expression (IL-2 and IFN-y) after TCR triggering during 
the primary immune response (94). This mechanism is not achieved in effector CD4 T 
cells, as these genes (IFN-y) are controlled via c-Rel independent mechanism or not 
expressed to the same abundance as naive or terminal Th populations (discussed above). 
c-Rel provides an essential role in re-modeling the 300-base pair region of the IL-2 
promoter (95) and trans-activating the 11-2 gene in activated CD4 T cells (96). c-Rel(-/-) 
mice versus WT mice demonstrate a 50-fold decrease in IL-2 production when T cells are 
stimulated via the TCR (a-CD3/CD28) (97). In view of these studies, it is not surprising 
that studies performed in vivo in CD4 T cell-specific IkBoc gene-defective cells describe 
these mice as being unable to mount sufficient Thl immune response due to low- 
abundance proliferation, Thl differentiation, and low concentration of IFN-y production 
(98). IkBoc gene-defective cells were also shown to be intrinsically unable to proliferate 
and produce IFN-y in IL-12-supplemented CD4 T cell cultures in vitro (98). Lastly, NF- 
kB  1 (p50) expression is important in CD4 T cells as illustrated by N F -k B  1(-/-) being 
susceptible to Thl-driven infectious pathogens such as the intracellular parasite
Leishmania major (99). Their susceptibility was due to the intrinsic inability to 
proliferate directly due to reduced levels of IL-2R expression on the T cell surface after 
activation and indirectly reduced IFN-y production (99). Importantly, these genetic 
studies illustrate the role for individual NF-kB genes and proteins and collectively the 
activation of NF-kB complexes plays an essential, non-redundant role in CD4 T cell 
function.
1.5.4 NFAT family
The NFAT family plays an important role in the regulation of CD4 T cell cytokine 
production (59). The functional enhancement (or repression) of a variety of effector 
cytokine genes is mediated by NFAT transcriptional activity (100). NFAT proteins 
function via rapid calcineurin-dependent translocation to the nucleus to induce regulation 
of multiple cytokine genes upon T cell activation (101) (Fig. 1.4). The NFAT family is 
comprised of four key calcineurin-dependent members, termed NFATcl-4 (102). 
NFATcl and NFATc2 both play an active role in the regulation of various Thl and Th2 
cytokine genes: including TNF, IFN-y, IL-4, IL-5 and IL-13 (59). NFAT can act 
synergistically with AP-1 (Jun:Fos) proteins on composite DNA binding elements to 
form stable ternary complexes to regulate multiple inducible genes (100). Additionally, 
GATA proteins have also been hypothesized in CD4 T cells to interact with NFAT (59), 
following known examples of interactions of NFATc4:GATA-4 (103) and 
NFATcl :GATA-2 (104) in cardiomyocytes and skeletal muscle tissue, respectively. In 
summary, NFAT proteins are activated via calcium/calcineurin-dependent signaling
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which promotes NFAT dephosphorylation, nuclear translocation, and gene activation 
required for multiple productive immune responses in CD4 T cells.
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Figure 1.4. NFAT activation in CD4 T cells.
Represents a simplified cartoon o f  the activation o f  the NFAT pathway in CD4 T cells. NFAT proteins are 
phosphorylated (P) and reside in the cytosol o f resting CD4 T cells. Upon stimulus NFAT proteins are 
dephosphorylated by calcineurin, translocate to the nucleus and become transcriptionally active DNA 
binding proteins. This pathway provides a direct link between Ca2+ flux and gene expression.
Considerable information is known about individual NFAT members involved in CD4 T
cells cytokine regulation through studies involving genetic knock-outs and constitutively
active NFAT mutants. IL-4 production in NFATcl(-/-) (105) and NFATc2(-/-) (106)
mice is both enhanced and repressed in CD4 cells in vivo and in vitro, depending on the
temporal stage at which the T cells were studied. Overall, data from NFATcl(-/-) mice
show a significant decrease in a CD4 T cell IL-4-driven immune response (105).
Conversely, ectopic expression of a constitutively active mutant version of NFATcl into
naive CD4 T cells skew T cell differentiation towards a Thl phenotype, by inhibiting IL-
4 production and preferentially enhancing IFN-y producing in neutral, Thl, and Th2
polarizing conditions (107). A direct mechanism for the constitutively active NFATcl to
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skew a naive CD4 T cell differentiation towards a Thl cell-fate is unclear. NFATc2(-/-) 
CD4 T cells are described to have early defects in their ability to produce IL-4; however 
under Th2 culture conditions, IL-4 production is higher then corresponding driven WT 
cells after day 7; whereas production of IL-2 and IFN-y were similar to wild-type 
conditions throughout all time-points (106). Importantly, this differential effect on early 
and late levels of IL-4 production in NFATc2(-/-) CD4 T cells was shown both in vitro 
and in the context of an Th2-driven immune response in vivo (106). NFATc2 expression 
is directly targeted by IL-6 in CD4 T cells, especially by IL-6-producing Th2 cells (108). 
The direct effect of IL-6 on NFATc2 expression in differentiating CD4 T cells was 
shown to directly enhance IL-4 expression (108). Collectively, the NFATcl or NFATc2 
transcriptional activity within CD4 T cells is clearly temporal and dependent on multiple 
factors (for example with the accessibility of a target regulatory region).
1.5.5 AP-1 family
Although the AP-1 family members were first discovered over twenty years ago the 
biological basis and physiological functions of this highly interactive family is still not 
clear, especially in terms of individual complexes regulating CD4 T cells (109). 
Whereas, NFAT are activated by calcineurin, AP-1 members are activated by protein 
kinase C (PKC)/Ras signaling which promote the synthesis, phosphorylation and 
activation of AP-1 members (109). After activation, protein-protein interactions play an 
essential role in downstream gene expression targeting mediated by AP-1 family 
members (109). AP-1 complexes are basic region-leucine zipper (bZIP) elements, 
comprising of Jun (c-Jun, JunB, JunD, JDP1, JDP2), Fos (c-Fos, FosB, Fra-1, Fra-2) and
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closely related activating transcription factors (ATF2, ATF3, and B-ATF) subfamilies 
(109). In CD4 T cells, differential AP-1 complexes form transcriptional enhancesomes 
with non-related proximal transcription factors to regulate various cytokine gene 
expression (59). Some key cytokine-mediated transcription factors known to dimerize 
with AP-1 members include Maf (c-Maf and v-Maf) and NFAT (NFATcl and NFATc2) 
(59). Therefore, it is not surprising that several studies have described the recruitment of 
AP-1 complexes to enhance cytokine gene expression for IFN-y, IL-2, IL-3, IL-4, IL-5, 
IL-10, and IL-13 genes (59). In summary, specific target genes for different AP-1 
complexes and the mechanisms that govern the subsequent co-activation of AP-1 
complexes at the DNA binding-level demonstrate that AP-1 members play an important 
role as CD4 T cell transcriptional regulators.
For this thesis the focus will be on the AP-1-associated Jun subfamily, which has recently 
been shown to regulate IL-10 expression in CD4 T cells (110). c-Jun is a well-described 
component of the AP-1 family, in that c-Jun can mediate different-types of downstream 
gene expression profiles based upon its dimerization upon TCR triggering (100, 109). c- 
Jun forms the strongest heterodimers with c-Fos (JunrFos) to transcriptionally activate 
target tumor suppressor genes in various cell-types (100). In CD4 T cells, Jun:Fos dimers 
are known to enhance various pro-inflammatory/effector cytokines: IFN-y, IL-2, IL-3, IL- 
4, IL-5 and IL-13 (100, 111). Conversely, c-Jun can heterodimerize with JunB (Jun:Jun), 
which attenuates Jun:Fos transcriptional capacity and activates a separate array of target 
genes (111, 112). Additionally, JunB:c-Maf can interact and at the 11-4 locus there co­
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operation was shown to /raws-activate the IL-4 promoter (113). In conclusion, different 
AP-1 complexes can mediate activation of different gene expression profiles.
The ability of AP-1 complex (Jun:Fos) to bind other “third-party” complexes is also 
critical for functional downstream gene expression activation (109). Various DNA 
regulatory regions within cytokine genes are occupied by AP-1 and composite NFAT 
putative binding sites. Furthermore, the Jun:Fos:NFAT ternary complex was elegantly 
described to be necessary to enhance IFN-y, IL-2, IL-3, IL-4, IL-5 and IL-13 gene 
expression in activated CD4 T cells (100). Conversely, TNF and IL-6 cytokine 
expression is exclusively dependent on NFAT-mediated signaling, without AP-1:NFAT 
interactions (100). These studies used various mutated NFAT proteins - that upon 
activation were unable to bind AP-1 complexes - in order to investigate whether the 
ternary AP-1:NFAT complex was required to enhance cytokine gene transcription (100). 
Importantly, in this study (100), the differentiation of CD4 T cell populations was 
established (i.e. the re-modeling of regulatory regions of effector cytokine loci was 
established) before TCR-mediated AP-1:NFAT interactions were analyzed (Jurkat cell- 
lines). This method was in contrast to gene-deficient models (AP-1 and NFAT) where 
differentiation from a primary naive CD4 T cell precursor cell is likely disrupted at early- 
time-points (due to deficiency in AP-1 or NFAT proteins) and further specific-effector 
cytokine gene regulation becomes disrupted. In conclusion, it is speculated that specific 
inhibitory interactions via Jun:Fos heterodimers and also AP-1:NFAT ternary interactions 
could lead to a degree of differential cytokine expression in the primary differentiation 
stage as well as in the secondary stimulus.
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1.6 Molecular mechanisms in 11-10 gene regulation
Despite the central role of IL-10 in the immune response not a great deal is known in 
terms of the molecular mechanisms regulating 11-10 gene expression in CD4 T cells or 
other IL-10-producing immune cells. When I started my thesis in August 2003, no 
reports on the molecular mechanism of 11-10 gene regulation within primary CD4 T cells 
were published. However, as I have began to finish my thesis some initial reports of II- 
10 gene regulation have been published that describe specific chromatin re-modeling 
regions (DNase I HSS) and potential regulatory regions for control of 11-10 gene 
transcription (110, 114, 115). I will outline the findings of these first papers detailing II- 
10 gene regulation at the chromatin-level and secondly transcription factors that have 
been associated with 11-10 gene regulation.
1.6.1 Regulation of the 11-10 gene at the chromatin-level
The first report on chromatin-level regulation of the 11-10 gene (performed in D5 (Thl) 
and DIO (Th2) cell-lines and primary Thl/Th2 cells) clarified several regions of DNase I 
HSSs (114). The Im et al. group showed that the 11-10 locus is not re-modeled in naive 
CD4 T cells and a differential degree of re-modeling is established between Thl and Th2 
cells at the chromatin-level (cell-lines and primary cells). Importantly, this group used 
probes spanning either IL-10 exon 3 or exon 5 to show HSS in 16-kb BamHI fragments 
containing regions weighted primarily towards the 3’ end of the murine 11-10 locus (114). 
This group suggests the proximal 5’ region (promoter) of the 11-10 gene is both 
exclusively (1) re-modeled and (2) transcriptionally “active” in Th2 cells as opposed to
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Thl cells. This was determined by analyzing the promoter region in both Thl and Th2 
cells for DNase I HSS patterns (cell-lines) and status of acetylation of histone H4 using 
Chromatin immunoprecipitation (ChIP) with primers spanning the promoter region (cell- 
lines) (114). Together, the group identified 6 potential HSSs located throughout the 11-10 
locus (summarized in Figure 1.5). This was the first chromatin-level study to be 
performed in murine CD4 T cells and provided the first evidence of differential 
chromatin-level regulation for 11-10 gene regulation.
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Figure 1.5. Initial 11-10 locus chromatin-level results performed in CD4 T cells.
The 11-10 locus at the chromatin-level in CD4 T cells as first described by Im et al. DNase I HSS were 
described in either Thl or Th2 cells. Black boxes represent exons (5 total) and white boxes represent the 
untranslated regions (UTRs) o f the 11-10 gene.
The second DNase I HSS study was performed in similar cell-lines from CD4 Th cells 
and further added to the previous study by defining a regulatory region within the 11-10 
locus and putative transcription factors that enhanced IL-10 production at this site (110). 
Wang et aL, defined a conserved noncoding sequence (CNS) region expressed in both 
Th2 (DIO cell-line) cells and Thl (AE7 cell-line) cells located in the 3’ region of the II- 
10 gene, termed CNS-3. This region of the 11-10 locus contained a conserved (human 
and mouse) putative AP-1 binding site. They further showed that AP-1 family members, 
c-Jun and JunB, were recruited in vivo to this site in stimulated primary Th2 cells and not 
in stimulated primary Thl cells (ChIP). Furthermore, retro-viral transduction of c-Jun or
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JunB into naive CD4 T cells was shown to enhance IL-10 production in primary cells in 
the absence of other effector cytokines 3 days post-transduction (ELISA). Finally, they 
show the CNS-3 sequence can enhance 11-10 expression in reporter assays when cloned 
together with the full-length minimal IL-10 promoter (1.5 kb), transfected into DIO cells 
and triggered with PMA/Ionomycin. This is in sharp contrast to parallel experiments 
where the full-length minimal promoter by itself was unable to enhance 11-10 
transcription after PMA/Ionomycin triggering in DIO cells. Wang et al., were the first 
group to collectively show a molecular mechanism for 11-10 gene regulation by DNase I 
HSS, in vivo recruitment of putative transcription factors to the corresponding HSS and 
enhancement of IL-10 production in primary CD4 cells with RV-mediated transduction 
of the putative transcription factors (c-Jun and JunB).
Up-to-date the most complete study on chromatin-level 11-10 gene regulation was 
performed by Saraiva et al. within primary naive CD4 T cells, effector CD4 T cells, IL- 
10-Treg CD4 T cells and bone marrow (BM)-macrophages (115). In this study, 
“common” HSS within the 11-10 gene are described at the 5’ proximal region (promoter), 
intron 3 and intron 4 within both primary IL-10-producing CD4 T cells: Th2 and IL-10- 
Treg cells (the HSS described by Wang et al. were not analyzed in this study, as Saraiva et 
al. used a probe located 7 kb upstream of the 11-10 start site of transcription). This study 
was the first to describe chromatin-level regulation of the 11-10 gene in IL-10-Treg. The 
authors go further and describe shared HSS in IL-10-producing (stimulated with LPS 
(lipopolysaccharide), or other stimuli) BM-macrophages (5’ proximal region, intron 3, 
and intron 4) and a novel BM-macrophages specific HSS (-4.5 kb upstream of the IL-10
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start site, HSS-4.5) not shared with IL-10-producing CD4 T cell populations. Within the 
novel BM-macrophage HSS a conserved (human and mouse) putative NF-kB binding 
site was shown to recruit the NF-kB p65/RelA subunit in stimulated BM-macrophages 
(115). HSS-4.5 was further shown to have increased acetylated histone H3 (ChIP) in 
either resting or activated BM-macrophages and enhanced 11-10 gene expression in the 
/raws-activation studies when HSS-4.5 was cloned up- or down-stream of the full-length 
minimal IL-10 promoter (115). Finally, primary BM-macrophages where shown to 
exhibit a dose-dependent decrease in IL-10 mRNA and protein secretion when treated 
with an IKK inhibitor, indicating NF-kB activation is necessary for optimal IL-10 
expression in BM-macrophages (115). Together, this study demonstrates that different 
IL-10-producing immune cells can have different potential regulatory regions that 
influence 11-10 gene regulation in a cell-type specific manner. Conversely, they also 
show that “core” HSSs (5’ proximal region (IL-10 promoter), intron 3 and intron 4) are 
conserved across IL-10-producing cells: BM-macrophages, Th2 cells, and IL-10-Treg 
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Figure 1.6. Chromatin-level analysis of the 11-10 locus.
The 11-10 locus at the chromatin-level in CD4 T cells as first described by Im et al., Wang et al. and 
Saraiva et al. Transcription factors binding and regulating gene transcription are shown with the 
corresponding investigative authors. “Core” HSSs for high-IL-10-producing cells are labeled (*) at the 5 ’ 
proximal region, intron 3, and intron 4.
1.6.2 IL-10-associated transcription factors
A comprehensive picture of all the necessary transcription factors to evoke instructive 
and essential enhancing or repressive regulation of the 11-10 gene is not clear. Recent 
chromatin-level studies have determined as discussed in detail earlier transcription factors 
(c-Jun and JunB in CD4 T cells (112) and NF-kB in BM-macrophages (115)) acting 
directly at exposed regulatory regions within the 11-10 gene to enhance IL-10 production. 
In macrophages, the proto-oncogene c-Maf is reported to act to regulate the 11-10 gene 
based on the following observations: (1) c-Maf fr-cm-activates the “minimal” IL-10 
promoter (-.190 kb from 11-10 gene start codon) in RAW264.7 cells and (2) c-Maf was 
shown by ChIP to be associated with the IL-10 promoter in IL-10-producing human 
monocytes (-.190 kb from 11-10 gene start codon) and (3) transfection of c-Maf into 
human monocytes up-regulates IL-10 transcription stimulated by LPS (116). SMAD-4 is 
functionally shown to enhance CD4 T cell IL-10 production in Thl-driven conditions 
(117). Transduction of SMAD-4 into naive primary CD4 T cells differentiated under Thl
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conditions induces differential gene expression of IL-10; however a clear direct 
molecular mechanism for this effect is not understood (117). Several IL-10-enhancing 
transcription factors have been shown - only in cell-lines -  to trans-activate the minimal 
IL-10 promoter. For instance, non-cell-type specific transcription factors Spl/Sp3 (118) 
and c/EBP-p (119) have been shown to /r<ms-activate the minimal IL-10 promoter in 
reporter assays performed in various non-immune derived cell-lines. In conclusion, 
whether these molecules are involved in enhancing 11-10 gene expression via instructive 
events leading to IL-10 modifications, at the level of the chromatin, or at site-specific 
regions accessible in differentiated IL-10 producers remain unclear.
Two recent transcription factors have been implicated in CD4 T cells as possible direct 
repressors of 11-10 gene regulation (although to our knowledge no clear direct molecular 
mechanism is yet understood). Transcription factor-mediated repression of the 11-10 gene 
is intriguing because it may help explain why some populations of CD4 T cells with 
similar HSS differentially bind enhancing transcription factors (ex: AP-1 family members 
in the 3’ region) and produce IL-10 whereas other do not. The initial chromatin report by 
Im et al. suggested that both intron 3 and intron 4 was re-modeled but “silenced” in Thl 
cells (D5 cells) as opposed to being acetylated at histone H3 and H4 (“active”) in Th2 
cells (DIO cells). This was shown primarily via increased histone deacetylase HDAC1 in 
Thl cells at positions within intron 3 and intron 4 (ChIP). They further show that 
NFATc2 binds at a conserved (human and mouse) putative binding site within intron 4, 
exclusively in Thl cells (D5 cells) and not in Th2 cells (DIO cells) (ChIP). They 
speculate that functionally, NFATc2 may act as a key repressor-like molecule for IL-10
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expression by binding within intron 4, “silencing” IL-10 expression as shown by 
increased histone deacetylase HDAC1 at this position. Another transcription factor 
functionally described to repress IL-10 expression is the proto-onco transcription factor, 
Ets-1 (72). Knock-out Bts-1 (-/-) CD4 T cells produce significantly higher levels of IL-10 
in both effector populations, although especially seen in Thl cells (1% (WT) to 57% 
(Ets-1 (-/-)) by ICS FACS) (72). Although the exact molecular mechanism by which Ets- 
1 may repress IL-10 production is not known, it may act directly on a transcriptionally 
active region of the 11-10 locus or conversely re-model a region of the 11-10 locus 
allowing for repressing factors to bind. Together, the likely interaction of several 
transcription factors in “silencing” potential regulatory region remains an intriguing 
possibility but a clear mechanism is still not understood.
A collective cartoon of 11-10 gene regulation (chromatin-level and transcription factors- 
mediated) is shown here in Figure 1.7.
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Figure 1.7. Gene regulation of the 11-10 locus in various IL-10-producing immune cells.
Represents a collective cartoon o f the regulatory mechanism understood to regulate the 11-10 gene outlined 
throughout this chapter.
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1.7 CD4 Treg: cellular and molecular properties
1.7.1 CD25+Treg
Natural occurring CD25+(IL-2Ra) Treg represent a CD4 T cell population that have 
shown the capacity to regulate immune response to auto- and alloantigens, autoimmune 
diseases, allergy and infections (27, 120-125). CD25+Treg were first discovered in mice 
(120, 121), and later an identical phenotypic and functional population of regulatory T 
cells has been defined in humans (126). In both mice and humans the CD4+CD25+ 
population comprises approximately -10% of the peripheral CD4 T cell compartment 
(125). The naturally occurring immunosuppressive population of CD4 T cells is not only 
involved in the regulation of various autoimmune diseases, allergy, or atopy but can also 
provide effective anti-tumor immunity and tolerance to transplantation (27, 127). Below, 
I will introduce the lineage specific transcription factor for these natural occurring CD4 
Tregj FoxP3, and possible cellular mechanisms for CD25+Treg suppression.
1.7.1.1 FoxP3
FoxP3, a member of the forkhead-winged-helix family, has been classified as the 
signature lineage specific transcription factor in natural occurring Treg (122, 124, 128, 
129). Functional studies involving FoxP3 over-expression initially showed that FoxP3 
induced suppressive properties in naive CD4 T cells to inhibit naive T cell proliferation in 
vitro (122). Further studies confirmed in vivo that FoxP3 acts as the regulatory T cell 
lineage specification factor, irrespective of CD25+ expression (129). The induction of 
FoxP3 expression is speculated to at least partly occur within the thymus (130) and
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further FoxP3 induction in peripheral naive CD4+CD25- T cells, is speculated but not yet 
clearly understood (127, 131). The overall maintenance or homeostasis of CD25+Treg in 
the periphery is supported or “fuelled” by critical IL-2 uptake (132). Another clear 
pathway maintaining FoxP3 expression in peripheral CD25+ Treg is via the presence of 
transforming growth factor (TGF)-p (133). Specifically; TGF-pl has been shown to 
support the expression of FoxP3 within peripheral CD25+Treg and therefore, the 
homeostasis of peripheral CD25+Treg population (133,134).
The role of FoxP3 in the regulation of the immune response is shown clearly by genetic 
diseases in mice and humans that are tracked to defects in the foxp3 locus (135). Mice 
deficient for the DNA-binding motif for foxp3, Scurfy (sf) mice, exhibit an activated T 
cell phenotype, produce excessive amounts of a number of effector cytokines upon 
activation, lack differentiated T regulatory cells and die by week three of age (128, 136, 
137). This further supports the crucial role of FoxP3 in the regulation of peripheral CD4 
T cells. Humans suffer from a similar disorder clinically termed immunodysregulation, 
polyendocrinopathy and enteropathy, X-linked syndrome (IPEX) brought about by 
various point mutations within the foxp3 gene (135, 138). Interestingly, the severity of 
the phenotype between humans differs based on the location of the point mutations 
within the foxp3 gene (139). Mutations in both the DNA-binding region (FKH) and to a 
milder degree the protein-protein interaction domain of the foxp3 gene predispose 
humans with symptoms clinically associated with IPEX (135, 139). These IPEX- 
mediated point mutations within the foxp3 gene clearly illustrate that FoxP3 regulates the 
expression of target genes via DNA-binding regions and also to some degree through
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protein-protein interactions (135,139).
The exact role of FoxP3 in CD25+Treg is currently being defined by several groups. It is 
clear that ectopic expression of FoxP3 in naive CD4 T cells is sufficient to confer 
regulatory function (122, 128, 129). Another clue to the direct mechanism of FoxP3 
function in CD25+Treg is the apparent direct repression of pro-inflammatory (IL-2) (137) 
and effector (IFN-y, IL-4) cytokine expression and production via inhibition of NF-kB 
and NFAT proteins to bind target DNA regions (137, 140). More investigation into other 
transcription factors either interacting with FoxP3 or independently adding to CD25+Treg 
ability to survive without the ability to produce proliferative cytokines upon TCR 
triggering will be discussed later.
1.7.1.2 Cellular mechanisms for in vitro or in vivo suppression by CD25+Treg
Multiple mechanisms of in vitro or in vivo suppression by C D 2 5 + T reg have been 
addressed; although a universal mode of immunosuppression by C D 2 5 + T reg is still not 
established ( 1 2 7 ) .  Some postulated mechanisms for suppression by C D 4  Treg include: 
the local in vivo secretion of cytokines such as T G F - p  or I L - 1 0 ,  direct cell-cell 
interactions, and/or transcriptional control of the 11-2 gene in C D 4 + C D 2 5 -  T  cells ( 1 2 7 ) .  
Well-described assays and disease models for systemically understanding the multiple 
levels of suppression by C D 2 5 + T reg in vitro and in vivo have been essential to 
investigating their possible suppressive properties.
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Throughout the numerous studies on the mechanism for CD25+Treg suppression, three 
clear themes with regards to potential suppressive mechanisms are universally recognized 
(127). First, in vitro studies using defined systems where cells are separated by 
permeable membranes have illustrated that in vitro Treg suppression of naive or effector T 
cells is mediated via a cell-contact-dependent mechanism (141). Secondly, the presence 
of APCs is not required as in vitro APC-ffee mixed cultures of CD4 Treg and naive or 
effector cells are suppressed to levels equivalent to APC-driven -naive and CD4 Treg 
culture systems - although these studies are not widespread and do not rule out an effect 
of CD25+Treg on APC (127). Lastly, in vitro studies have clearly shown that activation 
of CD4 Treg via TCR ligands or antibody to CD3 is essential for CD4 Treg ability to 
suppress naive or effector T cell proliferation (11).
1.7.1.L1. Cell-cell contact
The CD28 receptor family members, cytotoxic T lymphocyte-associated antigen 
(CTLA)-4, inducible T-cell co-stimulator precursor (ICOS) and programmed cell death 
(Pcd)-l (also known as programmed death (PD)-l), have all been postulated to exhibit 
proximal suppressive properties in direct cell-cell interactions via CD25+Treg and naive 
or effector T cells (142). A sufficient amount of data describing CD4 Treg 
immunosuppressive properties in vitro centers on the expression of CTLA-4. CTLA-4 is 
actively ligated by two ligands termed: CD80 (B7-1) and/or CD86 (B7-2), and these 
ligands are recently shown to be expressed on effector CD4 T cells as well as multiple 
APCs (143) (discussed more below). The systematic deletion of these B7 ligands, CD80 
and/or CD86, within in vitro systems has conclusively shown that cell-cell contact
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mediated suppression by CD25+Treg of CD4 effector cells is significantly reduced as 
compared to wild-type CD4 effector T cells in APC-free CD4 Treg suppression assays 
(127). These studies imply that cell-cell immunosuppression in vitro, is dependent on 
activated CD25+Treg expressing CTLA-4 that can interact directly with the ligand CD80 
and/or CD86 expressed on effector CD4 T cells. Additionally, CTLA-4 expression on 
CD4 Treg has been shown to transfer suppressive function, for the activation of naive and 
effector CD4 T cells, to CD80 and/or CD86 expressing APCs (142) (discussed more 
below).
CTLA-4 can exert inhibitory effects directly to professional APCs or via direct cell-cell 
contact. Interestingly, a ligand independent form of CTLA-4 (liCTLA-4) has been 
recently shown to exist predominately in CD4 memory/Treg cells. Furthermore, the 
liCTLA-4 form is shown to be differentially expressed in resting T cells as opposed to the 
full-length version of CTLA-4 being up-regulated on activation (144). In vivo studies 
showed that the liCTLA-4 form was responsible for susceptibility to type 1-diabetes in a 
mouse model (145). This dichotomy of resting versus activation expression profiles 
leads to the postulate that liCTLA-4 inhibits initial low-threshold T cell activation; 
whereas the full length CTLA-4 is regulated by the strength of the TCR stimulus and thus 
serves to dampen high-affinity T cells (146).
CTLA-4 is found on a variety of T cells including CD4 Treg» which have been shown to 
exert suppressive function by interacting with dendritic cell derived CD80 and/or CD86 
and thereby inducing indoleamine 2,3-dioxygenase (IDO) activation (125). IDO further
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metabolizes tryptophan and lowers the amounts of free tryptophan within DCs, which 
leads to the lowered capacity of DCs to activate CD4 T cells (142). However, this 
pathway has been shown to be not essential in CD4 Treg suppression assays in an in vitro 
setting, as APC-free Treg cultures also exert suppressive properties (127, 143). Cell-cell 
ligand/receptor binding of CTLA-4 and CD80 or CD86 has been reported in two separate 
environments: CD4 Treg-effector cells and CD4 effector-effector cells (127, 143). 
Importantly, CD4 T cells up-regulate CD80 and CD86 ligands upon activation, and these 
ligands have been shown to be required for in vitro CD25+Treg suppression. CD4 Treg- 
effector cell interaction has been postulated to occur on recent TCR triggering allowing 
CTLA-4 to engage the effector cell CD80 and/or CD86 ligand (127). This interaction 
triggers an ‘outside in’ suppression of the target effector cell (146). Other reports show 
that certain effector cells express CTLA-4 (142). Therefore, CD4 effector-effector cell 
interactions are suggested to regulate each other via cell autonomous CTLA-4 signaling.
The mechanism by which CTLA-4 exhibits suppression is somewhat unclear. One role 
that was been postulated is CTLA-4 antagonizing effects on the necessary secondary T 
cell receptor, CD28 (142). Full length CTLA-4 may competitively remove CD80 and/or 
CD86 available for activating necessary proliferative secondary signals through CD28 
(144). Secondly, ligation of CTLA-4 may directly inhibit the TCR pathway (142). One 
clear mechanistic role of CTLA-4 is within DCs where activation of CTLA-4 by CD80 
and/or CD86 induces IDO signaling within DCs, which indirectly reduces the ability for a 
DC to activate subsequent naive T cells (125). Taken together, the multiple forms of 
CTLA-4 and cell-type interaction dynamics that govern CTLA-4 various pathway-
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specific functions elude to its robust ability to suppress proliferation within the T cell 
compartment.
Another CD28 homolog shown to exhibit tolerance on CD4 T cells is ICOS. ICOS has 
one natural B7 family ligand, ICOSL, which is expressed in T cells, B cells, DCs, 
macrophages, and other non-lymphoid tissues (142). ICOS is up-regulated on both CD8 
and CD4 T cells upon activation and is present in all types of effector and memory cells 
(142). Both Thl and Th2 cells express ICOS; however ICOS is present in higher levels 
on Th2 versus Thl cells (147). ICOS is similar to CD28 - but not dependent on CD28 - 
in that it can augment cytokine expression and drive differentiation in both Thl and Th2 
effector cells as shown with various in vivo disease models performed in CD28 gene- 
deficient mice (148, 149). One clear difference between CD28 and ICOS lies in the fact 
that ICOS ligation is not able to drive early production of IL-2, while CD28 is required 
for maximum naive T cell activation and further downstream IL-2 production (150). 
Another clear role for ICOS lies in its ability to drive B cell differentiation, 
immunoglobulin class switching, germinal center formation, and memory B cell 
development (147, 149). Definitive studies have illustrated that ICOS(-/-) mice are 
severely affected in their ability to mount sufficient T cell-dependent B cell responses 
(151-153).
Several studies have clearly shown the effect of ICOS during the course of an effector 
Th2 response. Firstly, Coyle et al. showed in vitro that blocking ICOS, with ICOS-Ig, in 
recently activated primary Th2 cells reduced cytokine production of IL-4 and IL-5, by
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over 50%, independently of CTLA-4 or CD28 activation (147). This group went on 
further to test blockade of ICOS in an in vivo hyper-active Th2-associated disease model, 
by administrating blocking ICOS-Ig to mice before transferring highly polarized Th2 
cells (147). ICOS-Ig recipient mice exhibited a significant reduction in clinical signs of 
pathology and this was associated to production with IL-5 being reduced by over 80% 
versus control mice (147). In a separate study, researchers treated mice with antagonists 
or blocking antibodies for ICOS (ICOS-Ig and/or a-ICOS) at day 0, 8, or 21 days after 
airway priming in a similar Th2-driven disease model (154). Blocking antibodies for 
ICOS had no effect on cytokine production at day 0 or 8, versus control. However, at day 
21, mice receiving ICOS-Ig or a-ICOS had significant reduction in IL-10, IL-5, and IL- 
4. Furthermore, up-regulation of Th2-associated chemokine receptors CCR3, CCR4, and 
CCR5 was shown to be significantly reduced at day 21, from cells pooled from the 
draining lymph nodes in mice receiving a-ICOS. These preliminary studies suggest, 
blocking ICOS can regulate an established Th2 driven immune response via reduced 
cytokine production and cell-surface homing markers (chemokine receptors); however 
early differentiation of Th2 cells is likely to be less dependent on ICOS.
ICOS expression has also been implicated in CD4 Treg. Firstly, ICOS expressing CD4 T 
cells were isolated from secondary lymph nodes in unmanipulated mice and categorized 
as ICOShlgh, ICOSmedlum, and ICOSlow expressing cells after re-stimulation for their 
cytokine profiles (155). ICOShlgh cells were linked to IL-10 production, ICOSmedlum cells 
to IL-4, IL-5, and IL-13, and ICOSlow cells were loosely-linked to production of IL-2 and 
IFN-y(155). One report generated CD4 Treg with ex vivo mature pulmonary DC that
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were isolated from mice primed with respiratory allergen and showed that the subsequent 
generation of IL-10-Treg was possible from these DCs but dependent on the 
ICOS:ICOSL interactions (156). This study implied that the combinations of the 
ICOS:ICOSL pathway and local presence of IL-10 was critically important for mature 
DC to drive CD4 Treg in the lung and thereby prevent development of airway hyper 
reactivity (AHR). However, other models where mice were challenged with pathogens 
and CD4 T cells were collected and re-stimulated show different cytokine profiles 
relating to ICOS expression levels (157).
Taken together, ICOS is important in the effector phase of T cell differentiation and 
especially key to Th2 effector function. Furthermore, ICOS ligation on CD4 T cells does 
not up-regulate IL-2 production, an especially crucial feature of early differentiating CD4 
T cells. Finally, high-density expression of ICOS has been implicated in stimulating IL- 
10 production (156), which may provide a mechanism for CD4 Treg suppression.
Programmed cell death (Pcd)-1 constitutes an important pathway regulating T cell 
activation and tolerance (158). Pcd-1 - a CD28 family member - is related closely to 
CD28 and CTLA-4 (158). Pcd-1 is expressed on thymic double negative cells (158), 
peripheral CD4 and CD8 cells (159, 160), B cells, and monocytes upon activation (160). 
Unlike CD28 and CTLA-4, Pcd-1 is expressed on a broad range of lymphocyte-derived 
cell-types. There are two natural ligands for Pcd-1 termed: PD-L1 and PD-L2, which are 
expressed on B, myeloid, and DC upon activation (161). Interestingly, PD-L1 is also
46
expressed on naturally occurring CD25+Treg, although its function within this population 
has not been systemically addressed (161).
Within CD4 T cells, Pcd-1 acts similarly to CTLA-4, in that, low amounts of Pcd-1 are 
able to potently inhibit T cell activation at an early developmental state (162). Co­
localization at the cell surface level of Pcd-1 to TCR/CD28 receptor complexes is 
essential for Pcd-1 inhibitory function (162, 163). Although unlike CTLA-4, Pcd-1 has a 
well-established functional target in that it inhibits expression of the cell survival gene 
bcl-XL, thereby inhibiting T cell activation and proliferation (163). T (CD4 or CD8) cells 
stimulated via the TCR/CD28 and PD-Ll:Pcd-l displayed dramatically decreased 
proliferation and the intrinsic inability to produce significant levels of IL-2 (163).
Recently, a group has isolated CD4 Treg that express Pcd-1, irrespective of CD25+ (164). 
These cells either produce IL-10 and IL-4 upon re-stimulation, but little to no IL-2 and 
IFN-y. The mechanism by which these CD4 Treg inhibit naive CD4 T cell proliferation in 
vitro was determined to be IL-10 and IL-4 independent, but partially CTLA-4 dependent.
Some members of the tumor necrosis factor (TNF) receptor family have been implicated 
m CD4 Treg cell—mediated suppression by CD4 Treg (165). The most studied member of 
this family is the glucocorticoid-induced tumor necrosis factor receptor (GITR). Initially, 
GITR was thought to be a CD25+Treg specific marker, and its activation on CD4 Treg was 
demonstrated to repress CD4 Treg-mediated suppression (166), while a simultaneous 
independent study required activation of CD25+Treg along with IL-2, in order to abrogate
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GITR-mediated suppression (167). It is now understood that GITR expression is not 
restricted to the CD25+Treg population and activated effector CD4 T cells can also 
express GITR to signal either TCR-driven activation or cell death (168). Triggering of 
another TNF receptor family member, 0X40 (CD 134), has also been shown to abrogate 
CD25+Treg mediated-suppression and restore effector T cell proliferation, IL-2 
transcription and effector CD4 T cell cytokine production (169, 170). However, similar 
to GITR, 0X40 is expressed on activated effector CD4 T cells and thus is not specific for 
CD25+Treg (169). A combinatorial in vitro study of both GITR and 0X40 expression 
specific for CD25+Treg revealed that oc-GITR treatment abrogated CD25+Treg suppression 
of effector CD4 T cells before and after TCR activation, while similar <x-OX40 treatment 
of CD25+Treg only abrogated suppression before CD25+Treg activation (170). Together, 
both GITR and 0X40 activation on CD25+Treg can inhibit suppression under certain 
conditions, however since GITR and 0X40 show high abundance expression in activated 
effector CD4 T cells this limits the ability to isolate direct GITR and/or 0X40 
CD25+Treg-mediated effects in vivo.
1.7.1.1.2 Cytokines
Independent studies have suggested that the primary mechanism for in vitro suppression 
by CD4 Treg is the consumption of exogenous IL-2 (141, 171, 172). While it is clear that 
IL-2 is essential to initiate proliferation of suppressive CD4 Treg (172, 173), it is not clear 
whether the consumption of IL-2 by CD4 Treg is the primary means to which CD4 Treg 
translate their suppressive properties for naive and/or effector T cells (127). Furthermore, 
in vivo studies involving gene-deficient (IL-2R(-/-)) mice have shown that competitive
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CD4 Treg consumption of IL-2 is not sufficient to suppress various autoimmune responses 
(173). Recent definitive studies have demonstrated that both CD25(-/-) and IL-2(-/-) 
FoxP3-expressing cells were able to fully suppress proliferation of CD4 T cells in vitro 
(132). Thus, IL-2 consumption by CD4 Treg in the periphery likely plays a role in CD4 
Treg maintenance and proliferation; however, it cannot be considered the essential 
mechanism for in vitro or in vivo naive and effector T cell suppression.
Although CD25+Treg do not have the ability to produce IL-10 directly upon stimulation 
after ex vivo isolation from unmanipulated hosts, IL-10 has been considered an essential 
molecule for CD4 Treg -mediated in vivo immunosuppression within certain immune 
responses (11). It was initially shown that generation of CD4 Treg via repeated in vivo 
antigenic stimulation by specific peptide, resulted in anergic CD4 T cells that secrete 
large amounts of IL-10 (174-177). One area of intensive study in CD4 Treg function is 
observations from the development of mucosal inflammation to intestinal antigens (21). 
Intestinal inflammation occurs spontaneously after adoptive transfer of naive CD4 T cells 
from normal mice into T and B cell immunodeficient recipients (21). The resultant 
pathology (colitis) is due to an excessive Thl-driven immune response (21). The co­
transfer of CD25+Treg into these immunodeficient hosts inhibits colitis and this 
suppression is dependent on the production of IL-10, as CD45RBlow cells (which contain 
effector cells, CD25+Treg and other CD4 Treg) treated to mice with IL-10R antibody or 
IL-10(-/-) CD45RBlow cells were unable to control intestinal inflammation (22). These 
findings provided clear evidence that IL-10 plays a non-redundant role in the functioning 
of CD4 Treg that control inflammatory responses towards enteric bacteria (22).
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Interestingly, the investigators determined that the effect of IL-10 was specific for 
“antigen-specific” effector CD4 T cell populations, and that additional regulation of the 
naive CD4 T cell pool was likely via a cell-cell mechanism, and therefore IL-10 
independent, since CD25+Treg from IL-10(-/-) could regulate pathology induced by naive 
T cells (23). An additional report with regards to adoptive transfer and intestinal 
inflammation in immunodeficient hosts, demonstrates that CD25+Treg-derived IL-10 can 
inhibit pathology (colitis) in an innate immune response (24). In these studies colitis was 
triggered with the bacterium Helibacter hepaticus (not via transferred naive CD4 T cells 
responding to an enteric bacteria antigen) in immunodeficient hosts, thereby driving T 
cell-independent intestinal inflammation via the constitutive innate immune response. 
Helibacter hepaticus-mfected immunodeficient hosts receiving adoptively transferred 
CD25+Treg were protected from development of colitis (induced in a T cell-independent 
fashion). This response was cytokine dependent as CD25+Treg transferred into mice 
treated with IL-10R antibody or IL-10(-/-) CD25+Treg cells completely ablated the ability 
of CD25+Treg to inhibit intestinal inflammation via the innate immune response. In 
summary, IL-10 plays an essential role in some CD4 Treg suppressive-mediated 
microenvironments; however the IL-10 effect is complex in these contexts and in vivo 
CD25+Treg may use various mechanisms for suppression depending on the disease model 
and the level of inflammation.
Another important cytokine in the functional regulation and homeostasis of CD25+Treg, is 
the pluripotential cytokine TGF-(3 (127, 134). Upon activation, CD25+Treg have been 
shown to express high levels of membrane-bound TGF-pl (178). Initially, the
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production of TGF-pl was thought to directly regulate CD4+CD25-T cells (178); 
however more recent studies have concluded that CD25+Treg expression of TGF-pl is 
likely to specifically suppress antigen-specific CTLs but not effector CD4 cells (179, 
180). Therefore, direct suppression by CD25+Treg via TGF-pl production is likely 
restricted to the CD8 T cell population while microenvironments that include TGF-pl 
favor generation and/or proliferation of CD25+Treg (as described above) but not direct 
suppression of effector CD4 T cells (127).
1.7.2 Trafficking of CD25+Treg
The homing of CD25+Treg to sites of activated effector T cells within the host has been 
suggested to play a critical role in CD25+Treg suppressive function (125). Chemokines or 
chemoattractants regulate leukocyte migration and likely play a key role during 
inflammation in the local recruitment of both effector T cells and CD4 Treg (181, 182). 
Early clues to trafficking of CD25+Treg have been addressed by studies showing the up- 
regulated expression of chemokine receptors, CCR4 and CCR8, upon TCR activation 
(183). These chemokine receptors are postulated to dictate regional trafficking of 
CD25+Treg to areas where mature DCs secrete their target ligands: CCL17 and CCL22 
(183). Analysis of chemokine receptor expression from antigen challenged CD25+Treg 
populations indicated that CD4 Treg selectively expressing CCR8 produced IL-10 upon ex 
vivo re-stimulation (184). Both CCR4 and CCR8 expression have also been shown to be 
up-regulated with TCR and CD28 stimulation in associated Th2 cells (185, 186). CCR6 
is another candidate for CD4 Treg specific homing in select immune responses. Mice 
lacking the chemokine receptor CCR6, were shown to have a 2 to 15-fold increase in T
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cell populations in response to select antigens targeting the intestinal mucosal tissue; 
whereas other systemic immune responses to subcutaneous antigens were unimpaired 
(187). The same group also postulated that CCR6  function was critical for AHR, as 
eosinophil accumulation in the lung and cytokine production by allergen-specific Th2 
cells were reduced in CCR6 (-/-) mice in response to a model for allergic pulmonary 
inflammation (188). More recently, CCR6  was shown to be expressed on a distinct 
subset of CD25+Treg that are shown to exhibit markers of recent activation and expansion 
that are indicative for what the authors refer to as regulatory effector-memory T cells or 
Trem (189). Trem were also shown to express high levels of IL-10 after re-stimulation ex 
vivo and be enriched within the central nervous system after induction of EAE suggesting 
homing into potentially destructive immune responses directly in inflamed tissues (189). 
Finally, CXCR5 expression is characterized with an anergic cytokine profile in activated 
CD4 T cells and up-regulated expression of CD28 family member, ICOS (190-192). 
CXCR5+ T cells are found localized in T-B cell follicles where induction of the 
chemokine target ligand, BCL (BCA-1 in humans) (181). Given their ability to provide 
efficient help to antibody production and localization within follicles, CXCR5 expressing 
T cells have been referred to as follicular B helper T cells (Tfh) (181). The fact that 
CXCR5 expression is reported to be absent on naive CD4 T cells and CXCR5 expression 
leads to poor cytokine producing CD4 T cells upon activation suggests that CXCR5 
could play a role in immune surveillance. Taken together, chemokine receptors - CCR4, 
CCR6 , CCR8 , and CXCR5 - have been implicated to play a homing role in populations 
of cells exhibiting suppressive properties demonstrated by various gene-deficient(-/-) and 
functional animal models.
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Lastly, the adhesion molecule CD 103, specifically classified as a ocEintegrin, is 
expressed on recently activated peripheral CD4 Treg (193). CD103+CD25+Treg were 
initially shown to control IBD and peripheral T cell homeostasis (193). 
CD103+CD25+Treg were highly enriched in gut-associated lymphoid tissue as compared 
to CD103-CD25+Treg (193). One implication that has been put forward is CD 103 
expression marks recently activated CD4 Treg in the periphery (194) and these 
CD103+CD25+Treg may be homing to sites of inflammation (195, 196). Therefore, 
similar to chemokine expression, CD 103 may act as marker of a recently homing CD4 
Treg and not lineage or antigen-specific CD4 Treg as was first described.
1.7.3 IL-10-Treg
The in vitro IL-10-Treg population -  unlike the in vivo equivalents -  can be generated in 
large numbers for addressing molecular mechanisms for 11-10 gene regulation and their 
anergic and suppressor function (197). Our lab has previously generated a second 
regulatory CD4 population termed: IL-10-Treg (197). This homogeneous population is 
generated from naive CD4 T cells differentiated with the combination of two 
immunosuppressive drugs, la,25-Dihydroxyvitamin D3 , the active form of Vitamin D3  
(vitD3) and a synthetic glucocorticoid receptor (GR) agonist, dexamethasone (DEX) 
(197). Similar to the natural occurring CD25+Treg, the homogenous population of IL-10- 
Treg produce little to no proliferative (IL-2) or effector cytokines (IFN-y and IL-4) upon 
secondary TCR triggering (197). Functionally, IL-10- Treg have been shown to regulate 
naive CD4 T cells in vivo and in vitro, in similar systems to the CD25+Treg suppression,
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and regulate autoimmune disease in vivo (174, 197,198) although these IL-10-Treg do not 
express the natural occurring Treg linage specific transcription factor, FoxP3 (174). We 
believe that these cells are the equivalent of antigen-specific IL-10-producing Treg that are 
induced by repeated challenge of mice with soluble antigen (175, 177) in that like the 
vitDa/DEX generated IL-10-producing cells they do not express FoxP3 or IL-2 (174).
1.7.3.1 Background: DEX and vitD3
The initial use of immunosuppressive drugs vitD3 and/or DEX to generate populations of 
anergic CD4 T cells has a relatively long history in terms of modem immunology (199, 
200). Today, DEX and vitD3 both separately and together have been shown to induce 
regulatory cells that inhibit naive T cell proliferation in mouse (174) and human (201) 
systems and inhibit cytokine production by human Th2 cells (201). The presence or 
treatment of vitD3 on CD4 T cells was initially speculated (1984) as a potential model 
system for understanding the molecular mechanisms by which IL-2 production could be 
inhibited (199). Similar to initial studies on vitD3 , DEX was described (1992) to 
“interfere” with TCR-mediated activation signals and directly inhibit IL-2 transcription 
(200). In fact, these authors were more direct than the initial vitD3 studies and described 
the lack of AP-1 and NFAT co-operation at the IL-2 promoter, which in turn allowed 
DEX to inhibit IL-2 gene transcription. As I write this thesis it is nearly 22 years since 
vitD3 and 14 years since DEX were described in some detail in CD4 T cell biology and 
there remains to be defined a clear definition for their individual or combinatorial 
mechanisms at the molecular level in CD4 T cells.
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Molecular mechanisms in which DEX suppresses CD4 T cells was initially described as 
direct inhibition of the NFAT:AP-1 complex to bind effectively to the known DNA 
binding targets (200). Additionally, the NF-kB family was shown to be targeted by 
DEX, as described by the inhibition of NF-kB transcriptional activity (202). Other DEX 
targets include the expression of receptor activator of nuclear factor-KB ligand (RANKL) 
(203) and interference of NF-kB subunits to bind known target genes, including areas for 
optimal IFN-y transcription (204, 205)). Work by Riccardi et al., identified a DEX- 
induced transcription factor in CD4 T cells (206), glucocorticoid-induced leucine zipper 
(GILZ), which was further shown to directly inhibit the expression of TCR-activated 
genes: Fas Ligand, IL-2, and IL-2R. The suppression of these transcripts was facilitated 
via GILZ interaction with specific NF-kB proteins (207). Another group has 
demonstrated that GILZ acts to bind and inhibit specific AP-1 family members, Jmr.Fos 
dimers, limiting the activity of the AP-1 complex ability to bind target DNA (Jun:Fos) 
(208). Recently generated CD4-specific trans-genetic (TG) GILZ over-expression mice 
up-regulate IL-4, IL-5, IL-13 and IL-10 production on ex vivo stimulus as opposed to ex 
vivo production from CD4 WT cells (209). CD4 T cells from TG mice also down- 
regulate IFN-y when compared to WT cells; however no significant difference in IL-2 
production was witnessed in naive CD4 T cells from either ex vivo stimulated TG or WT 
mice (209). Taken together, the inhibitory effect of DEX (or DEX induced transcription 
factors) on T cell activation and survival appears to be achieved through the antagonizing 
role of three key TCR activation pathways: AP-1, NF-kB and/or NFAT activity.
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The immunosuppressive drug, vitD3 , has been shown to modulate T cell activation (210, 
211) and inhibit secretion of cytokines, IL-2 (212) and IFN-y (213), via vhL>3 direct 
interaction with either NFATp: AP-1 complexes (214) or NF-kB proteins (215). In terms 
of cytokine genes, vitD3 down-regulates IFN-y mRNA via inhibition of transcription via 
the minimal promoter region of the Ifh-ygQne {Cippitelli, 1998 #249}. VitD3 has two 
direct mechanisms in inhibiting IL-2 mRNA transcription: (1) inhibition of the 
NFATc2:AP-l complex to bind to the 11-2 gene (214) and (2) vitD3 ability to reduce 
levels of NF-kB proteins in treated CD4 T cells which indirectly lowers IL-2 expression 
(215). VitD3 has also been described to enhance the ability of CD4 naive T cells to 
differentiate into a Th2 population in an in vitro APC-free culture system (216). VitD3  
treated CD4 T cells were shown to express Th2-associated transcription factors, GATA-3 
and c-Maf, as opposed to neutral (no polarizing cytokines) driven CD4 T cells (216). 
However, the vitD3 -induced effects of differentiating naive CD4 T cells were further 
shown to be mediated through IL-4, extrinsically (216). Together, these results suggest 
that the skewing of differentiating naive CD4 T cells towards an effector Th2 population 
in the presence of vitD3 may be a direct result of early augmentation of initial TCR- 
triggered differentiation away from Thl conditions (with inhibition of IFN-y production) 
and minimal IL-4 production which leads to subsequent IL-4R/STAT6 autocrine 
transcriptional control and Th2 development.
Taken together, that both DEX and vitD3 share the ability to suppress the transcriptional 
activity (NF-kB, NFAT) and protein-protein interactions (AP-1:NFAT) of several 
transcription factors provides a direct mechanism for effects on subsequent naive CD4 T
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cell differentiation. It is also clear that naive CD4 T cell development under the 
individual presence of vitD3 (216) or DEX-induced GILZ (209) seems to influence a Th2 
differentiation patterning. The molecular mechanism for the generation of IL-10-Treg 
which exclusively express IL-10 and little to no IL-2, IL-4 and IFN-y and their 
subsequent expression (in particular, transcription factor) profiles will serve as a major 
determinant in the results section of this thesis. This system provides a key mechanism to 
dissect the regulation of 11-10 gene and the subsequent effects on function of these cells.
1.7.3.2 Cellular mechanisms for suppression by IL-10-Treg
Similar to CD25+Treg the range of suppressive features mediated by IL-10-Treg under 
different physiological conditions is unclear. In vitro suppression assays have shown IL- 
10-Treg are equal to CD25+Treg in inhibiting CD4+CD25- T cell proliferation in vitro 
(174). IL-10-Treg suppressive ability to regulate CD4+CD25- T cell populations in vitro, 
is IL-10-independent, TGF-(3-independent and CTLA-4-independent, mimicking 
CD25+Treg (11, 174). Furthermore, exogenous IL-2 abrogated IL-10-Treg suppressive 
ability (174) in vitro in a manner similar to abolished in vitro CD25+Treg suppression 
(217). Clear evidence demonstrates that IL-10-Treg regulate certain in vivo autoimmune 
pathologies directly through production of IL-10 (197), as a-IL-lOR was shown to 
abrogate the ability of IL-10-Treg to regulate EAE (197). The role of IL-10 produced by 
CD4 Treg has been discussed in the previous CD25+Treg section for regulation of 
intestinal mucosal inflammation and studies involving regulation of allergic disease is 
another area of potential implications for IL-10- Treg- Nonspecific therapies such as 
glucocorticoids are a common agent for allergic or asthmatic conditions in humans which
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in turn is known to induce IL-10 T cell populations (30). Furthermore, allergen 
immunotherapy under the appropriate conditions is reported to induce protective 
allergen-induced IL-10-secreting T cells (218-220). The in vivo generation of IL-10-Treg 
in the case of allergen-specific immunotherapy is of current interest for this novel method 
to provide long-lived immunological recall to allergen-specific stimuli to dampen a 
potentially dangerous acute pro-inflammatory immune response (27). Taken together, 
IL -1 0 -T r e g  are dependent on I L - 1 0  production for control of certain in vivo autoimmune 
or allergic pathologies; however in vitro systems demonstrate that the complete 
mechanism for IL-10- Treg suppression of CD4+CD25- T cells is not entirely IL-10 
dependent and remains unclear, but it is also accompanied by lack of IL-2 production and 




Female BALB/c mice WT and BALB/c IL-4(-/-) mice, housed in specific pathogen-free 
animal facilities at the National Institute for Medical Research (NIMR) were used as a 
source for CD4 T cells. All mice were between ages 10-14 weeks of age.
2.2 Media and Reagents
Tissue culture medium used was RPMI 1640 supplemented with 10 mM HEPES buffer, 
100 U/ml penicillin and 100 U/ml streptomycin, 2 mM L-glutamine, 1 mM sodium 
pyruvate (all from Bio Whittaker, Walkersville, MD), 0.05 mM 2-ME (Sigma-Aldrich), 
and 10% FCS (Labtech International). Monoclonal Antibodies (mAbs) used in cultures 
were anti-IFN-y (XMG1.1) and anti-IL-4 (clone 11B11). Anti-mouse CD3 (clone 2C11) 
and CD28 (clone 37.51) mAbs used for T cell stimulation were purchased from BD 
PharMingen. mAbs used for T cell enrichment were anti-B220 (clone RA3-6A2), anti- 
CD8  (clone C291.2.43), anti-ClassI-Ad/I-Ed (clone 2G9), and for T cell isolation were 
anti-CD4-FITC, -PE or -CyChrome® (clone RM4-5), anti-CD62L-PE (clone Mel-14), 
anti-CD45RB-FITC or -PE (clone C363.16A) and biotinylated anti-CD25 (clone 7D4) 
was followed by streptavidin (SA)-CyChrome® or SA-APC, and isotype controls (all BD 
PharMingen). mAbs used for intracellular staining were anti-IL-2-FITC, -PE or APC 
(clone JES6-5H4) , anti-IL-4, PE (clone 11B1), anti-IL-5, PE (clone TRFK5), IFN-y, 
FITC (clone XMG1.1) and anti-IL-10-PE or -APC (clone JES5-16E3), anti-TNF-ct-PE 
or APC (clone MP6-XT22) and isotype controls (all BD PharMingen). Luminex 
conjugated beads for ELISA was purchased through UpState Signaling (Mouse Beadlyte 
Cytokine 9-Plex Kit).
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2.3 FACS cell preparation
Female BALB/c mice were culled using schedule 1 kill guidelines and whole spleens 
were immediately harvested using sterile technique and placed in cRPMI (this work is 
done in the pathogen-free animal facilities at the National Institute for Medical Research 
(NIMR)). Spleens were pooled and transported to a sterile-hood environment for further 
processing within the laboratory. Spleens were mashed (with the sterile back-end of a 2- 
ml syringe) and washed through a 70-micron filter in the presence of cRPMI. 
Homogenized or “mashed” cells were collected and pooled into a sterile 50-ml falcon 
tube and spun-down (1,300 rpm for 3 minutes) in Vr= 40 ml (cRPMI). Supernatant was 
discarded and cells were re-suspended in 40-ml of cRPMI and spun down again. 
Supernatant was discarded and cells were re-suspended in Ammonium Chloride, NH4 CI 
(0.83%) (Vt= 2 ml per spleen). After 3 minutes cells were spun-down and supernatant 
was discarded (containing the lysed re-blood cells). Cells were re-suspended in 40-ml 
FACS sort buffer (SB) (5% FCS, 100 U/ml penicillin and 100 U/ml streptomycin, and 
sterile PBS). Cells were spun-down and supernatant is discarded. Cells were re­
suspended in 40-ml FACS SB and spun-down a second-time. Finally, cells were re­
suspended in FACS SB at Vf= 0.5 ml per spleen.
Depleting antibodies were prepared in FACS SB for depletion of APCs and CD8  T cells 
(anti-B220, anti-CD8 , anti-Mac-1) and combined in Vr= 0.5-ml per spleen. Each 
antibody was filtered though a .2-micron filter unit. Cells and depleting antibody cocktail 
were combined (Vf= 1 -ml per spleen) and thoroughly mixed and placed on ice for 2 0  
minutes. Magnetic beads (Vi= 2-ml per spleen) were washed with FACS SB (3x) within
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a sterile 50-ml falcon tube placed on the provided magnetic rack. After the final wash the 
magnetic beads, are re-suspended in FACS SB, VT = 0.5-ml per spleen. After a 20- 
minute staining period, cells were washed twice in 40-ml ice-cold FACS SB, and re­
suspended in FACS SB, Vi= 0.5-ml per spleen. Cells and magnetic beads were 
combined and mixed thoroughly, Vt= 1 -ml per spleen, and placed on a slow-rotating 
rotor for 30 minutes in 4°C temperature conditions.
Cells/magnetic beads were placed in a sterile 50-ml falcon tube in the magnetic rack 
provided by Miltenyi magnetic beads were allowed to collect on the magnetic strip 
adjacent to the falcon tube (3 minutes). Media was aspirated and placed in the second 
falcon tube for further collection of magnetic beads and 15-ml of FACS SB is re-placed 
in the first falcon tube for second enhancement of left-over non-magnetic bead-bound 
cells. This process is repeated 3x and a diagram is shown in Figure 2.1.
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Magnetic bead extraction schematic
(removal of APCs and CD8 cells)




Tube #1 Tube #2 Tube #3
Magnetic Racl
Tube with magnetic bead/cells Tube with purified CD4 T cell (no beads)
Figure 2.1. Magnetic bead depletion for CD4 T cell purification
This schematic represents the process o f steps required to remove magnetic bead/cell complexes in order to 
purify CD4 T cells for FACS.
Following magnetic bead depletion, purified CD4 T cells were spun-down. Supernatant 
was withdrawn and cells were re-suspended in 40-ml of FACS SB and spun-down. 
Supernatant was withdrawn and cells were re-suspended in V j -  0.5-ml per spleen in 
FACS SB. Sort cocktail of the necessary antibodies in FACS SB were prepared at the 
appropriate concentrations for mix with cells to a Vt= 1-ml per spleen. Wait 20 minutes 
for cells to be stained with appropriate antibodies (ice-cold conditions). Cells/antibodies 
were spun-down and supernatant was removed, cells were re-suspended in 40-ml of 
FACS SB, and re-spun-down. Supernatant was removed and cells are re-suspended in 
Vy= 0.5 ml per spleen, filtered through a 40-micron filter and placed in 5-ml falcon tubes 
for MoFlo isolation via fluorescent activated cell sorting. A typical recovery of naive 
CD4 T cells is shown below as a FACS plot.
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2.4 In vitro tissue culture conditions







Figure 2.2. Naive FACS isolation and re-analysis
(a) An example o f  a naive T cell (CD4+CD62L+CD45RB+) FACS sort, (b) A typical post-sort re-analysis 
o f the isolated CD4+CD62L+CD45RB+ population, always quality-controlled to be greater than 98% pure.
After naive CD4 T cells were isolated MoFlo (CD4+CD62L+CD45RB+) (Figure 1), cells
(lxlO6 cells/ml in cRPMI) are immediately plated in 24-well plates (lxlO6 cells per well)
and stimulated in a sterile APC-free environment with plate-bound antibodies for CD3
(a-CD3) (10 |4g/ml) and soluble a-CD28 (2 |dg/ml) and their corresponding cytokine
cocktail in cRPMI.
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Table 2.1. Cytokine and Antibody Cocktails for Cultured CD4 T Cell Population
T cell population Cytokine Cocktail
neutral a-IL-4 (20 pg/ml), a-IFN-y(5 pg/ml)
Th1 IL-12 (5 ng/ml), a-IL-4 (20 pg/ml)
Th2 IL-4 (10 ng/ml)
IL-10-Treg vitamin D3 (4x1 O’4 M), Dexamethosone (4x1 O'6 M)
Cells are grown in a sterile incubator (37C, 5% CO2 ). Each cell population was grown as 
described in Figure 2.3, with the key highlights being summarized below. On day 3, cells 
were split in a 1:3 dilution with their corresponding cytokine cocktail into new wells (24- 
well plate) in the absence of a-CD3 and a-CD28. On day 7, neutral and Thl cells are 
collected and a portion was stimulated via the TCR pathway for intracellular cytokine 
production, protein production and mRNA. Th2  and IL-10-Treg are re-stimulated 
overnight in their corresponding cytokine cocktail (1.5xl06 cell/well) with plate-bound oc- 
CD3 (1 jig/ml) and soluble a-CD28 (2 jxg/ml) in the presence of IL-2 (5 ng/ml). On day 
8 , cells are removed from the a-CD3 and a-CD28 stimulus and moved to a new 24-well 
plate. On day 10, a 1:3 split is performed with their corresponding cytokine cocktail, 
including IL-2. On day 14 cells are re-stimulated overnight in their corresponding 
cytokine cocktail (1.5xl06 cell/well) with plate-bound a-CD3 (1 lig/ml), soluble a-CD28 
(2 jig/ml) and IL-2, similar to day 7. On day 15, cells are moved to new 24-well plate. 
On day 18, a 1:3 split is performed with their corresponding cytokine cocktail, including 
IL-2. On day 21, Th2 and IL-10-Treg are collected and a portion was stimulated via the 
TCR pathway for intracellular cytokine production, protein production and mRNA.
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Figure 2.3. Schematic of key points throughout in vitro differentiation process for CD4 T cells.
This schematic highlights the cell-confluence in the 24-well format and concentration o f stimulus at each 
time-point (day 0, day 7, day, 14) during the in vitro differentiation o f neutral, Thl, Th2, and IL-10-Treg.
2.5 Quality controls for homogeneous primary CD4 T cell populations
The isolation and/or generation of homogeneous populations of primary T cells were 
critical for analyzing their respective transcriptional profiles. Cytokine production at the 
respective time of collection is checked at the mRNA level (qPCR), and protein level: 
both at the single cell level (ICS FACS) and the quantitative level (ELISA). Two other 
important populations are collected ex vivo: naive T cells and CD25+Treg (only with post­
sort analysis >98% purity).
2.6 ICS FACS
Intracellular staining (ICS) FACS staining was an integral part of this thesis. Each week 
T cell cultures are quality-controlled largely based on their ICS FACS profiles and 
further the RV system used the ICS to determine whether differential cytokine profiles 
were induced under the gene-of-interest (GFP+) RV system (discussed more below). ICS 
FACS was done consistently with two types of CD4 TCR pathway activation, soluble
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PMA (50 ng/ml)/Ionomycin (500 mg/ml) and plate-bound aCD3 (2 pg/ml)/soluble 
aCD28 (2 ^g/ml).
Firstly, ex vivo or cultured CD4 T cells are washed completely of any residual 
antibodies/cytokines/immunosuppressive drugs and re-suspended at a concentration of 
1.5 x 106  cells per ml in cRPMI. 24-well plates were prepared with 3x concentrated, Vt= 
340 jil, of either TCR pathway activation stimuli (a-CD3/CD28 or PMA/Ionomycin) in 
cRPMI. 660 pi of CD4 T ells were added to TCR stimuli prepared 24-well plate and the 
plate was placed in the incubator (37°C, 5% CO2 ) for two hours. After two hours 10 pi 
of Brefeldin A (stock @ 1 mg/ml) is added to each well. After addition of Brefeldin A 
(which will encapsulate the cells), cells were replaced in the incubator for an additional 
two hours. After two hours (four hours total), cells are harvested and spun-down in ice- 
cold PBS. Ice-cold PBS wash is repeated. Cells were re-suspended in 0.5-ml of ice-cold 
PBS and then 0.5-ml 4% formaldehyde was added to fix the cells (mix vigorously). After 
20 minutes, ice-cold PBS was added and cells were spun-down. Repeat the wash with 
ice-cold PBS, a second-time. PBS was discarded and re-suspended cells were replaced 
with 1-ml of PBS/BSA/Azide buffer (500 ml PBS/0.5 ml of 1.0 M Azide/2.5 grams of 
dissolved BSA). Store cells at 4°C or proceed immediately to ICS.
“Plate-out” approximately 2 xlO5 of cells per well in 96-well U-bottom plates. Cells 
were “plated-out” or spun-down by centrifuge at room temperature at 1,600 rpm for < 1 0  
sec with the 96-well U-bottom plates. After spin-down supernatant was “flicked-out” in 
the sink. Immediately add 150 ml of permeabilization buffer (PBS/BSA/Azide/0.5%
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Saponin) per well and mix gently with pipette. Wait 10 minutes at room temperature. 
Cells were spun-down and supernatant has flicked-off. Add appropriate concentration of 
cocktail of various fluorochromes directly conjugated to cytokine antibodies, Vf= 35-ml 
per 96-well. Incubate for 30 minutes, RT. Add 100 ul of permeabilization buffer to each 
well, and spun-down. Supernatant was flicked-off, and cells were re-suspended in 200 fil 
of permeabilization buffer and spun-down.. Supernatant was flicked-off, and cells were 
re-suspended in 150 pi of PBS/BSA/Azide buffer, spin-down.. Supernatant was flicked- 
off, and cells were re-suspended in 150 pi of PBS/BSA/Azide buffer and transferred to 
ICS FACS analysis tubes. ICS FACS was performed on Beckton Dickinson FACS 
Caliber with CellQuest software under manufactures instructions.
2.7 Real-time quantitative RT-PCR (qPCR)
RNA from the different T cell subsets was extracted using RNeasy Mini-Kit (Qiagen), 
DNase treated (Roche), and reverse transcribed with oligo pdT12-18 (GE Bioscience), 
random hexamer primers (Promega) and Superscript II RNaseFT reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions. cDNA was analyzed for the 
expression of cytokine genes with primers designed to span intronic regions. qPCR was 
performed in 96-well plates (Applied Biosystems) containing: cDNA, primers, and 
SYBR Green (ABgene) reagents and was analyzed with either the ABI Prism 7000 or 
7900 Sequence Detection System (Applied Biosystems). Quantification of target gene 
cDNA expression (Ct value) was normalized to the ubiquitin mRNA levels (Ct value) as 
measured from the same corresponding biological sample (cDNA) on the same plate. 
cDNA was analyzed for the expression of all other genes with primer/probes
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(TAM/FAMRA reporter) purchased through the inventoried stock from Applied 
Biosystems (with the expectation of c-Maf, for which a primer/probe was designed with 
the help of designmyprobe.com). Primer/probes were used with Mastermix (ABgene) 
and analyzed identically to SYBR Green generated Ct values for cytokine genes with 
either the ABI Prism 7000 or 7900 Sequence Detection System (Applied Biosystems). 
Quantification of target gene cDNA expression for primer/probe pairs was normalized to 
the corresponding cDNAs HPRT1 (Applied Biosytems) Ct value, similar to normalized 
cytokine gene expression as described with the control or housekeeping gene being 
ubiquitin Ct values. Relative expression for all genes was calculated by the following 
empirical equation in Microsoft Excel:
Relative expression^ POWER(1.8,((Ct, housekeeping gene)-(Ct, gene of interest))) * 10
2.8 ELISA
ELISA results are shown here with the use of the Luminex xMAP 100 Instrument and 
Beadlyte Mouse Multi-Cytokine reagents. ELISA reactions were performed on Millipore 
Multiscreen 96-well plates, with UpState Beadlyte Mouse Multi-Cytokine Standard sets 
(Standard 2 and 4) containing 5 ng/ml for each cytokine or CD4 T cell supernatant, and 
Beadlyte Anti-Mouse Cytokine Bead Sets for IL-2, IL-3, IL-4, IL-5, IL-6 , IL-10, IL-13, 
IFN-y and TNF-a.
Firstly, cytokine standards were re-suspended and placed in a 1:3 dilution series for a 
total of 7 dilution steps from the neat concentration, 5 ng/ml (5 ng/ml -  6.9 pg/ml). 
Duplicates of 50 jil from each dilution set were pipetted into labeled wells on the
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Millipore Multiscreen plates. “Blank” wells were included (50 pi of cRPMI) as the final 
(base-line) data point on the standard curve. Sample supernatants were immediately 
pipetted into each well in single-cates and diluted from a “neat” concentration, 1:9 
dilution and 1:27 dilution (3 wells for samples: neat or 1:1,1:9,1:27). Beadlyte Cytokine 
Anti-Mouse Beads (9 total) are immediately mixed together with the appropriate amount 
of Cytokine Assay Buffer (UpState Signaling). 25 pi was added of pooled Cytokine 
Anti-Mouse Beads to each well with either the standard mix or sample supernatant, 
vortexed briefly, and allowed to incubate on a plate-shaker at room temperature for two 
hours (Vf= 75 ul per well). While plate is incubating, the secondary Beadlyte Anti- 
Mouse Cytokine-Biotin were combined for all measured cytokines and mix thoroughly 
and placed on ice. After the two-hour incubation the vacuum manifold was applied to the 
Millipore Multiscreen plate to remove the liquid and each well was re-suspended in 50 pi 
of Cytokine Assay Buffer, vacuumed again, and each well was re-suspended in 75 pi of 
Cytokine Assay Buffer. Plate was vortexed and 25 pi of secondary Beadlyte Anti-Mouse 
Cytokine-Biotin was added to each well (Vi= 100 ul per well). Plate was vortexed and 
incubated for 1.5 hours on the plate-shaker in room temperature conditions. After 1.5 
hours, 25 pi of diluted Beadlyte Strepavidin-Phycoerythrin was added to each well, 
mixed and incubated on the plate-shaker at room temperature for 0.5 hours (Vf= 125 ul 
per well). After 0.5 hours, 25 pi of Beadlyte Stop solution was added to each well, mixed 
and incubated on the plate-shaker at room temperature for 5 minutes (Vf= 150 ul per 
well). After, 5 minutes the vacuum manifold was applied to the Millipore Multiscreen 
plate to remove the liquid and re-suspended in 125 pi of PBS, vortexed and placed at on a 
plate-shaker for 1 minute. Plate was then processed on the Luminex 100 Instrument with
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Multi-Plexv4.0 (Bio-Rad) software to quantify concentration amounts first generated 
from the known standard curves and these set amounts are then related to samples from 
unknown concentrations from sample supernatants for the 9 corresponding cytokines (IL- 
2, IL-3, IL-4, IL-5, IL-6 , IL-10, IL-13, IFN-y and TNF-a).
2.9 GeneChip: RNA preparation to GeneSpring v7.0 presentation
Cells were FICOLL-separated before total RNA was prepared with the RNeasy Mini 
Columns (Qiagen) according to the manufacturer’s instructions. Cell numbers were 
approximately 5x106  in order to generate at least 3pg of total RNA. For ex vivo- 
generated populations (naive and CD25+Treg), 20 mice were culled per condition to 
generate 3pg of total RNA post-sort. Total RNA is then quality controlled for integrity 
(quantitative and qualitative) on a Nano LabChip (Agilent) with the Agilent Bioanlyzer 
2100. Upon passing the quantitative (> 3 pg of total RNA) and qualitative (>1.9 28s/18s 
ratio) tests between 3-5 total micrograms of total RNA was further processed with one- 
cycle Affymetrix-recommended cRNA protocols (Roche Applied Science). Briefly, 
according to the manufacturer’s instructions mRNA is transcribed to cDNA, cDNA is 
transcribed to cRNA, and 15 micrograms of cRNA target was fragmented and hybridized 
onto an Affymetrix M430A or M430v2.0 GeneChip, stained with phycoerythrin (PE), 
washed, and scanned on a con-focal based laser scanner.
Two computational algorithms were compared when analyzing the GeneChip image 
generated by the con-focal laser scanner: MAS5.0 (Affymetrix) and GC-RMA (GC-
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Robust Multiarray Analysis, www.bioconductor.org). Both, MAS5.0 or GC-RMA were 
used to generate the independent biological experiments and the replicates were pooled 
per T cell population and condition (12 total: 6  populations, 2 conditions). Each 
algorithm used the image file (.cel file) and the absolute values were processed with the 
support of GeneSpringv7.0 software (Silicon Genetics) for further normalizations. The 
MAS5.0 algorithm is run from GCOSv2.0 application (Affymetrix) and the GC-RMA 
algorithm was computed from the GeneSpringv7.0 (Silicon Genetics) application. 
Irrespective of the algorithm used to generate absolute values for each transcript, 
individual GeneChip generated datasets were normalized to the 50% median (log2  =1) 
from each GeneChip and the for each gene. Each chip was further quality-controlled 
after normalizations, to check for relative average expression values in respect to other 
global expression values on other chips. For data presentation, normalized expression 
was transformed to log2  scale (log2  = 1 .0 , being the median) and genes are shown as 
reported in comparison to other normalized conditions as a differential log-based value.
2.10 Algorithm for GeneChip analysis
I evaluated various computational algorithms (MAS5.0, GC-RMA, dChip, and RMA) in 
order to obtain the greatest signal-to-noise ratio for the quantitative signal reported 
without compromising signal specificity. I determined that the algorithm that is chosen 
to compress the gene expression (raw probe set signal, .cel file) is critical for increasing 
sensitivity across the GeneChip. The Affymetrix GeneChip is designed to have 11 
specific ‘perfect-match’ (PM) probes, each 25-basepairs long, that span the full length 
transcript for each gene measured, weighted towards the 3’ end of the transcript
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measured. Each transcript also has 11 ‘mis-match’ (MM) probes, which are identical to 
each complementary PM probe expect for the 13th base pair is reversed. In the 
commonly used MAS5.0 algorithm (221), provided by Affymetrix, the raw probe set 
signal between the PM and MM probes is internally controlled for background noise and 
cross-hybridization. The raw probe-set signal is calculated (average difference value) 
between all 1 1  pairs and summed for the entire transcripts total probe signal using a 
common Tukey-weight equation. Importantly, the MAS5.0 algorithm flags and discards 
average value differences if less than 20% (PM -  MM), or automatically if the MM 
signal value is higher than the PM value. This feature becomes critical when evaluating 
low expressing transcripts. A more recent algorithm for GeneChip processing is the GC- 
Robust Multiarray Analysis (GC-RMA) algorithm (222, 223). The cornerstone of the 
GC-RMA approach lies in its removal of the PM/MM average difference value 
calculation and instead GC-RMA sums only the PM probe signals to determine the raw 
probe set signal. To account for background noise and cross-hybridization errors, GC- 
RMA specifies global signal differences at the specific PM probe with two variables; the 
quantitative level of GC bounds in each PM probe (theoretical sensitivity), and the signal 
at the specific PM probe across all GeneChips assayed (experimental dynamic range). 
When more than 10 arrays are compared the GC-RMA algorithm reports significantly 
higher intensity for all relative expression transcripts, especially those genes in the lower 
expression spectrum (222). We also found that the GC-RMA algorithm gave higher raw 
probe set signal (across all levels of expression) and achieves a more accurate coverage 





Figure 2.4. The GC-RMA algorithm reduces noise at low-expressing transcripts.
This figure represents a scatter plot illustrating the differences between normalization algorithms MAS 5.0 
and GC-RMA. Both plots (MAS 5.0 and GC-RMA) are generated from the same GeneChip raw images, 
and raw signal for each population is displayed for all transcripts (>45,000) (x-axis = CD25+Treg 
unstimulated, y-axis = naive unstimulated).
2.11 In  silico 11-10 gene analysis
Comparative genomic alignments and predicted transcription factor binding sites are all 
performed from the website: http://dcode.org (provided freely by the Lawrence 
Livermore National Laboratory). The 11-10 gene from the murine sequence (version: 
mm4) was used as the base sequence and aligned in http://ecrbrowser.dcode.org to other 
species available, using several vertebrate genomes available from the ECR browser and 
GALA database. The total sequence analyzed, and shown on all figures, is “-3x” zoomed 
out from the 5.12 kb coding region of the 11-10 locus (RefSeq annotation), which can be 
formatted easily in the bottom window of the ECR browser. The total sequence analyzed 
is ~15.3kb, with approximately lOkb non-coding regions shown (3’ and 5’ non-coding 
regions). The human genome alignment (blastx) is shown in the results section but other
74
species (rat and dog) have similar homology to the murine 11-10 locus. Evolutionary 
conserved regions (ECRs) between murine and human sequences are shown with default 
criteria settings: 70% homology over at >100 bp and images are exported via the 
http://zDicture.dcode.org image tool. The genome alignment portal of the ECR browser 
also permits fast automated transcription factor prediction alignments with generic 
transcription factor binding site position weight matrix’s (PWMs) (>85% confidence 
shown) as determined by the computational algorithms from http://rvista.dcode.org which 
is closely interconnected with the TRANSFEC database. The ECRs and predicted 
transcription factor binding sites in the murine 11-10 sequence are shown in the results 
section. Taken further, the individual murine 11-10 sequence and human genomic 
alignments can be further annotated and distilled by selecting the link within the ECR 
Browser labeled: “Synteny/Alignments”. Within this window you can further select 
individual sequences from other species that are shown to align with the base sequence 
(murine 11-10 locus), and directly investigate either similarity through phylogenetic 
shadowing analysis (http://mulan.dcode.org) or transcription factor binding sites 
(http://rvista.dcode.org). In this thesis, I have chosen the two sections from the human 
genome that align with the murine 11-10 locus and further investigated the conserved 
regions of both these sequences in http://rvista.dcode.org. Within the rvista 2.0 website 
you can select specific transcription factors to scan your conserved regions of multiple 
species sequence alignments. In this thesis, I show conserved sequence alignments 
between both human sequences that correspond to known and novel IL-10-associated 
transcription factors described from the results section. This data analysis was formatted 
on the http://rvista.dcode.org website and results were exported to zPicture website for
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presentation purposes. In conclusion, the entire in silico analysis was performed within 
the suite of applications available on the http://dcode.org website.
2.12 Retroviral (RV) transduction of CD4 T cells
RV-mediated transduction of investigated transcription factors into primary naive CD4 T 
cells cultured in various cell-type specific media is described here. Firstly, the cloned 
gene (cDNA) of interest is inserted into a SV40-promoter driven expressing vector that 
conveniently, contains a bicistronic IRES inserted between the gene of interest and the 
eGFP-reporter tag. On day 0, the packaging cell-line PLAT-Es were plated in 6 -well 
plates in DMEM media (w/ 10% FCS) for a cell-confluence of around 75%. On day 1, 
FuGene (lipofectamine-based transfection reagent) (Invitrogen) (96pl) and the specific 
SV40-driven expression vector with your gene of interest ( 4 jll1 from 1 mg/ml 
concentrated stock) are mixed in DMEM (FCS-ffee) according to manufacturers 
requirements. Then from the stock solution, 100 pi of this solution is added drop-wise to 
each well of PLAT-E packaging cells and gently mixed by hand for five minutes. Day 2, 
media is gently aspirated from the PLAT-Es and replaced with 1 ml of DMEM (w/ 10% 
FCS) and the packaging cells are returned to the incubator. Further, on Day 2 naive CD4 
T cells are MoFlo isolated and stimulated in normal conditions (neutral, Thl, Th2, etc.) 
described above. Day 3, PLAT-E media containing the RV is gently collected and 
pooled. PLAT-E media is replaced with 1 ml of DMEM (w/ 10% FCS) and returned to 
the incubator. Aspirated, pooled RV media is spun at 13,000 rpm for 45 minutes at 4°C. 
Concentrated RV is collected, (bottom 1/3 of volume from spin) and added drop-wise to 
CD4 T cells. Additionally, IL-2 is added to CD4 T cells at a corresponding concentrated
amount to achieve normal 5 ng/ml concentration for total volume. Day 4, PLAT-E media 
containing the RV is gently collected and pooled (same procedure as Day 3). Aspirated, 
pooled RV media is spun at 13,000 rpm’s for 45 minutes at 4°C. Concentrated RV is 
collected, (bottom 1/3 volume from spin) and added drop-wise to CD4 T cells. No 
additional IL-2 is required on Day 4. Day 5, cells should be split 1:2 and removed from 
OC-CD3/CD28 conditions (a portion of the cells can be checked here via FACS for 
transduction efficiency, GFP+). Media conditions are according to respective population 
conditions (Table 1) except IL-2 is supplemented (5 ng/ml). CD4 T cells are 
differentiated for 7 days in the respective population conditions and cytokine production 
is measured by ICS upon re-stimulation. RV-mediated transduction efficiency varies 
from experiment to experiment but usually 10-30% transduction was achieved with 
higher percentages in both Thl and Th2 driven conditions (probably due to higher cell- 
cycle rates). For RNA preparation and ELISA, transduced cells are further purified by 
MoFlo isolation based on bicistronic eGFP expression.
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PLAT-E cells CD4 T cells
Day 0 -P late PLAT-E in 6 well p lates (2 x  10s per well)
•Use 2 ml of media per well
(media = 10% FCS in DMEM w/ no AB)
Day 1 -Add 100 ml total of mix into each  well (add dropwise): 
(2ml) vector w/  GFP and gene of interest 
(6 ml) FuG ene
(92 ml) DMEM (no FCS. no AB)
"Use m anufactures recom m ended step s  for mixing
Day 2 W ash media from well and add 1 ml of fresh DMEM w/ no AB media. -FACS Sort CD4 T cells and plate a t 1 x  10s cells per well in 24-well plates.
-U se 1 ml VT in each  well under normal day 0 plate-bound 
aC D 3 (10 ng/ml) soluble aCD 28 (2 ng/ml) conditions 
-Use regular media for T cells (cRPMI)
Day 3 Collect m edia from PLAT-Es and spin a t 13,000 rpm for 45 minutes. Rem ove top 800 ml and collect the bottom 200 for 
transfer to  T cells. Add 1 ml of fresh DMEM w/ no AB into 
each  PLAT-E well for 2 nd round transfection.
-Add 200 ml of concentrated PLAT-E supernatant per well 
and IL-2 (5 ng/ml)
Day 4 Collect m edia from PLAT-Es and spin a t 13,000 rpm for 45 minutes. Rem ove top 800 ml and collect the bottom 200 for 
transfer to  T cells. Discard PLAT-E cells
-Add additional 200 ml of concentrated PLAT-E 
supernatant per well and IL-2 (5 ng/ml)
Day 5 Move T cells and media. Split accordingly (usually 1:2). M easure transduction via FACS (GFP+).
Figure 2.5. Schematic of the key points during the RV process.
This schematic highlights the parallel cell culture system key points during the first six-days. PLAT-E cells 
represent the packaging cell-line used to generate the high-titer viral supernatant and CD4 T cells are 
representative o f the transduced population of cells.
2.13 Chromatin accessibility by real-time (ChART)-PCR assay 
IL-4(-/-) or WT naive CD4 T cells were transduced with a “transcription factor of 
interest’’-RV and a Mock retrovirus or cultured under normal Th condition and chromatin 
were isolated from unstimulated cells and non-digested or digested with 1.0 or 2.5 pg/ml 
of DNase I (Sigma) (224). For the digestion process cells are pelleted and washed with 
ice-cold PBS. Cells are re-suspended in 5-ml of ice-cold reticulocyte standard buffer 
(RSB), avoiding clumps. Lysis buffer (0.5% NP-40 in RSB), 3-ml, is added, mixed and 
cells are placed on ice for 5 minutes. Ice-cold RBS is then added to Vt= 50-ml, and 
spun-down at 1,100 rpm for seven minutes at 4°C. Supernatant was discarded and pellet
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is re-suspended in 1-ml ice-cold RBS. Three tubes for either un-treated, 1.0- or 2.5- 
pg/ml of DNase I is prepared here, each tube with 1 jllI  of CaCk and 100 |il of ice-cold 
cells in RBS. At 37°C the incubation last four minutes for untreated, 1.0-, or 2.5-p.g/ml 
DNase I digestion and an example is illustrated in Table 2 (mixing vial contains DNase I 
at 0.5 pg/ml).
Table 2.2 DNase I digestion timetables, with the appropriate concentrations of DNase I. Time o f addition 
correlates to the time-point when DNase I (0.5 pg/ml) is added and time o f stopping correlates to addition 





Time of addition Time of stopping
0 0 0 4 minute
1.0 0.2 1 minute 5 minutes
2.5 0.5 2 min. 30 sec. 6 min. 30 sec .
The 100-ml stop solution contains: 12 ml of 5 M NaCl, 2 ml of 1 M Tris pH 8.0, 2 ml of 
0.5 M EDTA, 10 ml of 10% SDS, and 74 ml of H2 O. After stopping the reaction PK (70 
pg) is added per tube and the tubes were then incubated at 56°C overnight. The 
following morning the DNA is extracted with a normal phenol extraction with EtOH and 
re-suspended in the appropriate volume (1 pg/ml) of TE.
The digested DNA was purified and 10 ng used as template for real-time PCR 
amplification with specific oligonucleotides (primers) and SYBR green as described in 
qPCR studies. Primers were designed throughout the 11-10 locus under criteria discussed 
in the results (and according to PrimerExpressv2.1 annealing guidelines). Each set of 
primers was designed to have an optimal amplicon of 100 bp. Each primer set had to be 
further quality controlled upon arrival and further normalized by generating a standard 
curve (Ct values) via amplifying known amounts of template genomic DNA
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(1,2,3,4,5,6,7,8,9,10 nanograms o f DNA) with the corresponding set o f primers. These 
standard curves were used to convert experimental Ct values for untreated and DNase I- 
treated biological samples to absolute amount o f PCR product obtained in each condition. 
In accordance with previous reports (225) the absolute amounts o f PCR products were 
used to calculate the percentage o f chromatin accessibility. The reported % Chromatin 
Accessibility was calculated for each primer pair with the following equation: [(No 
DNase I (gDNA)-DNase I (gDNA))/No DNase I (gDNA)]*100%. Following this calculation, 
when a particular site is exposed to DNase I digestion, less absolute amount o f PCR 
product is obtained with primers that span that site, and this will be reflected in a higher 
percentage o f chromatin accessibility.
2.14 Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed with unstimulated or stimulated primary CD4 T cells (lh  in 
the presence of PMA/Ionomycin) (226) (115). Cells were fixed by adding 1/10 volume 
of 10% formaldehyde in the fix solution (0.1 M NaCl, 1 mM EDTA, 0.5 M mM EGTA, 
50 mM Hepes, pH 8.0). Cells and fix solution were mixed well and left for 10 minutes. 
Following fixation, a stock solution of glycine was used to adjust the final concentration 
in the cell sample to 125 nM glycine. Wait 5 minutes. Cells were harvested and washed 
with ice-cold PBS and re-suspended in 10-ml of lysis buffer (0.25% Triton-X, 0.5% NP- 
40, 10 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl pH 8.0, and 1 tablet of protease 
inhibitor cocktail, PIC). Cells and lysis buffer were placed on ice and swirled briefly for 
10 minutes. After 10 minutes nuclei was pelleted (1,500 rpm for 5 min,) and re­
suspended in post-lysis buffer (0.2 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris-
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HC1 pH 8.0, and 1 tablet of protease inhibitor cocktail, PIC). Nuclei was pelleted (1,500 
rpm for 5 min,) and re-suspended on ice in sonic buffer (1 mM EDTA, 0.5 mM EGTA, 
10 mM Tris-HCl pH 8.0, and 1 tablet of protease inhibitor cocktail, PIC). Samples were 
sonicated up to lOx with a 20-second constant burst. Between each burst the suspension 
was cooled on ice for 1 minute. The average fragment size was achieved to be between 
0.3-1 kb. Debris was removed after sonication steps by spinning in a clinical centrifuge 
(speed 4) for 10 minutes. Supernatant was transfer to another 50-ml falcon tube and 
pellet was discarded.
Chromatin extracts were precleared for 2h at 4°C with salmon sperm-blocked protein A 
beads (Amersham) overnight. Immunoprecipitation (IP) was performed by diluting the 
chromatin sample in RIPA buffer (1% Triton-X, 0.1% Na deoxycholate, 0.1% SDS, 140 
mM NaCl, PIC) and adding 5 micrograms of the appropriate antibody (GATA-3, 
acetylated histone H3, etc.) in 0.5-ml, Vj. Complexes were incubated overnight at 4°C. 
Meanwhile, Protein A Sepharose beads were washed twice in RIPA buffer and incubated 
with sonicated salmon sperm DNA (0.1 mg/ml, final concentration), overnight at 4°C. 
The following morning, DNA-protein complexes were recovered by adding 20 pi of the 
pre-cleared Protein A Sepharose beads for three hours (4°C). After the incubation, 
immunoprecipitates are wash thoroughly (7x) in 1-ml of RIPA wash buffer (1% Triton- 
X, 0.1% Na deoxycholate, 0.1% SDS, 500 mM NaCl). Each wash was done at 8,000 rpm 
for 1 minute and supernatant was aspirated carefully leaving beads intact. After the final 
wash, the beads were re-suspended in 150 pi of H2 O add adjusted to 0.5% SDS (add 5 pi 
of 10% SDS). Proteinase K was added to a 0.2 mg/ml final concentration and incubated
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for three hours at 55°C. Then incubate overnight at 66°C, in order to reverse the 
formaldehyde cross-linking. The following morning, the samples were extracted with 
phenol/chloroform, and then chloroform. Finally, ethanol precipitates the samples with 
NaOAc and 20 pg glycogen as the carrier. The samples were washed twice with ethanol, 
and resuspended in 50 pi of H20. Immunoprecipitated DNA was used as a template for 
real-time PCR with specific oligonucleotides for the 11-10 locus and the IL-5 promoter. 
Ct values for GATA-3 (or antibody of interest) and control antibody (anti-rabbit IgG) 
were normalized to the input Ct (with same primer pair) from the same sample 
preparation, and the GATA-3 versus control ratio was reported using the same formula as 
relative gene expression results (qPCR).
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RESULTS
3. Profiling CD4 T cell populations
Six primary derived CD4 T cell populations (naive, neutral, Thl, Th2, IL-10-Treg, 
CD25+Treg) were generated (ex vivo or in vitro) for analysis of both 11-10 gene regulation 
and CD4 Treg-mediated functional properties. The six populations of CD4 T cells chosen 
for this study represent a homogeneous repertoire of populations that exist in the 
peripheral T cell compartment of a host: naive T cells, effector Th cells, and Treg. In this 
Chapter, I have used the Affymetrix Mouse 430v2.0 GeneChip to profile their transcript- 
ome. Affymetrix GeneChips were chosen for two general reasons: (1) extensive 
coverage of the murine transcript-ome (>45,000 transcripts) and (2) confidence in 
reproducibility achieved through high manufacturing quality-control features and 
multiple probes (11) for each transcript (for more information refer to the Materials and 
Methods). One limitation in GeneChip experiments is the investment in both money and 
time and therefore one time-point was chosen for the stimulated condition. The kinetics 
(1 hr -  24 hr) of both cytokine and transcription factor expression was initially evaluated 
via qPCR and the 6 hour time-point was chosen as the profiled “stimulated” time-point. 
In conclusion, the GeneChip profile for each population was resting state and activated 
state (6 hours after stimulation via the TCR pathway).
CD4 T cells are also profiled here for expression of transcription factors outlined in 
regulation of effector and regulatory populations and their products and function 
(Introduction). The transcription factor expression profiles are described by their 
population-specific mRNA up-regulation, but also strongly chosen as a focus by the 
absence or low-abundance expression in other CD4 T cell populations. Also of note in
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this chapter, I describe side-by-side activation of two different well-described CD4 T cell 
TCR-pathway stimuli, PMA/ionomycin and plate-bound a-CD3/soluble a-CD28, in 
terms of their subsequent cytokine profiles (mRNA and protein). Importantly, each 
population was stimulated in parallel with either PMA/ionomycin or a-CD3/CD28 to 
eliminate non-stimuli specific variables. PMA/ionomycin stimulation is widely used as a 
method to stimulate CD4 T cells; however this stimulus bypasses TCR and co­
stimulation regulated signaling. Therefore, validation (qPCR) was performed via an a- 
CD3/CD28 stimulus, mediated via the extra-cellular receptor (more representative of 
APC:TCR interactions), which consequently induces TCR-pathway activation in the 
context of co-stimulators. Finally, this chapter validates the homogeneous nature of each 
CD4 T cell population through their unique cytokine and transcription factor profiles as 
well as setting the stage for their use in subsequent result chapters. The classic cytokine 
and hallmark gene expression markers from each individual population are profiled here.
3.1 CD4 T cell populations have unique cytokine profiles
3.1.1 Protein
CD4 T cell populations were stimulated for 48 hours in cytokine/antibody-free media 
with either soluble PMA/ionomycin or plate-bound a-CD3 and soluble a-CD28 (Fig.
3.1). Each population was stimulated in the absence of cytokines, APCs, and at a 
universal concentration/confluence. The protein concentration was detected using the 
Luminex multi-plex (xMap) system and shown here in Figure 3.1. The cytokines are 


































Figure 3.1. Cytokine production in CD4 T cell populations.
Cytokine protein concentration levels were measured with the Luminex xMap bead assay. Antibody- 
coated beads were acquired from UpState signaling. Results are a representation from one well (96-well 
plate) for each stimulus (a-CD3/CD28 or PMA/ionomycin) measuring 9 cytokines simultaneously for each 
CD4 T cell population. Standard curves for each cytokine were generated from standards supplied by 
UpState Signaling. This figure is representative o f at least 3 biological replicates.
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IL-2, IL-3, and TNF are labeled in Figure 3.1a to signify their presence in effector and 
naive populations. IL-2 production was more prominent in the naive and neutral 
populations, IL-3 production more specific to effector populations, and TNF production 
shared to some degree between naive and effector populations. As predicted, IFN-y is 
exclusively produced by Thl cells and represents a unique profile as opposed to the other 
analyzed cytokines here (Fig. 3.1b). IL-10 production is produced at high concentrations 
in both the Th2 and IL-10-Treg populations, and relatively low concentration production 
in Thl cells (Fig. 3.1c). IL-4, IL-5, IL-6, and IL-13 are produced predominately by the 
Th2 cells and low concentration amounts of IL-4 and IL-5 in the IL-10-Treg (Fig. 3.Id). 
Both stimuli (PMA/ionomycin versus a-CD3/CD28) induce similar cytokine profiles; 
however some cytokines (TNF, IL-6 and IL-13) were detected with slightly higher- 
concentration amounts with PMA/ionomycin versus a-CD3/CD28 TCR triggering. In 
summary, protein profiles of proliferative, effector and regulatory cytokines confirm 
homogenous populations and both TCR-activation induce similar protein profiles within 
each CD4 T cell population.
3.1.1 Affymetrix GeneChip Profiles
Each CD4 T cell population was profiled for their representative gene expression 
profiles. Total RNA was isolated at the corresponding time-points and mRNA was 
further processed to a representative target cRNA for hybridization on the oligo-based 
GeneChip. The GeneChip data was processed with the GC-RMA algorithm to determine 
the quantitative abundance of each transcript (>45,000). Each individual GeneChip is 
further normalized with respect to the collective GeneChips quantitative signal and the
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final individual transcript-abundance is profiled with the Genespringv7.0 application. I 
have generated various differential expression profiles and I will begin with a parallel 
expression profile Figure 3.2 corresponding to the protein profiles in Figure 3.1 in 
stimulated conditions.
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Figure 3.2. Profiling key cytokines in stimulated CD4 T cells.
GeneChip profiles for signature CD4 T cell cytokines (stimulated condition, 6 hr. post-TCR pathway 
activation). Cytokines are displayed in an unsupervised hierarchical cluster format. The GeneChip image 
was compressed with the GC-RMA algorithm and normalized values (log2) are shown within each 
rectangle. More information is available in Materials and Methods for the computational details.
GeneChip profiles in Figure 3.1 parallel the protein results shown in Figure 3.2.
Differential expression values for individual transcripts are normalized to a medium
logarithmic value, 1.0. The vertical progression of each transcript is the result of an
unsupervised hierarchical clustering technique (as described in the Materials and 
Methods). IL-2 and TNF are up-regulated in naive and effector populations, whereas, IL- 
3 is up-regulated in effector populations (Fig. 3.2). IFN-y forms a unique cluster with up- 
regulation on activation in the Thl population and slight up-regulation in IL-10-Treg (Fig.
3.2). Th2-associated cytokines, IL-4, IL-5, IL-13, cluster together with high differential 
up-regulation in Th2 cells and slight up-regulation in IL-10-Treg (Fig. 3.2). Finally, 
significant and differential up-regulation of IL-10 in both Th2 and IL-10-Treg populations 
(Fig. 3.2) correspond with the IL-10 protein results in Figure 3.1. Confirming protein 
results, CD25+Treg do not differentially up-regulate cytokine transcripts (Fig. 3.2). 
GeneChip data illustrates the individual low-abundance of cytokine transcripts in naive, 
neutral, and CD25+Treg as compared to Thl and Th2 high-abundance levels (Fig. 3.2). In 
a similar fashion, Thl and Th2, clearly cross-regulate the cytokine expression of their 
corresponding hallmark cytokines, IFN-y and IL-4, respectively, in keeping with previous 
reports (Fig. 3.2) (4, 5).
3.1.1 qPCR profiles
Figure 3.3, shows key cytokines validated from the GeneChip profiles with real-time 
quantitative PCR (qPCR) at the corresponding time-point, 6 hours after stimulus. Both 
pathway of stimulation are included in the qPCR data (Fig. 3.3a and 3.3b). The relative 
amount of expression between populations for individual cytokines shown here does not 
vary with stimulus. The qPCR cytokine results are in agreement with the cytokine 
protein results, in that either stimuli will induce a similar quantitative cytokine profile 
(mRNA and protein). Together, the qPCR results verify the differential mRNA results
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acquired via the GeneChip (Fig. 3.3) and provide a quantitative relative expression value 
to compare across the CD4 T cell populations.
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Figure 3.3. qPCR validation of key cytokine in CD4 T cell populations.
Real-time reverse transcriptase PCR (qPCR) for selected cytokine genes, (a) CD4 T cells were stimulated 
with (X-CD3/CD28, mRNA collected at 6 hr. post-TCR activation, converted to cDNA and qPCR was 
performed with primers and SYBR Green mix to measure relative expression of labeled cytokine 
transcripts on the ABI Prism 7000. (b) CD4 T cells were stimulated with PMA/Ion, mRNA collected at 6 
hr. post-TCR activation, converted to cDNA and qPCR was performed with primers and SYBR Green mix 
to measure relative expression of labeled cytokine transcripts on the ABI Prism 7000. Three biological 
samples were used to generate the displayed relative expression value for each transcript, and standard 
deviation (+/-) was calculated as shown.
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3.2 Signature Transcription Factors in Effector Th and CD25+Treg
Similar to the previous GeneChip cytokine transcript profiles (Fig. 3.2), key transcription 
factors are profiled here. Transcription factors were chosen here as outlined within the 
“Introduction” section as being essential in differentiating effector and CD4 Treg 
populations. Specifically, T-bet, Ets-1, Hlx are profiled here for their regulation of the 
Ifn -y  gene, GATA-3, c-Maf, GFI-1, for regulation of Th2-associated genes, and the 
lineage-specific transcription factor for CD25+Treg, FoxP3. Transcription factors profiled 
below are only shown at the unstimulated time-point. This was done for three reasons. 
Firstly, each transcription factor is regulated at its own locus via different mechanisms 
after TCR-mediated stimulus. Secondly, the range of kinetics for optimal transcription 
after stimulus is variable between transcription factor genes (whereas, the cytokine genes 
were similar at the 6 hr. time-point) and therefore the stimulated GeneChip data may not 
demonstrate the ideal time-point for up-regulation for each transcription factor. Thirdly, 
the achieved function of each of these profiled transcription factor genes occurs before 
secondary TCR triggering or very shortly after TCR-pathway stimulus and is a hallmark 
of each differentiated CD4 T cell population. Thus, their differential expression profile 
will be profiled at the unstimulated time-point.
3.2.1 Affymetrix GeneChip profiles
Key CD4 T cell transcription factors are profiled here (Fig. 3.4).
91








Drflerenlliil Expression (lag i(
B 'H
0 .5 -------  ► 4.0
Figure 3.4. Profiling key transcription factors in CD4 T cell populations.
GeneChip profiles for signature CD4 T cell transcription factors in CD4 T cells. The GeneChip image was 
compressed with the GC-RMA algorithm and normalized values (log2) are shown within each rectangle. 
More information is available in Materials and Methods for the computational details.
Figure 3.4 demonstrates Thl, Th2 and CD25+Treg express the signature transcription 
factors T-Bet/Ets-l/Hlx (Thl); GATA-3/c-Maf/GFI-l (Th2); FoxP3 (CD25+Treg), 
respectively. IL-10-Treg population express low levels of both Thl- and Th2- associated 
transcription factors: T-Bet, Hlx, GATA-3, and c-Maf; however GFI-1 and not 
surprisingly FoxP3 (174) are not detected in IL-10-Treg by GeneChip (Fig. 3.4). 
Furthermore, the CD25+Treg express low amounts of T-Bet, GATA-3, c-Maf and GFI-1 
(Fig. 3.4). Lastly, the transcription factors T-bet and GATA-3/c-Maf are highly cross­
regulated in both Th populations, which mirrors the high cross-regulation of their target 
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Transcription factors shown in Figure 3.4 were validated by qPCR to show quantitative 
levels of expression was similar to the differential levels of expression reported via the 
GeneChip. Together, the qPCR results (Fig. 3.5) shown below verify the differential 
mRNA results acquired via the GeneChip (Fig. 3.4) and provide a quantitative relative 
expression value to compare across the CD4 T cell populations.
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Figure 3.5. qPCR validation of key transcription factors in CD4 T cell populations.
Real-time reverse transcriptase PCR (qPCR) for signature CD4 T cell transcription factors in CD4 T cells 
(same as Figure 3.4). mRNA was isolated from unstimulated CD4 T cells, converted to cDNA and qPCR 
was performed with primer/probes acquired from ABI (inventoried: assay-on-demand) and mastermix 
(ABGene) was used to measure relative expression o f labeled transcription factor transcripts on the ABI 
Prism 7900. This figure is representative o f at least 3 biological replicates.
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3.3 Discussion
Six populations of ex vivo and in vitro generated CD4 T cell populations were profiled to 
represent phenotypic CD4 populations that could exist in the peripheral-host environment 
after immune challenge with various pathogens, allergens or other antigens (5). The 
cytokine and transcription factor profiles shown here demonstrate that each CD4 T cell 
population is phenotypically different as described by their cytokine profile (mRNA and 
protein) after TCR-pathway stimuli and transcription factor profile (mRNA) at the 
unstimulated time-point. The differentiation process of naive CD4 T cells towards T 
helper cell populations is necessary for expression and production of key effector- 
molecules: cytokines. This process is mediated by highly-regulated intrinsic signaling 
which up-regulates expression of necessary transcription factors essential in cytokine 
gene regulation. These key transcription factors were profiled here at the unstimulated 
time-point and for cytokines after stimuli. As expected the CD4 T regulatory populations 
express or produce little to no effector-mediated cytokines, although as expected IL-10- 
Treg produced IL-10. However, within the CD4 Treg, IL-10-Treg and CD25+Treg differ in 
their respective amounts of FoxP3 expression, which has been shown to induce strong 
regulatory properties as demonstrated by its transduction into naive CD4 T cells (122, 
124). This suggests that IL-10-Treg acquire their regulatory phenotype without the 
expression of the lineage-specific “natural-occurring” CD4 Treg marker FoxP3 as 
described (discussed later) (174). This section also validates the level of confidence to 
which we can compare the GeneChip generated mRNA profiles to quantitative qPCR 
generated mRNA profiles, for both the high-expression transcripts (cytokines) and low- 
expression transcripts (transcription factors). In summary, this chapter validates the
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homogeneous, phenotypic profile of each CD4 T cell population while confirming the 
ability to compare cytokine mRNA profiles (GeneChip or qPCR) to protein profiles 
(Luminex) for either PMA/ionomycin or (X-CD3/CD28 TCR-pathway stimuli as the basis 
of the future studies in this thesis.
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4. IL-10-associated transcription factors in CD4 T cells
The 11-10 gene can be regulated by several transcription factors as demonstrated by 
studies performed in various cell-types (mostly cell-lines); however a universal 
understanding of 11-10 gene regulation is not yet clear, especially in terms of IL-10- 
producing CD4 T cells. A section of literature has shown enhancement of 11-10 gene 
transcription using dual-transfection of (1) the minimal 11-10 promoter region (proximal 
5’ region, ~ 1.5 kbp) and (2) specific transcription factors (Spl (118, 227), Sp3 (227), c- 
Maf (116) and c/EBP-p {Liu, 2003 #137}) which induce increased IL-10 expression. 
These studies further showed each transcription factor bound putative sites within the 
proximal IL-10 promoter as demonstrated when these sites were mutated the 
corresponding IL-10-enhancing transcription were reduced in the dual-transfection 
studies (performed in cell-lines). Additional 11-10 gene regulation studies use 
transfection or transduction of transcription factors (c-Maf (116), SMAD-4(117), c-Jun 
(112) and JunB (112)) into primary immune cells to induce IL-10 expression upon 
stimulus. Conversely, two transcription factors (Ets-1 (72) and NFATc2 (114)) have 
been implicated in repression of IL-10 expression. Many questions remain in terms of II- 
10 gene regulation especially at the molecular level.
Therefore, I will start the analysis of 11-10 gene regulation by comparing global 
expression profiles of two phenotypically different CD4 IL-10-producing populations 
(Th2 and IL-10-Treg) versus four non-IL-10-producing CD4 T cell populations (naive, 
neutral, Thl, CD25+Treg). Thl cells transcribe and produce small amounts of IL-10 upon 
stimulus; however for our purposes here I will initially consider Thl cells to be a “non”-
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IL-10-producing population in the global expression-profiling studies. To increase the 
computational sensitivity and specificity from the GeneChip data, I have included 
populations of non-IL-10-producing CD4 T cells at different levels of CD4 
differentiation and secondly utilized computational techniques (GC-RMA algorithm) to 
amplify signal-to-noise levels of low-expressing transcripts from the GeneChip 
(transcription factors inherently express low quantitative levels of transcripts in 
comparisons to other gene families). I will establish criteria to filter all possible 
transcription factors (transcriptions factors are defined from gene ontology (GO) 
classification as “DNA-binding genes”). Any of these may be involved in 11-10 gene 
regulation in CD4 T cells based upon their mRNA profile. The general assumption 
being, I will be able to identify novel and major instructive transcription factors involved 
in 11-10 gene regulation because such transcription factors will be differentially expressed 
in IL-10-producing CD4 T cell populations versus a robust panel of non-IL-10-producing 
CD4 T cell populations.
4.1 Known IL-10 associated transcription factors
Multiple transcription factors have been reported to regulate 11-10 gene expression as 
described through their corresponding studies above. Since the mechanism for some of 
these transcription factors, in terms o f 11-10 gene regulation, is not yet clear I will profile 
both unstimulated and stimulated time-points. “Known” transcription factors that may 
enhance or repress IL-10 production are profiled here by their mRNA expression in both 
non-IL-10-producing and IL-10-producing CD4 T cells (Fig. 4.1).
97
Known IL-10 transcription factors in CD4 T cells
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Figure 4.1. Profiling known IL-10-associated transcription factors in CD4 T cell populations.
GeneChip profiles for known IL-10-associated transcription factors in CD4 T cells. The GeneChip image 
was compressed with the GC-RMA algorithm and normalized values (log2) are shown within each 
rectangle. More information is available in Materials and Methods for the computational details.
Transcription factors Spl and Sp3 are expressed in all CD4 T cell populations (data not
shown, qPCR) and not exclusively expressed in IL-10-populations (Fig. 4.1).
Interestingly, c/EBP-fi and c-Maf are differentially up-regulated in unstimulated IL-10-
producing populations, and c-Maf is differentially up-regulated exclusively in IL-10-
producing populations (IL-10-Treg and Th2) (Fig. 4.1). Jun family members, c-Jun and
JunB, are shown here to be expressed in many CD4 T cell populations; however both c-
Jun and JunB become up-regulated in IL-10-producing populations in stimulated
conditions (Fig. 4.1). SMAD-4 is not differentially expressed in IL-10 producing
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populations, but is up-regulated to a small extent in CD25+Treg (Fig. 4.1). Potential IL-10 
repressors: NFATc2 (114) is up-regulated in both IL-10-producers (Th2 and IL-10-Treg) 
as well as Thl cells at the unstimulated time-point (Fig. 4.1).
4.2 Novel IL-10 associated transcription factors
The expression of transcription factors exclusively expressed in IL-10-producing cells 
from the Affymetrix data is reported here. The criteria for stratifying theses “IL-10- 
associated transcription factors” are listed below.
(1) IL-10-associated transcription factors must have a minimum level of raw signal 
(>200 with GC-RMA) within the IL-10-producing populations.
(2) IL-10-associated transcription factors must be exclusively expressed above a 
minimum fold differential (>1.8 fold) in both IL-10-producing populations.
(3) The initial list of candidate IL-10-associated transcription factors includes genes 
with a known DNA-binding motif in their structure (4,000 transcripts).
I will describe three lists of IL-10-associated transcription factors, which were 
independently generated using the criteria: (1) all time-points, (2) unstimulated time- 
points and (3) stimulated time-points. It should be noted that transcription factors 
associated with IL-10-producing cells could be involved in directly down-regulating 
other cytokines absent in IL-10-producing cells; however this type of transcription factor 
can only be defined with subsequent functional studies. Figure 4.2 represents the IL-10- 
associated transcription factors isolated using the criteria above including both 
unstimulated and stimulated time-points.
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IL-10-associated transcription factors in both unstimulated and stimulated CD4 T cells
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Figure 4.2. Profiling IL-10-associated transcription factors in CD4 T cell populations.
GeneChip profiles for IL-10-associated transcription factors in CD4 T cells. The GeneChip image was 
compressed with the GC-RMA algorithm and normalized values (log2) are shown within each rectangle. 
More information is available in Materials and Methods for the computational details.
These six transcription factors are highly expressed in IL-10-Treg and Th2 cells before
and after stimulus but some are also expressed at a low-level in Thl cells (which produce
low amounts of IL-10): JDP2, PPAR-y, Asb2, and Prdml (Fig. 4.2). Transcription
factors in Figure 4.2 are down-regulated in unstimulated naive and neutral CD4 T cells.
Three of these six transcription factors, JDP2 (jun dimerization protein 2), PPAR
(peroxisome proliferative activated receptor)-y and cbp/p300 (Fig. 4.2), have been
described to some respect in their ability to mediate transcriptional activity. JDP2 was
first described to bind to c-Jun subunits and thereby suppress c-Jun ability to form active
Jun:Fos dimers (228). The functional inhibition of Jun:Fos dimers is intriguing due to the
well-described role of AP-1 (Jun:Fos) dimers in regulating cytokine genes upon TCR
activation (59). However, this is speculative because little is known about the function of
JDP2 in CD4 T cells. PPAR-y is a nuclear receptor that is activated through nuclear
ligand/receptor interactions which induces active protein-protein interactions and DNA
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binding. There is a large body of literature suggesting that activation (ligand-mediated) 
of endogenous PPAR-y in precursor mesenchymal cells activates differential gene 
expression targets and influences subsequent differentiation (229). The mechanism by 
which active PPAR-y, influences this decision-point in the precursor mesenchymal 
differentiation process is not clear (i.e.: via repression or enhancement of gene 
transcription). In CD4 T cells, two known ligands for PPAR-y, 5-deoxy-Delta 12,14- 
PGJ2 (15d-PGJ2) and ciglitazone, are described to mediate inhibition of IL-4 (230) and 
IFN-y (231) upon TCR activation. However, the mechanism for these results was not 
clear, due to mixed cultures (APCs and CD4 T cells) and the cell-specific potential 
effects of the potent ligands, 15d-PGJ2 and ciglitazone (230, 231). cbp/p300 is 
functionally classified as an important partner in the RNase II polymerase transcriptional 
machinery, but little is known about its differential expression being involved in lineage- 
dependent or target gene regulation (232). Very little is known about the general 
function or role of Asbl, Prdml, and 3526402J09Rik genes to bind putative DNA motifs 
or functionally regulate gene transcription.
In order to expand the list of possible candidate transcription factors that would correlate 
with expression of IL-10, I have generated lists of hypothetical IL-10-associated 
transcription factors by applying the same criteria in Figure 4.2 but normalizing 
GeneChip profiles at unstimulated (Fig. 4.3) or stimulated (Fig. 4.4) time-points 
independently of each other.
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Figure 4.3. Profiling IL-10-associated transcription factors in unstimulated CD4 T cell populations.
GeneChip profiles for IL-10-associated transcription factors in unstimulated CD4 T cells. The GeneChip 
image was compressed with the GC-RMA algorithm and normalized values (log2) are shown within each 
rectangle. More information is available in Materials and Methods for the computational details.
In Figure 4.3, I have isolated nineteen transcription factors by only evaluating the 
unstimulated time points from the GeneChip data. From this list I have validated (qPCR) 
six genes (four are shown in subsequent Chapters). Two genes, GATA-3 and c-Maf, 
already have been described to influence the chromatin structure and trans-activation of 
specific Th2-associated cytokine loci (40). GATA-3 and c-Maf are shown here in be up-
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regulated the Th2 and IL-10-Treg (which do not express Th2-associated cytokine genes or 
at least at a very low amount: IL-4, IL-5, IL-13) populations. We show here that c/EBP- 
p, which has been described to /raws-activate the IL-10 promoter in minimal promoter 
enhancement studies (233), to be up-regulated in resting IL-10-producing CD4 T cells. 
The unstimulated GeneChip data will serve as important means for justifying IL-10- 
producing transcription factors in the upcoming Chapters.
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Figure 4.4. Profiling IL-10-associated transcription factors in stimulated CD4 T cell populations.
GeneChip profiles for IL-10-associated transcription factors in stimulated CD4 T cells. The GeneChip 
image was compressed with the GC-RMA algorithm and normalized values (log2) are shown within each 
rectangle. More information is available in Materials and Methods for the computational details.
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Finally, Figure 4.4 reveals seventeen IL-10-associated transcription factors isolated by 
evaluating the stimulated GeneChip data independent of the unstimulated condition.
4.3 Discussion
Figure 4.4 concludes the novel IL-10-associated transcription factor search derived the 
GeneChip profiles. This Chapter represents an essential part of the search for 11-10 gene 
transcription factor regulators in CD4 T cells. Firstly, I have taken an “unsupervised” 
approach in collecting over 4,000 possible transcript profiles (based on DNA-binding 
motifs) and mined their expression profiles with a broad criteria developed to isolate 
correlating IL-10-associated expression profiles. This represents a strong hypothesis- 
driven approach to discovering novel IL-10-associated transcription factors. In general, 
the IL-10-associated transcription factors were detected in IL-10-Treg and Th2 cells both 
of which produce high amounts of IL-10 (Fig. 3.1). This process was possible because of 
the format in which GeneChip (or other mRNA arrays) generate global expression 
profiles. However, this ambitious, global, unsupervised approach has its drawbacks in 
that it can increase the probability of collecting false-positives (as well as missing false- 
negatives that do not follow IL-10-associated expression profiles). Therefore, the lists of 
IL-10-associated transcription factors will be compared to (1) literature-based 
information available on potential function (2) comparative studies involving the in silico 
evaluation of the 11-10 locus for potential putative regulatory binding sites (next Chapter) 
before they are further analyzed for functional regulation of the 11-10 gene.
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5. In silico and ChART-PCR of the 11-10 gene
The combination of publicly available bioinformatic information and increasingly robust 
computational algorithms has allowed researchers to complement hypothesis-driven lab 
research performed at the bench with an equal amount of in silico data (234). For this 
thesis I have shown select transcription factors, which are differentially up-regulated in 
IL-10-producing CD4 T cells. In order to complement this data, an independent in silico 
analysis of the 11-10 gene using computational algorithms (dcode.org) was made to 
predict putative transcription factor binding sites (motifs) throughout the 11-10 locus. 
Furthermore, by highlighting genomic sequence-specific DNA orthologs from cross­
species comparisons we can generate evolutionary conserved regions (ECRs) (235) 
which reveal conserved non-coding sequences throughout the 11-10 locus region. ECRs 
from noncoding regions of mammalian genomes are generally assumed to hold several 
keys for sophisticated gene regulation signals that determine when, where and to what 
extent lineage dependent decisions are made at the transcriptional level (235). Thus, 
using ECRs and putative binding sites in silico data will enrich the search for IL-10- 
associated transcription factors.
ECRs have also proven to add-value to labor-intensive DNase IHSS studies (234), which 
have been described as the “gold-standard” in forecasting regions of gene regulation 
(234). Promoters, enhancers, suppressors, inducible gene regulatory regions and 
generalized locus control regions (LCR) have all been associated with HSS (234). DNase 
I HSS-generated data is advantageous for our purposes because we can use different CD4 
T cell populations and assess the nucleosome-free regions of the 11-10 locus, allowing for
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identification of differentially exposed ubiquitous or lineage specific regulatory elements. 
In this study I used a highly sensitive DNase I digestion technique, chromatin 
accessibility by real-time (ChART)-PCR, to compare low-abundance IL-10-producing 
Thl chromatin and high-abundance IL-10-producing Th2 chromatin for differential areas 
of re-modeling within the 11-10 locus in unstimulated conditions. This technique 
(described in detail within the Materials and Methods Chapter) requires that the 
regulatory elements be first previously defined since PCR primers are then designed 
flanking the regulatory elements. In summary, freely available comparative genomic 
with predictive transcription factor binding sites programs will help profile the 
evolutionary content and lab research performed at the bench by the DNase I digestion 
ChART-PCR technique will define the architecture of the 11-10 locus in differential IL- 
10-producing populations. Together, these studies help select transcription factors to 
pursue in functional studies.
5.1 Predicted transcription factor binding sites
To analyze the 11-10 locus in silico I have selected -15.4 kbp of the IL-10 murine 
sequence (chrl: 130884907-130900284) which includes approximately 5 kbp upstream 
and downstream of the 11-10 coding region (5.12 kbp). Initially, the analysis of this 
sequence for putative transcription factor binding sites (with default settings) using a 
complete list of predicted transcription factor matrixes over 8,200 transcription factor 
binding sites are predicted (data not shown, rvista.dcode.org). A more supervised 
approach is performed by selecting regions of potential regulatory regions through 
analyzing ECRs (234). ECRs are identified by blastx alignment of (1) the 11-10 gene
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from a base sequence and (2) whole genomes from multiple other species. ECRs in this 
thesis are identified by having at least 70% identity over a span of at least 100 base-pairs. 
For the purpose of this study I will show the alignment of the mouse (base sequence) to 
human genome. This result is shown in Figure 5.1a. Figure 5.1b further predicts 
transcription factor binding sites (corresponding to the murine genomic sequence) in the 
identified ECRs.
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ECRs within the 11-10 locus (m ouse versus human)
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Figure 5.1. ECRs within the mouse and human 11-10 locus and ECR-associated predicted 
transcription factor binding sites.
(a) 11-10 gene alignment between the murine (base sequence) and human sequence. Homology is shown as 
a smooth dot plot with the range from 50% to 100% sequence-specific homology over a sliding 100 bp 
window in corresponding locus regions (color-coded, legend appears on the left-side of the Figure), (b) 
Predicted (rvista.dcode.org) transcription factor binding sites are shown (>85% confidence limit) from 
ECRs generated from a blastx alignment o f the 11-10 gene (mouse) and the complete human genome.
One striking feature of Figure 5.1b lies within intron 4, where a high degree of conserved
transcription factor putative motifs and two conserved TATA boxes proximal to intron 5
are predicted. Both these observations suggest that this location could provide regulatory
capacity for the 11-10 gene (discussed more later).
A higher degree of biological confidence is demonstrated in Figure 5.2, where ECRs and 
predicted transcription factor sites are only shown for locally highly conserved regions 
between species. In this prediction model the computational program (rvista.dcode.org) 
only reports select putative transcription factors: (1) the conserved murine and human 
regions must share a sliding window of least 20 bp of 80% homology and (2) the core 
transcription factor binding motif must be 100% conserved between species. Finally, 
only the “known” and “novel” IL-10-associated transcription factors (as defined from the 
previous chapter) are included in the hypothetical list of surveyed transcription factor 
binding motifs.
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Figure 5.2. ECRs and IL-10-associated transcription factors binding sites.
(a) Murine and human 11-10 locus alignment and the corresponding IL-10-associated transcription factors 
binding sites (color-coded, legend appears on the left-side o f the Figure) within ECRs. (b) Murine 11-10 
locus alignment with a highly conserved non-coding sequence outside o f the human 11-10 locus and 
corresponding IL-10-associated transcription factors binding sites (color-coded, legend appears on the left­
side o f  the Figure) within ECRs.
From the “known” and “novel” list of IL-10-associated transcription factors, c/EBP-p is 
exclusively predicted to bind in the 5’ region of the conserved 11-10 gene sequences 
(Figure 20a). AP-1 binding sites are conserved within intron 3 and two non-coding 
sequences in the 3’ region. v-Maf (c-Maf homologue) and SMAD-4 are shown to 
putatively bind to intronic regions. A consensus NFAT binding site (114) and Ets-1 
binding site (72), which have both been speculated to repress 11-10 transcription, are 
shown to bind to two separate intronic and 3’ regions of the 11-10 locus, respectively.
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Interestingly, one NFAT:AP-1 composite site is conserved (intron 3), one singular NFAT 
is conserved (intron 4), and one singular AP-1 site is conserved (3’ region). GATA-3 is 
shown here to bind to a conserved region of DNA that is not shared within the human II- 
10 locus (Fig. 5.2b), but is shared with a consensus human genomic region 7 Mbp 
downstream (chrl:203324447-203339128) of the human 11-10 gene (chrl :27322548- 
27323066). Interestingly, the piece of homologous human DNA, which has a strong 
conserved GATA-3 putative binding site and the alignment of the murine 11-10 gene to 
human sequence fits “perfectly” with the non-conserved region of (intron 4) murine 
versus human 11-10 loci alignment. According to this model, Spl, Sp3, and c-Maf 
(within the proximal IL-10 promoter) would not be predicted to bind and enhance 11-10 
expression; however each has been demonstrated to enhance 11-10 transcription via 
specific-binding sites at the murine IL-10 promoter (116, 118, 227). This is a recognized 
limitation of the computational conserved putative binding site model employed here. 
Together, the combination of the two separate human genomic sequences 
(chrl:203324447-203339128, chrl :27322548-27323066) in sequence alignments with 
the murine 11-10 gene predicts putative binding sites for IL-10-associated transcription 
factors.
5.2 ChART-PCR: defining regulatory regions in the 11-10 locus
The prediction of HSSs can be supplemented with ECR analysis and/or by using 
information from previous studies that reported site-specific DNase I digestion via 
Southern blot. In our case we have used information from a comprehensive study 
performed in the lab (115), and additionally by review of ECRs within the 11-10 locus
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performed in silico. In summary, primary Th cell populations were differentiated and 
ChART-PCR was performed to identify areas of chromatin re-modeling across the 11-10 
locus.
Chromatin accessibility studies are designed to access whether genomic regions of 
chromatin are “highly” sensitive to DNase I digestion (more so than Southern blots) and 
therefore suggested to be re-modeled (or nucleosome-ffee) and consequently exposed 
to/or directly by transcription factors. Southern blots are classically described as the 
method to describe DNase I digestion regions throughout a probed locus; however 
Southern blots require high-amounts of cells and lack the specificity achieved with 
ChART-PCR which utilizes PCR primers. ChART-PCR technique requires specific 
oligonucleotides to be designed across predicted regions of target chromatin that might be 
probed for DNase I digestion. Each primer pair (or set) (labeled on Figure 5.3 for the II- 
10 locus) was used to amplify (qPCR) 10 ng of genomic DNA from untreated or DNase
I-treated chromatin samples. As an example, in Figure 5.3a I have labeled the 11-10 locus 
and HSSs assayed with PCR primers and a sample graph with raw Ct curves generated 
from a qPCR experiment using both a DNase I-untreated sample and DNase I-treated 
sample from either Thl or Th2 chromatin the primer set spanning HSS-0.860 (Fig. 5.3b). 
A standard curve was generated by amplifying known amounts of template genomic 
DNA with each set of primers and these standard curves are used to convert our Ct values 
for untreated and DNase I-treated samples to absolute amount of PCR product obtained 
in each condition (Fig. 5.3c). In accordance with previous reports (225) the absolute 
amounts of PCR products were used to calculate the percentage of chromatin
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accessibility (Fig. 5.3d) at specific sites within the 11-10 locus. In summary, when a 
particular site is exposed to DNase I digestion a higher raw Ct value is measured in the 
DNase I treated sample (Fig. 5.3b.), this leads to less absolute amount of PCR product 
being calculated when compared to the untreated sample (Fig. 5.3c.), and reflected in a 
higher percentage of chromatin accessibility (Fig. 5.3d.). The result for ChART-PCR 
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Figure 5.3. Highly sensitive DNase I digestion reveals Th2-specific HSS at the proximal 5’ region in 
the 11-10 locus within unstimulated Th cells
ChART-PCR was performed in unstimulated CD4 Th cells, (a) Schematic o f the fragment o f the 11-10 
genomic locus analysed in this study with the corresponding primer pairs used, (b) Th cells were lysed the 
nuclei isolated and left untreated (No DNase I) or treated with DNase I. The resulting DNA was purified 
and 10 ng used as template for SYBR Green real-time PCR amplification using specific oligonucleotides 
for the indicated sites. An example o f  the raw Ct curves for the primer set, .860 is shown with Thl or Th2 
chromatin (c) The Ct values obtained were converted to quantitative DNA amounts using a standard curve 
generated for each o f the primer sets using genomic DNA as template (data not shown), (d) Chromatin 
accessibility was calculated and expressed as a percentage o f the untreated (No DNase I) DNA.
no DNase ly no DNase I ^
DNase I-treated DNase I-treated
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The 5’ proximal region (IL-10 promoter (primers spanning -.860 bp), for our discussion 
here) of the 11-10 locus is differentially re-modeled in Th2 cells and not in Thl cells in 
these highly sensitive DNase I digestion conditions. Higher concentrations of DNase I 
(such as the concentrations used in Southern blot studies) may induce DNase I digestion 
in Thl at the IL-10 promoter (personal communication, Margarida Saraiva) but under the 
conditions shown here the IL-10 promoter is a Th2-specific DNase I HSS. This result 
(Th2-specific DNase I HSS at the IL-10 promoter) is also in agreement with Jones et al. 
that used primary Thl and Th2 generated cells to perform Southern blots (236). In 
summary, it is likely that the IL-10 promoter is strongly re-modeled in Th2 cells and only 
weakly so in Thl (personal communication, Margarida Saraiva), which may explain in 
part why these cells produce different amounts of IL-10.
One intriguing area from previous studies focused on possible differential re-modeling of 
intronic regions within Th population of the 11-10 locus (114). The ChART-PCR data 
shows that intron 3 and 4 are not differentially re-modeled between Th populations. In 
fact, both Thl and Th2 cells have DNase I digested intronic regions within the 11-10 gene 
(intron 3 and intron 4), suggesting that expression of differential transcription factors 
enhancing or suppressing 11-10 transcription may be differentially acting on the 11-10 
gene at these locations. The constitutive HSS in Thl and Th2 cells is in agreement with 
DNase I HSS studies within the lab (personal communication, Margarida Saraiva) and 
with Jones et al. (236). However, this is in disagreement with the initial report by Im et 
al., which described the intronic 11-10 locus region (intron 3 and intron 4) to be a Thl- 
specific HSS. This difference may arise from the nature of Thl/Th2 cell used for their
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study (D5 (Thl) and DIO (Th2) cell-lines), whereas we use primary Thl and Th2 cells 
(114). The 3’ region of the 11-10 locus is re-modeled to a similar degree in both Thl and 
Th2 cells. This is in agreement with published reports on chromatin-level regulation of 
the 11-10 gene in this region (112, 114). Primers spanning exon 5 were included to 
control for nonspecific digestion by DNase I and show no digestion. In summary, these 
data shows similar degrees of DNase I digestion in both intronic regions (intron 3 and 
intron 4) and previously reported highly conserved (human and mouse) 3’ regions of the 
11-10 locus between Thl and Th2 cells.
5.3 Discussion
Together, identification of putative transcription factors involved in 11-10 gene regulation 
can be addressed by their cell-specific expression and their potential role in function is 
then supported by comparative genomics and predicted transcription factor binding sites 
adding value to the global question of 11-10 gene regulation investigated here. These 
putative factors will then be tested functionally by their ability to induce IL-10 when 
transduced into non-IL-10-producing populations via the RV system (next Chapter). As 
an additional layer, in silico studies clarify where potential transcription factors would 
theoretically bind within the 11-10 locus and the ChART-PCR assay demonstrates areas of 
remodeled chromatin accessible to nuclear factors in differential IL-10-producing CD4 
Th populations. The in silico approach independently identified three “known” sites of 
transcription factor binding sites: an AP-1 (JunB and c-Jun) binding site in the 3’ region 
(112), a NFAT intron 4 binding site (114) and c/EBP-p binding site (233) in the proximal 
5’ region of the 11-10 locus. Secondly, in silico analysis predicted a “novel” putative
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transcription factor binding sites for IL-10-associated transcription factors: GATA-3 and 
Ets-1. The GATA-3 conserved putative binding site in intron 4 (murine), is highly 
related to a distant genomic sequence (-500 bp) in the human genome (7 Mb downstream 
from the 11-10 locus). The murine intron 4 sequence is important in terms of potential 
regulatory function as previous reports describe the intron 4 region - where a consensus 
putative GATA-3 binding site is located - to contain a HSS. The fact that in the human 
genome a highly conserved sequence in comparison to the murine 11-10 gene (which does 
not contain homology in the encoded human 11-10 gene) is located 7 Mbp downstream 
suggests a possible evolutionary trans-location of this specific non-coding genomic 
sequence (-500 bp) between the mouse and human genome. Finally, the fact that there is 
high conservation of multiple putative transcription factors in intron 4 along with two 
conserved TATA boxes proximal to the exon 5 coding region suggests a possible site for 
an alternate promoter (discussed further in Future Perspectives) within this intronic 
region. Although no precedent is yet described for cytokine genes, other genes (such as 
the transcription factor, GATA-3) are expressed under the instruction of at least two 
promoters (237).
Since some transcription factors are not able to bind inaccessible or heterochromatic 
regions of DNA the ChART-PCR assay analyzed low- and high-level IL-10-producing 
Th cells to determine whether differential sites of the 11-10 locus are accessible in these 
populations for these types of nuclear factors. The results in this Chapter demonstrate the 
5’ region of the 11-10 locus is exclusively re-modeled in Th2 cells and not in Thl cells. 
Furthermore, Saraiva et al. reported (Southern blot) the 5’ region of the 11-10 locus was
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re-modeled in IL-10-Treg. Therefore, the combination of the Southern blot data and the 
ChART-PCR results suggest that a transcription factor not present in Thl, but available 
in Th2 and IL-10-Treg cells, may provide an instructive mechanism for high-level IL-10- 
producing populations to strongly remodel the 5’ proximal region of the 11-10 locus. The 
in silico computational model to predict conserved putative transcription factors within 
the 5’ 11-10 locus region only predicts c/EBP-p and no other known or novel IL-10- 
associated transcription factors. This suggests that the computational model may not be 
able to predict functional transcription factors regulating 11-10 gene regulation at this 
location or the settings to predict conserved putative sites may be too strict to isolate 
potential regulators. On the other hand, conserved putative sites isolated from the 
computational model may bind transcription factors in high-IL-10-producing populations 
at locations outside the proximal 5’ region of the 11-10 gene and induce long-range 
chromatin accessibility specific to the proximal 5’ region of the 11-10 locus. In either 
case, it is clear that high-abundance IL-10-producing CD4 T cells differentially expose 
the proximal 5’ region of the 11-10 locus.
Both low-IL-10-producing (Thl) and high-IL-10-producing (Th2) Th populations exhibit 
similar re-modeling within intronic (intron 3 and intron 4) and 3’ regions of the 11-10 
locus. This suggests Thl and Th2 cells have a differential mechanism whereby different 
transcription factors may bind and act via either repressing or enhancing 11-10 
transcriptional activity in constitutively re-modeled intronic and/or 3’ regions (Thl and 
Th2 cells). This mechanism is attractive especially with respect to transcription factors 
not able to bind inaccessible or heterochromatic regions of regulatory regions. This
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mechanism could involve factors that are classically shown to be inducible upon TCR 
activation, as there is considerable evidence that this class of transcription factors (NFAT, 
AP-1) preferentially bind euchromatic regulatory regions (59). The abundance or 
differential dimerization of these factors upon TCR activation may play a role at the 
exposed regions (intron 3/4 and the 3’ region) of differential IL-10-producing Th 
populations. This type of mechanism has already been speculated by the Wang et al. 
report in which they show JunB and c-Jun can enhance IL-10 expression at their putative 
binding site in the 3’ region (HSS+6.40). However, this mechanism did not describe why 
high IL-10-populations (Th2 and IL-10-Treg) differentially remodel the 5’ proximal 
region of the 11-10 gene (which has been proposed to have enhancing regulatory 
elements) in comparison to low-IL-10-producing populations before TCR activation. In 
terms of the data presented here, it should be clear that chromatin accessibility is not a 
direct means to assay potential “active” or “silencing” regions of re-modeled genes and 
further studies assessing covalent modifications of histone tails would serve as another 
level of investigation into regulatory elements (within the 11-10 gene) in these Th 
populations, before or after TCR activation (discussed in Future Perspective). In 
summary, the degree to which either of these regulatory non-coding intergenic or intronic 
regions within the 11-10 locus controls 11-10 gene expression is most likely dependent on 
multiple factors; however the results in this chapter in addition to the previous expression 
profiles provide critical insight into 11-10 gene regulation.
In the next chapter I present evidence that the GATA-3 transcription factor plays an 
important role at the molecular-level in the regulation of the 11-10 gene.
119
6. GATA-3 re-models the 11-10 locus independently of IL-4
GATA-3 was selected as a potential candidate to regulate the 11-10 gene based on a 
number of observations. Firstly, mRNA profiling of six distinct primary CD4 T cell 
populations showed differential expression of the transcription factor GATA-3 within IL-
10-producing cells (Th2 and IL-10-Treg) (Fig. 3.5 and 6.1a). Secondly, a conserved 
putative GATA-3 binding site was isolated in the 11-10 locus as described in Chapter 5. 
Finally, GATA-3 has been speculated to play a role in 11-10 gene regulation from a 
number of studies outlined below. Although the 11-10 locus (chromosome 1) is at a 
distant location from the 11-4/11-5/11-13 cluster (chromosome 11), antisense inhibition (73) 
or conditional deletion (85) of GATA-3 in established murine Th2 cells has been shown 
to reduce IL-10 production. Conversely, over-expression of GATA-3 in a transgenic 
murine model caused an up-regulation of IL-10 production (238). However, the direct 
mechanism whereby GATA-3 may regulate IL-10 expression was never established. One 
reason for this lack of direct evidence for GATA-3 role in 11-10 gene regulation in these 
studies described above relates to the coordinate expression of IL-4, IL-5 and IL-13 in 
GATA-3-expressing or non-expressing CD4 T cells. Therefore, GATA-3 effect on the 
IL-10 production could be via indirect effects, for instance its regulation directly on IL-4 
production. To begin the GATA-3 studies - in terms of IL-10 production - I will 
introduce the RV system and the results of differential cytokine production in GATA-3- 
transduced primary naive CD4 T cells.
120
6.1 Ectopic expression of GATA-3 induces IL-10 production in primary CD4 T cells
The retroviral (RV) system was used to assess the functional potential of discovered 
transcriptional factors in terms of cytokine expression or proliferation via their 
transduction into naive CD4 T cells and differentiation in an environment where the 
(investigated transcription factor) was not up-regulated as shown with the GeneChip and 
qPCR data. The RV system has advantages in that each transcription factor can be 
essentially “turned on” in a primary naive CD4 T cell. Furthermore, the RV system has 
an internal control with parallel transduction of a Mock-RV vector alongside the 
transduction of a transcription factor of interest. The RV system has been shown in 
previous studies (77) to functionally validate and gain insight into transcription factor- 
mediated molecular mechanism and will be used here to functionally investigate isolated 
genes from the mRNA profiling and the in silico analysis.
To investigate the effect of GATA-3 on IL-10 production, purified naive CD4 T cells 
were transduced with a recombinant retrovirus expressing GATA3-RV or with a Mock- 
RV and cultured under neutral or Thl conditions. The use of a retroviral vector 
containing an IRES-GFP facilitated the monitoring of the expression of GATA-3 in the 
transduced cells at the single cell level by measuring GFP expression, which has 
previously been shown to reflect GATA-3 expression in transduced cells (77).
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GATA-3 mRNA Profile  (qPCR)






























Figure 6.1. GATA-3 enhances IL-10 production in CD4 T cells.
(a) Real-time PCR was performed to validate the results from the GeneChip for IL-10 and GATA-3 
expression in unstimulated or stimulated CD4 T cell populations. WT na'fve (CD4+CD62L+CD45RBhlgh) T 
cells were infected with a Mock or a GATA-3-expressing retrovirus and differentiated under Neutral (b, c) 
and Thl (d, e) conditions. Six days after infection, cells were stimulated with PMA/Ionomycin for 4 h, 
intracellular stained for IL-10 (b, d) or for IL-4, IL-5, IFN-y, and IL-2 (c, e) and analyzed by FACS. Cells 
were gated on GFP expression (x-axis) and the percentage o f GFP-positive cells expressing the respective 
cytokines is shown. Data shown is an accurate representation o f three biological replicates.
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T cells cultured under neutral conditions and transduced with the Mock retrovirus 
produced little to no IL-10 (Fig. 6.1b). However, ectopic expression of GATA-3 induced 
an increase in the number of IL-10-producing cells upon stimulation (29% versus 1% 
obtained with the Mock-RV) (Fig. 6.1b) and increased levels of secreted IL-10 as 
measured by ELISA (data not shown). In agreement with previous studies, the 
percentage of IL-4- and IL-5-producing cells (74, 77) was increased by the presence of 
GATA-3 (Fig. 6.1c). Interestingly, the percentage of IL-10-producing cells was 
increased to a higher degree than that of IL-4- or IL-5-producing cells, two known 
GATA-3 transcriptional targets. Finally, the percentage of IFN-y- and IL-2-producers 
was reduced by ectopic GATA-3 expression (Fig. 6.1c). The down-regulation of IFN- 
y production by GATA-3 was in keeping with previous studies (75, 77, 79).
Similarly to what was observed under neutral conditions, over-expression of GATA-3 in 
naive CD4 T cells differentiated under Thl conditions led to an increase of IL-10 
production (Fig. 6.Id). Increased percentages of IL-4- and IL-5-producing cells (Fig. 
6.1e) were also observed as previously reported (74, 77). Here in the Thl-driven culture 
conditions GATA-3 induced a much higher number of IL-10- than of IL-4- or IL-5- 
producing cells suggesting a potential direct effect of GATA-3 on the 11-10 gene (Fig. 
6. Id and 6.1e). The percentage of cells producing IFN-y and IL-2 was again significantly 
diminished in the presence of GATA-3 as compared to controls (Fig. 6.1e).
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6.2 GATA-3 induction of IL-10 production is independent of IL-4
GATA-3 has been shown to induce changes in the chromatin structure at the 11-4/11-5/11- 
13 locus (74, 78), and to drive subsequent production of these Th2-associated cytokines 
(73, 74, 77). Thus, the increased production of IL-10 observed in the presence of GATA- 
3 could result from indirect effects of Th2-associated cytokines (specifically IL-4, since 
IL-5 and IL-13 do not act directly on T cells (51)). To determine whether GATA-3 
enhanced 11-10 gene expression independently of IL-4, GATA-3 was transduced into 
naive CD4 T cells derived from IL-4(-/-) mice (239). The ability to use IL-4(-/-) CD4 T 
cells provided a key step to understanding whether or not GATA-3 was acting in a direct 
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Figure 6.2. IL-10 production induced by GATA-3 is independent of IL-4.
IL-4(-/-) na'ive (CD4+CD62L+CD45RBhlgh) T cells were infected with a Mock or a GATA-3-expressing 
retrovirus and differentiated under Neutral (a, b) and Thl (c, d) conditions. Six days after infection, cells 
were stimulated with PMA/Ionomycin for 4 h, intracellular stained for IL-10 (a, c) or for IL-4, IL-5, IFN-y, 
and IL-2 (b, d) and analyzed by FACS. Cells were gated on GFP expression (x-axis) and the percentage of 
GFP-positive cells expressing the respective cytokines is shown. Data shown is an accurate representation 
of three biological replicates.
Under neutral culture conditions, GATA3-RV induced a similar number of IL-10- 
producing cells in the presence (WT) (29%) (Fig. 6.1b) or absence of IL-4 (27%) (Fig. 
6.2a), showing that IL-4 is not necessary for IL-10 induction. However, the number of 
IL-4- and IL-5-producing cells was much lower (Fig. 6.2b) than the WT conditions (Fig. 
6.1c), with the IL-4-producers being eliminated (IL-4 (-/-) cells) and the number of R e ­
producing cells much lower in the IL-4(-/-) cells (Fig 6.2b) as compared to WT cells (Fig
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6.1c). Over-expression of GATA-3 induced similar changes in the percentage of IFN-y- 
producing cells (Fig. 6.2b.) as compared to WT cells (Fig. 6.1c) whereas IL-2-producing 
cells were similar in Mock-RV or GATA3-RV in IL-4(-/-) cells in neutral culture 
conditions (Fig. 6.2b.).
Transduction of GATA-3 in IL-4(-/-) naive CD4 T cells differentiated under Thl 
conditions induced a greater number of IL-10-producing cells than that observed for WT 
cells (Fig. 6.Id and 6.2c). The IL-10-producers in the GFP-negative/GATA-3-transduced 
population were also increased (Fig. 6.2c), which was also observed at the mRNA level 
(data not shown). This probably reflects the loss of GFP expression in a portion of the 
GATA-3-transduced cells (77). Therefore, as in all the conditions, the most accurate 
comparison is between the GFP+Mock-RV-transduced cells and GATA3-RV-transduced 
cells. Over-expression of GATA-3 induced similar changes in the percentage of IL-5-, 
IFN-y- and IL-2-producing cells in WT (Fig. 6.1e) or IL-4(-/-) cells (Fig. 6.2d). 
Together, the IL-4(-/-) RV studies allude to GATA-3 having a possible direct effect on 
the expression of the 11-10 gene.
To investigate the effect of GATA-3 on 11-10 transcription in WT and IL-4(-/-) CD4 T 
cells, GATA-3- or Mock- transduced cells were isolated by flow cytometry on the basis 
of their GFP expression on day 6 post-transduction. qPCR was performed on Mock-RV 
and GATA3-RV transduced cells (unstimulated and stimulated) to investigate cytokine 
expression and various transcription factors implicated in 11-10 gene regulation (Fig. 6.3).
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Figure 6.3. GATA-3 enhances IL-10 at the transcriptional level.
CD4 T cell populations described in Figures 6.1. and 6.2. were purified by flow-cytometry into GFP- 
positive populations and mRNA was collected at unstimulated time-point and after activation for 3 hr. with 
PMA/Ionomycin. Real-time PCR was performed to detect cytokine and transcription factor expression. 
Data shown is an accurate representation o f three biological replicates.
As expected, levels of GATA-3 mRNA (Fig. 6.3) was higher in the GATA-3-transduced 
GFP-positive T cells than in the Mock-transduced GFP-positive T cells. Independent of 
the polarizing conditions used and of the presence of IL-4, IL-10 transcription was 
significantly and consistently up-regulated by GATA-3 in keeping with the ICS FACS. 
IL-5 mRNA was also consistently up-regulated in the presence of GATA-3, to a 
maximum amount in WT cells under neutral conditions (Fig. 6.3).
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Transcription factor profiling was investigated to determine whether GATA-3 presence 
was directly influencing other possible direct regulators of IL-10 expression. One clear 
observation was that in IL-4(-/-) cells as opposed to WT cells, transduction of GATA-3 
did not induce the transcription of c-Maf (Fig. 6.3), confirming that c-Maf expression 
requires IL-4 and strongly correlates with IL-4 signaling (74). The expression of Ets-1 
was clearly down-regulated in the presence of GATA-3, independently of IL-4 
production and polarizing condition (Fig. 6.3). Other IL-10-associated transcription 
factors were analyzed and no other expression profiles indicated differential regulation in 
GATA-3- versus Mock-transduced cells in either polarizing condition at both 
unstimulated and stimulated time-points.
6.3 GATA-3 binds to the 11-10 locus
The results indicating that GATA-3 induced IL-10 mRNA and protein, in the absence of 
IL-4, suggested a direct, yet unknown effect of this transcription factor on the 11-10 locus. 
The molecular mechanism to which GATA-3 may regulate IL-10 expression was an open 
question. From the in silico analysis of the 11-10 gene I have described the comparison of 
the DNA sequence of the murine 11-10 gene to that of other species (human) revealed one 
conserved site for conserved putative GATA binding motifs in exon 4 within the 11-10 
gene (re-visited in Fig. 6.4a). Since the in silico analysis performed in the last chapter 
was unable to reveal the c-Maf and Spl/Sp3 functionally described putative binding sites 
in the IL-10 promoter, a intensive search of the mouse and human 5’ region was 
undertaken for other potential GATA binding motifs. Further analysis of the IL-10
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promoter revealed a double conserved (mouse and human) “core” putative GATA 
binding site. This double GATA-binding site was located -0.865 bp in the 5’ proximal 
region of the mouse 11-10 gene. Together, the discovery of the 5’ putative binding site 
and the conserved putative GATA binding site in intron 4 (both of which contain 
described HSS) lead us to speculate that GATA-3 might bind to these potential regulatory 
regions in vivo.
To assess whether GATA-3 bound to these sites in vivo primary IL-10-producing T cells 
(Th2 and IL-10-Treg) were generated and chromatin immunoprecipitation (ChIP) studies 
performed. Briefly, crosslinked DNA from polarized IL-10-producing T cells were 
immunoprecipitated with a specific antibody for GATA-3 or with a control antibody. 
The immunoprecipitated DNA was subsequently purified and amplified by real-time PCR 
using specific oligonucleotides for the sequence near or spanning the GATA-3 conserved 
putative binding motif on the 11-10 gene (Fig. 6.4a). Oligonucleotides specific for the 11-5 
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Figure 6.4. GATA-3 binds to the IL-10 promoter in vivo.
(a) Conserved GATA-3 transcription factor binding sites in the mouse 11-10 gene (+1 represents the start 
site). Indicated are the IL-10 exons (black boxes), the 5 ’ and 3 ’ UTR’s (white boxes) and the position o f 
the oligonucleotides used in (b) and the location o f the conserved GATA-3 binding sites (+ ) .  (b)
Crosslinked chromatin complexes from resting Th2 cells were immunoprecipitated with a GATA-3 or a 
control antibody. Specific oligonucleotides were used to amplify by real-time PCR the GATA-3 binding 
sites in the 11-10 gene or the IL-5 promoter, using the immunoprecipitated or untreated (Input) chromatin as 
template. Represented is the amount o f  PCR product obtained upon GATA-3 immunoprecipitation or 
control antibody immunoprecipitation, normalized to the amount o f  PCR product obtained for the Input 
chromatin. The error bars for each condition represent the standard deviation from 3 biological replicates, 
(c) The PCR products obtained as described in (b) were separated in a 2.5% agarose gel and stained with 
ethidium bromide. Data shown is an accurate representation o f three biological replicates.
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ChIP studies verify the presence of GATA-3 at both consensus putative binding sites in 
the 11-10 locus in both IL-10-producing T cells (Fig. 6.4b (qPCR) and 6.4c. (gel)) (IL-10- 
Treg data not shown), strongly supporting a direct role of GATA-3 in the expression of the
11-10 gene. As controls, binding of GATA-3 as expected was observed at the 11-5 locus 
(Fig. 6.4b and 6.4c), but was not observed in the region coding for the 11-10 exon 5 (data 
not shown).
6.4 GATA-3 induces changes in the chromatin structure at the 11-10 locus
The presence of GATA-3 at regulatory sites within the 11-10 locus suggested that GATA- 
3 might provide an instructive role in either trans-activating the 11-10 gene (similar to its 
effect of the 11-5 and 11-13 gene) or re-modeling the 11-10 locus (similar to its effects on 
the 11-4 gene). 7r<ms-activation studies revealed GATA-3 did not /raws-activate the full- 
length IL-10 promoter (data not shown). Therefore, whether GATA-3 was able to induce 
changes in the chromatin structure at the 11-10 locus was investigated. For this, CD4 
naive T cells from IL-4(-/-) mice were purified and transduced with a GATA3-RV or 
with a Mock-RV and ChART-PCR was performed in unstimulated cells to investigate the 
structure of the 11-10 gsne under the differential presence of GATA-3, independently of 
IL-4. This assay was performed at the earliest possible time (owing to transduction 
rates), which was day 3 post-transduction with IL-4(-/-) cells. Three separate biological 
replicates were assayed three days post-transduction and nuclei was isolated from 
unstimulated GATA-3- or Mock-transduced cells untreated or treated with low- 
concentration DNase I (225, 240). Based on the previous Chapters results and the study 
by Saravia et al., specific oligonucleotide pairs that span HSS of interest across the 11-10
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locus were used. In these studies I have included primer pairs that span described HSS 
detected upstream of the 11-10 start site (HSS-2.0), two primer pairs that cover the IL-10 
promoter region, intron 3 (HSS+1.65), intron 4 (HSS+2.98) and the 3’ non-coding region 
(HSS+6.40). Of particular interest were the HSSs detected in the 5’ proximal region of 
the 11-10 gene and in intron 4 since where in vivo recruitment of GATA-3 is shown by 
ChlP. As a control for the quality and quantity of the template DNA used, the chromatin 
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Figure 6.5. GATA-3 induces changes on the chromatin structure at the 11-10 locus.
(a) Schematic o f the fragment o f the 11-10 genomic locus analysed in this study (b) IL-4(-/-) naive T cells 
were transduced with a Mock-(Mock-RV) or a GATA-3-expressing retrovirus (GATA3-RV) and 
differentiated under neutral conditions. Three days after infection, cells were lysed the nuclei isolated and 
left untreated (No DNase I) or treated with DNase I. The resulting DNA was purified and 10 ng used as 
template for SYBR Green real-time PCR amplification using specific oligonucleotides for the indicated 
sites, (c) The Ct values obtained were converted to quantitative DNA amounts using a standard curve 
generated for each o f  the primer sets using genomic DNA as template (data not shown), (d) The chromatin 
accessibility was calculated as a percentage o f the untreated (No DNase I) DNA.
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In the presence of ectopic GATA-3 the chromatin accessibility at the 11-10 locus was 
increased (Fig. 6.5d). This effect was most pronounced at sites located in the proximal 5’ 
region of the 11-10 gene (HSS-0.860 and HSS-0.610) and described intronic HSSs, 
including sites that are near the putative GATA-3 binding site in intron 4 (Fig. 6.5d). 
Chromatin re-modeling was also observed at HSS+6.40 suggesting that GATA-3 may 
also induce long-range re-modeling of known positive regulatory regions. No significant 
differences in PCR product amplified (Fig. 6.5b and 6.5c) and on the percentage of 
DNase I digestion (Fig. 6.5d) was observed at exon 5, suggesting that the observed 
differences were specific and due to real changes in the chromatin accessibility at sites 
containing regulatory elements. GATA-3 induced chromatin re-modeling at specific sites 
of the 11-10 locus, even in the absence of IL-4. This re-modeling not only occurred at 
sites shown here to bind GATA-3 but also across the 11-10 locus at sites known to 
positively regulate the transcription of the 11-10 gene, as is the case for HSS+6.40. In 
summary, the ChART-PCR technique - which reveals potential regulatory regions 
(HSSs) - demonstrates that GATA-3 induces re-modeling of key enhancing regulatory 
regions (5’ proximal region) of the 11-10 gene before TCR activation and independently 
of IL-4.
6.5 GATA-3 induces acetylation of histone H3 and H4 to the 11-10 locus
The acetylation of histone (H3 and H4) at specific genomic regions has been 
demonstrated to forecast enhancement of gene expression. With this in mind, the 
acetylation status of histones H3 and H4 in primary CD4 T cells in the absence or
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presence of ectopic GATA-3 was investigated at the 11-10 gene. For this, naive CD4 T 
cells were transduced with GATA3-RV or Mock-RV, under neutral conditions and FACS 
purified based on GFP-positive expression at day 6 post-transduction. Crosslinked 
chromatin was isolated and immunoprecipitated with antibodies that specifically 
recognize acetylated residues of histones H3 and H4 versus control antibodies. 
Immunocomplexes were further purified and DNA was used as template for qPCR with 
oligonucleotide sets that cover the predicted GATA-3 binding sites in the 11-10 locus 
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Figure 6.6. GATA-3 induces acetylation of histones H3 and H4 across the 11-10 locus.
(a) Crosslinked chromatin complexes from resting and activated neutral cultured Mock-RV and GATA3- 
RV cells were immunoprecipitated with anti-acetyl-histoneH3, anti-acetyl-histoneH4, and control 
antibodies. Specific oligonucleotides were used to amplify by real-time PCR the GATA-3 binding sites in 
the 11-10 locus (-0.86 and +3.70 kbp) and HSS+6.70, using the immunoprecipitated or untreated (Input) 
chromatin as template. Represented is the amount o f  PCR product immunoprecipitated with specified 
antibodies normalized to the amount o f  PCR product obtained for the Input chromatin. The error bars for 
each condition represent the standard deviation from 3 replicates, (b) The PCR products obtained as 
described in (a) were separated in a 2.5% agarose gel and stained with ethidium bromide.
Clearly, both histones H3 and H4 were acetylated to a significantly higher amount when
cells had been transduced with GATA-3 (Fig. 6.6a and 6.6b). The acetylation of histones
H3 and H4 was readily observed in unstimulated GATA-RV cells, but was further
increased upon activation at HSS-0.860 and HSS+3.70 (Fig. 6.6a and 6.6b).
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The finding that GATA-3 induced histone acetylation at the 11-10 locus further supports 
the ChART-PCR data and GATA-3 role in instructing direct modifications of the 11-10 
locus that lead to IL-10 expression. However, it should be noted that the acetylation 
studies demonstrate an additional level of positive 11-10 gene regulation mediated by 
GATA3-RV transduction, because ChART-PCR indicates exposed HSS, but additional 
information about histone acetylation of H3 and H4 indicates that these HSSs are indeed 
positive regulatory regions. In a previous study on chromatin-level 11-10 gene regulation 
(114), intron 3 and intron 4 was described to be re-modeled in Thl cells, but subsequent 
ChIP studies showed an increased amount of histone deacetylase HDAC1 (and not 
acetylation of histone H3 and H4) at these regions indicating a “silenced” chromatin 
structure. This section demonstrates that GATA3-RV induces “active” chromatin 
structure in three potential 11-10 gene regions (HSS-.860, HSS+3.7, HSS+6.4). This 
molecular mechanism is similar to, but independent of, the effects of GATA-3 in re­
modeling the chromatin at the 11-4/11-5/II-13 locus and regulation of the Th2-associated 
cytokines (58, 74, 78). Taken together, our results suggest that GATA-3 acts as a direct 
regulator of the 11-10 locus inducing changes in chromatin structure as shown by DNase I 
digestion and histone acetylation.
6.6 Discussion
To investigate the regulation of 11-10 gene expression, the transcript-ome of several CD4 
T cell populations, including two distinctly regulated T cell populations (Th2 and IL-10- 
T reg) that expressed high amounts of IL-10. The expression of GATA-3 was up-regulated
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in Th2 and IL-10-Treg cells, but not in CD4 T cells that produced low amounts of IL-10, 
which only expressed little, but detectable GATA-3. In keeping with this, recent studies 
showed that reduction of GATA-3 expression, by antisense or gene deletion in 
differentiated Th2 cells decreased the production of IL-10 in addition to a decrease in IL- 
4 (73, 85). Further, using a transgenic knock-in model in which GATA-3 is ectopically 
expressed in CD4 T cells, induction of Th2 differentiation and subsequent IL-4, IL-5, and 
IL-10 production was observed (73,238). In these studies it was unclear whether GATA- 
3 was directly exerting its effect on the 11-10 gene or whether the effects on IL-10 were 
mediated by variation of IL-4 levels, which has an instructive role in directing Th2 cell 
differentiation that is accompanied by IL-10 production. Evidence provided in this thesis 
clearly demonstrates that ectopic expression of GATA-3 increased the transcription and 
secretion of IL-10 in primary naive CD4 T cells in the complete absence of IL-4.
The molecular mechanism whereby GATA-3 affected the 11-10 gene remained elusive, 
the questions being, was GATA-3 recruited to the 11-10 genomic locus and, if so could it 
trans-activate the IL-10 promoter and/or directly induce re-modeling of the chromatin? 
By comparing the DNA sequence of the 11-10 locus between different species two 
conserved putative GATA-3 binding sites were located at the 5’ proximal region (-0.865) 
and intron 4 (+3.785). The presence of GATA-3 was then shown at these sites in vivo in 
primary Th2 cells. However, unlike its effects on the IL-5 promoter, GATA-3 did not 
enhance the activity of the IL-10 promoter in in vitro reporter assays (data not shown). 
Trans-activation of the 11-10 locus by GATA-3 via regions other than the IL-10 promoter 
is currently under study.
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ChART-PCR was used to measure and quantify chromatin accessibility at the 11-10 
genomic locus, and showed that GATA-3 induced changes in the chromatin structure at 
the 11-10 locus, independently of IL-4. These changes were most pronounced in the 
vicinity of conserved GATA-3 binding sites, particularly at positions -0.860 and -0.610 
bp from the 11-10 transcription start site. This suggests that the presence of GATA-3 to 
this region enhanced its chromatin accessibility, possibly by stabilizing the 11-10 locus in 
an open, euchromatic form. Furthermore, the accessibility of a recently described 
positive regulatory region located in the 3’ region of the 11-10 gene (HSS+6.40) (112) 
was significantly re-modeled under the influence of GATA-3. These observations 
suggest that GATA-3 may also contribute to long-range changes of the chromatin 
structure at the 11-10 locus and therefore to the stabilization of the chromatin 
conformation needed for the accessibility of transcription factors required for IL-10 
expression. Positive regulatory transcription factors likely include the recently described 
Jun family members, c-Jun and JunB (112), which are shown to enhance IL-10 
expression at these long-range sites (CNS-3) (112). However, as no GATA-3 binding 
was detected by ChIP at HSS+6.4 (data not shown), direct interaction between GATA-3 
and this site is unlikely, although GATA-3 may induce changes in chromatin to allow its 
accessibility to Jun transcription factors.
In further support for an instructive role for GATA-3 in regulating the 11-10 gene, we 
found that in the presence of ectopic GATA-3 the histones located in the vicinity of the 
GATA-3 conserved sites become acetylated, in cells that normally do not express IL-10.
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Our data suggest that in the presence of GATA-3, regulatory regions across the 11-10 
locus become accessible (DNase I-sensitive) and “active” (acetylation of histone H3 and 
H4) to transcription factors.
Whereas changes in the chromatin structure at the 11-10 locus were induced by GATA-3 
prior to TCR stimulation (in unstimulated cells), IL-10 expression and secretion required 
secondary stimulation, even when ectopic GATA-3 was present. It is possible that 
GATA-3 instructs the changes at the 11-10 locus necessary for the action of other 
transcription factors, such as Spl, Sp3, SMAD-4, c-Jun, JunB and c-Maf, which have 
been described in different contexts to enhance IL-10 secretion. Similarly, the presence 
of GATA-3 may also expose the 11-10 locus to the function of possible repressors, such as 
the transcription factor Ets-1 (72).
We also showed that GATA-3-transduced neutral or Thl polarized T cells have a 
significant reduction in Ets-1 mRNA compared to the corresponding Mock-transduced 
cells. This is of interest as in Thl cells derived from the Ets-1 deficient mice a marked 
increase of IL-10 production was observed (72), suggesting that the transcription factor 
Ets-1 may act as a repressor for 11-10 gene expression. Since it is possible that Ets-1 acts 
directly on the re-modeled 11-10 locus to repress 11-10 transcription, we used crosslinked 
chromatin from WT neutrally polarized T cells (day 5 post-transduction) GATA-3- or 
Mock-transduced cells and immunoprecipitated with antibodies that specifically 
recognize Ets-1 motifs. Since GATA3-RV cells have potential regulatory 11-10 gene 
regions re-modeled as opposed to Mock-RV controls, we accessed whether Ets-1 was
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differentially present at the 11-10 locus in either GATA-3- or Mock-transduced cells. We 
detected Ets-1 was present with primers spanning intron 4 (HSS+3.70) in GATA-3- 
transduced unstimulated cells, but not in the corresponding Mock-RV cells (data not 
shown). Furthermore, we detected a consensus putative Ets-1 biding site in the murine II- 
10 gene within intron 4. We did not detect the presence of Ets-1 in GATA-3 or Mock- 
transduced cells with primers spanning HSS+6.40 (even though both conditions have an 
accessible HSS here), which contain a conserved putative Ets-1 binding site from our in 
silico 11-10 locus analysis. These findings suggest that Ets-1 is able to directly bind to the 
re-modeled 11-10 gene (intron 4) and may act to repress 11-10 expression as indicated by 
the Ets-1 (-/-) results. Additionally, our data suggests that Ets-1 binds only to previously 
re-modeled regions of the 11-10 gene. Together, we show that Ets-1 mRNA is down- 
regulated by GATA-3-RV transduced CD4 T cells when compared to Mock-RV controls; 
however Ets-1 protein is also exclusively present in GATA3-RV cells within a potential 
regulatory region of the 11-10 gene (intron 4). This could partly explain why in GATA-3- 
transduced neutral or Thl cells (72) the production of IL-10 is increased, but never to the 
extent observed in Th2 and IL-10-Treg cells (which have low-abundance of Ets-1 
expression).
The possible interactions between several transcription factors may allude to multiple 
layers of combinatorial effects of transcriptional enhancers and repressors acting directly 
on the 11-10 gene, GATA-3 being a key transcription factor that exposes the 11-10 locus to 
all these putative regulators. This hypothesis is very attractive and could explain why we 
detected a basal level of GATA-3 expressed in all cells that produce IL-10 despite their
141
variation on quantitative amounts of IL-10 production. In this chapter, we systematically 
found that the expression levels of GATA-3 correlated with IL-10 secretion by different 
populations of primary CD4 T cells. GATA-3 induced IL-10 expression in primary CD4 
T cells under various differentiation conditions, even in the absence of IL-4. We also 
showed that GATA-3 was present at the 11-10 locus and induced changes to the 11-10 
gene chromatin structure, and further induces an “active” transcriptional status 
(acetylation status of histone H3 and H4). Taken together our data suggests an 
instructive role for GATA-3 in the regulation of 11-10 expression by directly re-modeling 
the 11-10 gene.
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7. Potential role of additional transcription factors in 11-10 gene regulation
In this Chapter I will analyze other transcription factors potentially involved in 11-10 gene 
regulation. Transcription factors, c-Maf, PPAR-y, were functionally investigated in the 
RV system based upon their unique expression profiles isolated from the GeneChip 
studies (Fig. 4.2). c-Maf and PPAR-y were both expressed in IL-10-producing cells (Fig. 
4.2). The validated mRNA expression profiles for both c-Maf and PPAR-y are shown 
below in Figure 7.1.
c-M af mRNA Profile (qPCR) b PPAR-y mRNA Profile (qPCR)
u n stim u lated  stim u lated  u nstim ulated  stim u lated
Figure 7.1. c-Maf and PPAR-y are differentially expressed in IL-10-producing CD4 T cells
(a) Real-time PCR was performed to validate the results from the GeneChip for c-Maf and PPAR-y 
expression in unstimulated or stimulated CD4 T cell populations.
These two transcription factors were functionally studied for effects on 11-10 gene 
regulation primarily via RV-mediated transduction into naive CD4 T cells and 
subsequent polarizing conditions: neutral (no antibodies) and Thl driven culture 
conditions. Functional outputs were measured at the secondary re-stimulus time-point 
via cytokine profiles (ICS FACS) and proliferation numbers comparing (gene-of- 
interest)-RV versus Mock-RV transduced cells.
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This chapter briefly summarizes the findings from the RV system with these transcription 
factors, performed in primary naive CD4 T cell populations driven under various culture 
conditions in the presence of c-Maf-RV or PPARy-RV and Mock-RV as controls.
7.1 c-Maf weakly enhances IL-10 production in Thl culture conditions
In terms of CD4 T cell cytokine gene regulation, c-Maf is classically described to trans- 
activate the re-modeled IL-4 promoter (87). However three observations have lead to c- 
Maf being functionally tested in the RV system for its effects on IL-10 gene regulation. 
Cao et al. demonstrated that c-Maf can also trans-activate the proximal IL-10 promoter 
and induce IL-10 production in TLR stimulated BM-macrophages. Secondly, we showed 
differential expression of c-Maf in both IL-10-producing T cell populations (Th2 and IL-
10-Treg cells). Thirdly, in silico analysis defined two putative conserved AP-1 binding 
sites and one putative c-Maf binding site within intron 2 of the 11-10 gene as described in 
Materials and Methods. Therefore, the function of c-Maf-RV transduced cells in terms of 
IL-10 production in both neutral and Thl driven culture conditions (two conditions which 
normally do not express c-Maf) was tested.
Primary WT naive CD4 T cells were isolated and transduced with c-Maf-RV or Mock- 
RV and polarized in neutral or Thl conditions. CD4 T cells were re-stimulated on Day 6 
post-transduction to reveal effects of the transcription factor on subsequent cytokine 
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Figure 7.2. c-Maf weakly enhances IL-10 production Thl driven cell conditions, but not neutral 
conditions.
WT naive (CD4+CD62L+CD45RBhlgh) T cells were infected with a Mock or a c-Maf-expressing retrovirus 
and differentiated under neutral (a, b) and Thl (c, d) conditions. Six days after infection, cells were 
stimulated with PMA/Ionomycin for 4 h, intracellular stained for IL-10 (a, c) or for IL-4, IFN-y, and IL-2 
(b, d) and analyzed by FACS. Cells were gated on GFP expression (x-axis) and the percentage o f GFP- 
positive cells expressing the respective cytokines is shown. Data shown is an accurate representation of 
three experimental replicates.
Under neutral conditions c-Maf-RV and Mock-RV transduced cells showed no 
significant difference in cytokine expression as shown by ICS for IL-10-, IFN-y-, IL-4- 
and IL-2-producers (Fig. 7.2a and 7.2b). However, under Thl driven culture conditions 
c-Maf-RV showed a higher number of IL-10 producers (18%) when compared to Mock- 
RV IL-10 producers (7%) (Fig. 7.2c). IFN-y-, IL-4- and IL-2-producers had similar 
profiles when compared to c-Maf-RV and Mock-RV cells (Fig. 7.2d). IL-4-producers, a 
known target of c-Maf /raws-activation (87), were not significantly increased in either c-
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Maf-RV neutral or Thl culture conditions as compared to Mock-RV cells (Fig. 7.2b and 
7.2d). This suggests that the IL-4 promoter is not accessible and therefore trans- 
activation by c-Maf is not achieved.
In CD4 T cells, c-Maf has been shown to directly enhance IL-4 expression by binding to 
the re-modeled proximal IL-4 promoter (87). Other immune cells were shown to increase 
IL-10 expression via c-Maf enhancement within the IL-10 promoter (116). In the above 
RV studies we show that c-Maf transduced cells are not able to enhance IL-10 production 
in neutrally driven conditions, but are able to moderately enhance IL-10 production in 
Thl conditions. No IL-4 production is achieved in either neutral or Thl-driven c-Maf 
transduced populations, supporting previous studies where c-Maf could only enhance IL- 
4 production under neutral conditions (but only when IL-4 was not neutralized, i.e. could 
not achieve this effect in the complete absence of IL-4, in contrast to GATA-3 which 
could instruct re-modeling of IL-4 locus under these conditions (74, 78, 87)). The fact 
that c-Maf-RV does not enhance IL-4-producers when compared to the Mock-RV cells is 
probably because both neutral and Thl-driven culture conditions did not induce re­
modeling of the 11-4 locus and allow access for the described c-Maf-mediated trans- 
activation of the 11-4 gene (87). Unlike the 11-4 locus, the 11-10 locus is partially re­
modeled in Thl-driven conditions (ChART-PCR) and therefore the data presented here 
suggests c-Maf could act, through a similar mechanism as described for the 11-4 gene, and 
enhance IL-10 production once the locus is re-modeled. Cao et al. have reported c-Maf 
mediated trans-activation of the minimal IL-10 promoter in the RAW264.7 murine 
macrophage cell-line. Additionally they showed through deletion studies that a putative
basic leucine transcription factor (bZip) binding site at the -.190 bp position in the IL-10 
murine promoter acts as the location for c-Maf-mediated trans-activation. This group 
showed that transfection of c-Maf into primary human monocytes increased their ability 
to express IL-10 upon TLR activation. The combination of the Cao et al. study and our 
results involving increased IL-10-producers in Thl-driven culture conditions suggests a 
possible role for c-Maf in enhancing IL-10 expression.
In our studies it is interesting to note that under neutral conditions c-Maf-RV was unable 
to increase IL-10 production upon re-stimulus. A mechanism for this may be via the 
partial re-modeling of the 11-10 gene that we have shown in Thl-driven conditions, 
allowing for enhancing factors such as, c-Maf, to access sites within the 11-10 locus. The 
location whereby c-Maf may directly act to enhance 11-10 transcription is not clear from 
our studies. It should be noted that AP-1 sites in both the 3’ and intronic regions of the 
11-10 gene could be sites for c-Maf-mediated co-operation, as AP-1 complexes can 
include JunB:Maf (113). Further, we have shown using an in silico generated analysis of 
the 11-10 locus that there is a v-Maf conserved putative binding site within intron 2 of the
11-10 gene. Lastly, the minimal IL-10 promoter region has been described to be trans- 
activated by c-Maf (116); however whether the IL-10 promoter region is accessible in our 
c-Maf-RV cells polarized under Thl conditions is not known (however, Thl cells in our 
highly sensitive ChART-PCR do not re-model the IL-10 promoter during TCR- 
unstimulated conditions). In summary, c-Maf-RV weakly enhances IL-10 expression in 
CD4 T cells under certain conditions but the exact mechanism by which may function at 
the molecular level is not yet clear.
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7.2 PPAR-y
PPAR-y, a nuclear receptor transcription factor, was selected for functional studies based 
upon its IL-10-associated expression profiles described previously (Fig.7.1). PPAR-y is 
activated by ligand/receptor interactions thereby becoming transcriptionally active and 
repressing or enhancing target genes (229). The regulation of PPAR-y expression is not 
clear; however PPAR-y expression and activation in other developmental cell lineages 
has proven that PPAR-y can act as a repressive nuclear factor to influence subsequent cell 
differentiation (229, 230). Moreover, our expression profiles suggested PPAR-y could be 
involved in 11-10 gene regulation and its function was tested in the RV system under 
neutral and Thl conditions (two populations which did not express PPAR-y). 
Alternatively it is possible that PPAR-y could repress the expression of other cytokine 
genes or other functions in IL-10-producing cells.
In both culture conditions (neutral or Thl) there was no difference in differential cytokine 
producers or proliferation between PPARy-RV and Mock-RV transduced cells (data not 
shown, day 7). This suggested that PPAR-y did not play a role in neutral or Thl driven 
culture conditions for CD4 T cell cytokine production (IL-10, IFN-y, IL-4 and IL-2) or 
proliferation.
The fact that transduction of PPAR-y into neutral or Thl driven cells did not induce 
differential cytokine production might arise from the absence of PPAR-y ligands 
expressed in either neutral or Thl cells and therefore PPAR-y - a nuclear receptor - was
148
not transcriptionally active. A specific-ligand for PPAR-y activation was not available so 
these studies were not pursued. It may be likely that neutral or Thl cultured cells, which 
do not normally express PPAR-y, might not express an intrinsic ligand to activate PPAR- 
y. In summary, PPAR-y was selectively up-regulated in IL-10-producing CD4 T cells; 
however its RV-mediated transduction into differentiating neutral or Thl populations did 
not induce cytokine production or affect proliferation related effects when compared to 
Mock-RV cells.
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8. Molecular gene expression profiles in IL-10-Treg vs. CD25+Treg
CD4 Treg-mediated suppression in either the initiation or effector activation of peripheral 
immune response is currently of great interest (127). The major hypothesis-driven area 
of research initially set out to understand in this thesis was the regulation of the 11-10 
gene. However, in developing the panel of CD4 T cell populations the realization that 
two phenotypically different CD4 Treg populations presented a unique opportunity to 
investigate the mechanisms differing or shared between both CD4 Treg populations. Of 
specific interest was of the CD4 Treg were the naturally occurring CD4+CD25+ Treg and 
the antigen-driven IL-10- Treg which share the inability to produce proliferative and 
effector cytokines upon TCR triggering, and both are anergic when triggered through the 
TCR (21, 125, 174-177). In this Chapter, the investigation of shared intrinsic 
mechanisms within CD4 Treg populations suggests that each of these regulatory 
populations may use independent mechanisms to restrict pro-inflammatory expression of 
genes upon TCR activation, and to inhibit proliferation induced through TCR-signaling, 
but also these mechanisms may have some similarities with respect to the targeted 
pathway.
The classification of “natural occurring” CD4 Treg (CD25+Treg in our panel) is defined by 
their expression of the lineage specific transcription factor, FoxP3 (129). One central 
role for FoxP3 expression lies in its ability to functionally abrogate transcription of pro- 
inflammatory cytokine genes upon TCR activation. In CD4 Treg populations, both IL-10- 
Treg and CD25+Treg are similar in that they do not express pro-inflammatory cytokines 
upon TCR activation (21,174 Shevach, 2001 #221, 175-177). In CD25+Treg this is likely
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due to the fact that FoxP3 is expressed, however a FoxP3-equivalent in IL-10-Treg (which 
do not express FoxP3 (174)), or if IL-10-Treg have a FoxP3 equivalent, has not been 
described.
FoxP3 interacts with NF-kB and NFAT complexes to regulate their ability to bind DNA 
and activate gene transcription (137, 140). An alternative mechanism to abrogate NF-kB 
and NFAT transcriptional activity in IL-10-Treg is suggested by our findings and 
presented here. In this chapter, one potential transcription factor speculated to have some 
functional potential to induce an anergic phenotype was GILZ, which was expressed in 
IL-10-Treg (as I show in this Chapter). GILZ was tested in the RV system in neutral, Thl, 
and Th2 culture driven conditions to determine whether GILZ would interfere with 
cytokine production and/or proliferation as described in previous studies with 
transduction of FoxP3 (122, 124, 128, 129). In summary, the investigation into the 
potential mechanism whereby IL-10- Treg are inhibited in their ability to produce 
significant amounts of pro-inflammatory cytokines and to proliferate upon TCR 
activation, without the expression of FoxP3, will be the focus of this Chapter.
8.1 NF-kB family members
The activation of the NF-kB pathway is closely associated with targeting pro- 
inflammatory immune response genes after receiving external stimuli (90). In terms of 
mechanisms after TCR triggering, NF-kB complexes are well-described to undergo 
modifications that subsequently lead to activation of target gene expression (90). A 
central role for FoxP3 in CD4+CD25+ is suggested to involve its interaction with NF-kB
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complexes to abrogate their downstream activation of target gene expression (140). This 
mechanism fits with subsequent down-regulation of key NF-kB target pro-inflammatory 
genes in FoxP3-expressing cells (CD25+Treg). IL-10- Treg exhibits similar down- 
regulation of NF-kB target genes after TCR activation; however the mechanism is 
independent of FoxP3 as IL-10-Treg but do not express FoxP3. The regulation and 
expression of individual NF-kB genes may play a role in subsequent down-regulation of 
NF-kB target gene activation in IL-10-Treg. Below the GeneChip profiles (Fig. 8.1a) and 
qPCR (Fig. 8.1b) suggest that NF-kB family members, which are classically described to 
enhance pro-inflammatory and effector cytokine genes are down-regulated upon TCR 
activation in IL-10-Treg (Fig. 8.1).
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Figure 8.1. Profiling NF-kB pathway reveals down-regulated signature in IL-10-Treg
(a) GeneChip profiles for selected NF-kB genes in CD4 T cells. The GeneChip image was compressed 
with the GC-RMA algorithm and normalized values (log2) are shown within each rectangle, (b) mRNA 
was isolated from unstimulated and stimulated cells (6 hr.) (a-CD3/CD28), converted to cDNA and qPCR 
was performed with primer/probes acquired from ABI (inventoried: assay-on-demand) and mastermix 
(ABGene) was used to measure relative expression o f  NF-kB genes on the ABI Prism 7900. Data shown is 
an accurate representation o f three biological replicates.
Rel/NF-KB family genes are differentially expressed upon activation in CD4 T cell 
populations by Affymetrix Gene Chip analysis (Fig. 8.1a). To further validate and
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quantitate the expression of these transcription factors, qPCR was used (Fig. 8.1b). 
Within all the CD4 T cell populations the expression of NF-kB 1, NF-kB2, c-Rel, and 
RelA are significantly up-regulated upon TCR-triggering in both naive and CD25+Treg 
populations, and to a lesser extent in Thl and Th2 effector cells (Fig. 8.1). In IL-10- Treg 
NF-kB 1, NF-kB2, and c-Rel are expressed to a lower relative (GeneChip) (Fig. 8.1a) and 
quantitative amount (qPCR) (Fig. 8.1b) when compared to other CD4 T cell populations 
in the stimulated condition. However, most dramatically, the relative expression of c- 
Rel is minimal after activation in IL-10- Treg when compared to CD25+Treg and other CD4 
T cell populations (Fig. 8.1). Since NF-kB proteins, especially c-Rel, are necessary for 
expression of either the 11-2 (95) or Ifn-y (98) gene upon TCR-pathway activation, the 
fact that IL-10-Treg express relatively low-levels of these genes is of significance for the 
potential phenotype and function of these cells.
8.2 NFAT and AP-1 family members
AP-1-mediated target gene expression is strongly dependent on the interactive 
combinations, between AP-1 family members and on AP-LNFAT interactions (241). 
The differential combinations of AP-1 family members, Jun:Fos (c-Jun:c-Fos) versus 
Jun:Jun or Jun:Maf (c-Jun:JunB or JunB:JunB or JunB:c-Maf), can dictate differential 
downstream target gene expression (241). For example in CD4 T cells, Fos:Jun 
heterodimers are associated with activation of pro-inflammatory gene expression, 
whereas JunrJun or Jun:Maf dimers are loosely associated with a subsequent anti­
inflammatory gene expression profile (113, 241). Another major regulation step in the 
AP-1 families ability to activate target gene expression lies within their ability to form
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ternary complexes with NFAT family members (59). Jun:Fos dimers are suggested to be 
the key AP-1-associated dimer in ternary AP-1:NFAT binding (241). Cytokine genes are 
highly-concentrated with composite putative NFAT:AP-1 binding sites in their respective 
potential regulatory regions. In this respect, FoxP3 is suggested to interact with NFAT 
(137, 140), and interfere with NFATs ability to form NFAT:AP-1 ternary pairs (140). 
The NFAT:FoxP3 interaction is suggested to interfere with subsequent NFAT:AP-1 
target gene activation (137, 140). This is in agreement with NFAT:AP-1 ternary pairs 
being required for IL-2, IL-3, IL-4, IL-5, and IFN-y expression (59), and FoxP3- 
expressing cells do not produce these cytokines upon TCR activation.
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Figure 8.2. Profiling AP-1 genes reveals differential signature in 1L-10-Treg
(a) GeneChip profile for AP-1 in CD4 T cells, (b) qPCR profiles for selected AP-1 genes in CD4 T cells. 
The GeneChip image for both AP-1 genes was compressed with the GC-RMA algorithm and normalized 
values (log2) are shown within each rectangle. For qPCR data, mRNA was isolated from unstimulated and 
stimulated cells (6 hr.) (a-CD3/CD28), converted to cDNA and qPCR was performed with primer/probes 
acquired from ABI (inventoried: assay-on-demand) and mastermix (ABGene) was used to measure relative 
expression o f both NFAT and AP-1 genes on the ABI Prism 7900. Data shown is an accurate 
representation o f three biological replicates.
In the IL -1 0 -T reg or Th2 populations the expression of the A P -1  family member, c-Fos, is 
not up-regulated upon TCR-triggering, whereas Jun family members, c-Jun, JunB and c-
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Maf are up-regulated as compared to other CD4 T cell populations, although to c-Jun is 
up-regulated to a lesser extent in CD25+ Treg and Thl cells (Fig. 8.2a). This suggests 
that IL-10-Treg and Th2 cells may have higher relative amounts of Jun:Jun and JuniMaf 
as opposed to Fos:Jun dimers, which is suggested to correlate with a subsequent anti­
inflammatory gene expression profile after TCR activation (113, 241). Figure 8.2b 
demonstrates that c-Fos is up-regulated in stimulated naive CD4 T cells. Alternatively, c- 
Fos expression is down-regulated in both unstimulated and stimulated IL-10-Treg 
conditions (GeneChip) (Fig. 8.2b). JunD is not up-regulated or down-regulated (>2.0 log 
or <0.5 log) in any CD4 T cell population or condition as shown by GeneChip (Fig. 
8.2b). c-Jun is down-regulated in neutral and IL-10-Treg populations in unstimulated 
conditions and up-regulated in Thl (unstimulated) and IL-10-producing populations in 
stimulated conditions (Fig. 8.2b). JunB is up-regulated (2.0 log) in Thl and Th2 
populations and in CD25+Treg and IL-10 Treg upon TCR activation (Fig. 8.2b).
NFAT family genes are profiled below (Fig. 8.3).
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Figure 8.3. Profiling NFAT genes reveals differential signature in IL-10-Treg
(a) GeneChip profile for NFAT in CD4 T cells, (b) qPCR profiles for selected NFAT genes in CD4 T cells. 
The GeneChip image for both NFAT genes was compressed with the GC-RMA algorithm and normalized 
values (log2) are shown within each rectangle. For qPCR data, mRNA was isolated from unstimulated and 
stimulated cells (6 hr.) (oc-CD3/CD28), converted to cDNA and qPCR was performed with primer/probes 
acquired from ABI (inventoried: assay-on-demand) and mastermix (ABGene) was used to measure relative 
expression o f both NFAT and AP-1 genes on the ABI Prism 7900. Data shown is an accurate 
representation o f three biological replicates.
NFATcl is interesting in that it is not up-regulated from the baseline value (1.1 log2) in 
IL-10-Treg in the stimulated condition, while T hl, Th2 populations and CD25+ Treg up- 
regulate NFATcl to similar degrees although less so than naive T cell populations 
(quantitatively (qPCR) and differentially (GeneChip)) (Fig. 8.3). Other NFAT family 
transcripts (NFATc3 and NFATc4) do not exhibit any drastic differences in the degree o f 
up- or down- regulation between CD4 Treg and effector or naive populations (Fig. 8.3a).
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In summary, c-Fos is not significantly up-regulated in IL-10-Treg or Th2 cells (TCR- 
stimulated) but Jun family members (c-Jun and JunB) are up-regulated in stimulated IL- 
10-producing populations similarly to in other T cell populations.
8.3 Transduction of GILZ into different effector populations results in differential 
effects on T cell proliferation
GILZ was initially described as a glucocorticoid induced transcription factor, which (1) 
enhances CD4 T cell survival upon TCR-mediated stimulus (206) and (2) over­
expression of GILZ in the CD4 T cell lineage skews ex vivo cytokine production by CD4 
T cells towards Th2-associated cytokine profiles (209). The GeneChip profiles revealed 
high-level expression of GILZ in unstimulated naive and in both CD25+ and IL-10-Treg 
populations (data not shown, qPCR profiles are shown in Figure 8.4), although this 
expression is abrogated upon activation.








—  unstim ulated —  —  stim ulated —
Figure 8.4. GILZ is differentially expressed in unstimulated IL-10-T,
Real-time PCR was performed to validate the results from the GeneChip for GILZ expression in 
unstimulated or stimulated CD4 T cell populations.
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As previously reported, however, GILZ expression was significantly down-regulated in 
all GILZ-expressing populations after stimulation (206). Based on previous reports it can 
be speculated that the ability o f the three GILZ-expressing populations (naive, IL-10-Treg, 
CD25+Treg) to survive after re-stimulus (a-CD3/CD28) may be enhanced by their 
expression o f GILZ, and therefore the questions addressed were: would GILZ-RV 
transduced into neutral, Thl or Th2 populations affect the cell recoveries after 
stimulation? Secondly, would GILZ-RV transduced cells in neutral, Thl and Th2 
conditions affect cytokine production?
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Figure 8.5. GILZ induces reduced cell recoveries in neutral and Thl driven culture conditions and 
enhances proliferation in Th2 driven culture conditions upon secondary TCR stimulation.
WT naive (CD4+CD62L+CD45RBh,gh) T cells were infected with a Mock or a GILZ-expressing retrovirus 
and differentiated under neutral, Thl and Th2 conditions. GFP+ Mock or GILZ-expressing cells were 
purified by flow-cytometry into GFP-positive populations and re-stimulated day 6 post-transduction. 
Growth values were calculated at Day 14, 7 days after secondary TCR stimulus. Cell values are reported in 
millions o f cells counted.
Strikingly, when either GFP-positive Mock-RV and GILZ-RV populations (MoFlo- 
isolated day 4 post transduction) were stimulated (a-CD3/CD28), then re-stimulated with
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anti-CD3/CD28 and grown for another 7 days to assess effects on cell growth/recovery. 
GILZ-RV transduced cells in neutral and Thl driven culture conditions differentially 
showed extremely low recoveries as compared to Mock-RV cells (Fig. 8.5). Conversely, 
GILZ-RV transduced cells in Th2 driven culture conditions expanded at a rate -2.5 times 
greater than Mock-RV transduced cells (Fig. 8.5) after re-activation on day 7. The 
proliferation of Mock-RV transduced cells in Th2 driven culture conditions was similar 
to normal (non-RV-transduced cells) Th2 driven culture conditions (data not shown). 
The hyper-proliferation of GILZ-RV cells versus Mock-RV cells in Th2 driven culture 
conditions continued after Day 14 a-CD3/CD28 re-activation (data not shown). 
Importantly, before the initial re-activation (day 7), GILZ-RV versus Mock-RV showed 
no difference in proliferation rates under any condition (neutral, Thl, Th2) studied here.
All GILZ-RV transduced culture conditions (neutral, Thl, and Th2) exhibited a similar 
cytokine profile (Mock-RV versus GILZ-RV) (data not shown). This was partially in 
disagreement with recent results from ex vivo isolated CD4 T cells from transgenic mice 
with CD4 T cell-specific GILZ over-expression, which were reported to preferentially 
produce Th2-associated cytokines upon TCR activation (209). However this discrepancy 
may be a result of our proliferation results. The results shown here were interesting with 
respect to the lack of a differential GILZ-mediated cytokine production in either neutral, 
Thl or Th2 conditions; however, GILZ-RV populations dramatically induced 
proliferation in Th2 culture conditions while alternatively inhibiting TCR-mediated 
growth in neutral and Thl culture conditions, possibly by inducing apoptosis. Taken 
together, the data presented here is in agreement with certain aspects of the recent reports
161
from the GILZ TG over-expression mouse model with respect to enhanced survival of T 
cells (209), but not the conclusion that GILZ induces intrinsic Th2-associated cytokine 
production. Our data suggest that the apparent increase in Th2-assocaited cytokine 
production may actually result from increased proliferation/survival of Th2 cells, rather 
than by up-regulation of Th2-specific cytokine genes, and can only be achieved when IL- 
4 is already produced (Fig. 8.5). The mechanism by which GILZ mediates survival in 
Th2 conditions (a CD4 T cell population which normally does not express GILZ) after 
TCR triggering is not known.
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8.4 Discussion
Transcription factor regulation was our primary goal in undertaking this study with the 
global gene expression platform. We report that the known signature transcription 
factors driving differentiation in effector and CD25+ Treg population are clearly shown 
with the GeneChip and further validation with qPCR. Secondly, we were able to 
decipher TCR triggered gene regulation in nuclear factors that influence regulation of key 
cytokine genes particularly NF-kB and AP-1:NFAT gene expression signatures. With 
respect to the balance between the effector populations (Thl and Th2) we show that Thl 
cells differentially express higher levels of Rel family members (NF-kB 1, NF-kB2) upon 
activation; whereas the Th2 population expresses higher levels of expression between 
NFAT family members (NFATcl, NFATc2). Secondly, we postulate that the inability of 
IL-10-Treg and Th2 cells to up-regulate c-Fos transcripts explains the inability of both 
these populations to produce IL-2, however, since Th2 cells can use IL-4 as an alternative 
growth factor, whereas IL-10- Treg do not produce this cytokine, this would explain the 
anergic phenotype of IL-10-Treg that we have described. Furthermore, since IL-10-Treg 
also fail to up-regulate NFATcl and c-Rel this could suggest a mechanism as to why IL- 
10-Treg do not produce the array of Thl or Th2 cytokine genes that require c-Rel and AP- 
1 :NFAT signaling in order to initiate their expression after activation.
One hypothesis that we set out to understand in this study was the relationship between 
both regulatory populations ability to not produce proliferative and effector cytokines 
upon stimuli. Our data suggests that the mechanism for each regulatory population to 
achieve this may be independent, but also similar. Specifically, IL-10-Treg are
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significantly depressed in their ability to express some NF-kB (c-Rel) and AP-1 (c-Fos) 
and NFAT (NFATcl) family transcripts after activation. In contrast, CD25+ Treg produce 
high levels of NF-kB and AP-1 family transcripts after activation, but also produce high 
levels of FoxP3, a known inhibitory molecule for efficient NF-kB and AP-1:NFAT 
transcriptional activity (137, 140). Taken together, we postulate that both regulatory 
populations are able to similarly inhibit NF-kB and NFAT activation of cytokine genes, 
but accomplish this by different means. This part of the study in my thesis is no means 
complete but merely suggestive of the possible mechanisms whereby IL-10-Treg shut off 
effector cytokines and T cell proliferation. Furthermore, it remains to be seen whether 
this phenotype of IL-10- Treg driven in culture with vitDs/DEX represents the equivalent 
in vivo population of anergic IL-10-producing cells as previously reported (21, 174 
Shevach, 2001 #221, 175-177), driven by repeated administration of high amounts of 
peptide or protein antigen is the scope of future studies. Regardless of whether the 
effects that we report on the diminished transcription of particular transcription factors is 
achieved by an immunosuppressive drug mediated effect only, this is of importance with 




The transcription factor, GATA-3, is described in this thesis as a potent, instructive 
regulator of 11-10 gene regulation in CD4 T cells. Differential GATA-3 expression (Fig. 
6.1a) correlates with levels of IL-10 production by CD4 T cells (Fig. 3.1). Through 
utilization of a RV system (over-expression studies) it became clear that GATA-3 
induced production of IL-10 and this effect was independent of IL-4 (Fig. 6.2 and 6.3). 
In fact, the effect of GATA-3 expression (RV system) at early time-points in CD4 
differentiation, (up to day 4 after primary TCR stimulus, day 3 after GATA-3 
transduction) showed GATA-3 induced significantly higher amounts of IL-10 production 
versus IL-4 and IL-5 production upon TCR activation (data not shown). This suggests 
that GATA-3 plays a crucial role inducing IL-10 production at early time-points, possibly 
by allowing access or inducing “active” chromatin modifications at the 11-10 locus to 
nuclear factors - that are not only exclusively available in high-IL-10-producing cells but 
also other non-IL-10-producing CD4 T cell populations - upon TCR activation. To 
further support the early GATA-3 effect on the 11-10 locus, GATA-3 re-models the 11-10 
locus (ChART-PCR) (day 6 post transduction), in IL-4 independent neutral culture 
conditions (Fig. 6.5), to a similar chromatin-level profile (Southern blot) seen in high-IL- 
10-producing CD4 T cell populations (Th2 and IL-10-Treg) (110, 115). Furthermore, the 
“strong” re-modeling of a high-IL-10-producing CD4 T cell specific HSS (IL-10 
promoter, HSS-0.860 and HSS-0.610) is achieved by GATA-3 over-expression (Fig. 6.5). 
GATA-3 s direct effect is further supported by GATA-3 presence (ChIP) at the IL-10 
promoter and intron 4 before TCR triggering in high-IL-10-producing populations (Th2) 
(Fig. 6.4). Together, this suggests that the re-modeling of the 11-10 locus, but in
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particular the IL-10 promoter (classified as a high-IL-10-producing CD4 T cell specific 
HSS site), directly by GATA-3, allows access for certain non-cell specific TCR-triggered 
enhancing nuclear factors on the 11-10 gene. Conversely, IL-4 and IL-5 expression may 
be dependent on additional CD4 T cell differentiation and epigenetic imprinting (further 
chromatin re-modeling and/or transcription factor enhancers) to allow optimal production 
of these Th2-associated cytokines, as their expression is lower than IL-10 at earlier time- 
points in neutral and Thl GATA-RV culture conditions. It is well described that IL-4 
production by CD4 T cells acts in an autocrine fashion to drive additional IL-4 expression 
and terminal Th2 differentiation (5). IL-4 driven culture conditions in turn drive GATA- 
3 expression and GATA-3 drives its own regulation through an autocrine-signaling 
pathway (74). Therefore, previous to these studies the role of GATA-3 in CD4 T cells, 
independent of IL-4, has never been systemically addressed at the 11-10 gene. Figure 9.1 
represents a cartoon describing the systematic regulation collectively at play on the 11-10 
gene from a naive CD4 T cell in to either a low-IL-10-producuer or a high-IL-10 
producing CD4 T cell.
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Figure 9.1. 11-10 gene regulation in low and high IL-10-producing CD4 T cells
A theoretical model for the key molecular mechanisms described in this thesis and the relevant literature 
regulating differential 11-10 gene transcription in CD4 T cells.
Why does GATA-3 over-expression (neutral and Thl culture conditions) not induce 
high-level IL-10 producers similar to profiles (ICS) from high-IL-10-producing CD4 T 
populations (Th2 and IL-10-Treg)? I propose this may be dependent on at least three 
separate molecular mechanisms. Firstly, critical enhancers o f the 11-10 gene may not be 
available in neutral or Thl cultured CD4 T cells. GATA-3 induces accessibility to the II- 
10 locus (ChART-PCR) (Fig. 6.5.); however the effect of potential enhancers and 
compositions of key combinatorial factors upon TCR activation (AP-1 family members) 
are a likely critical regulator for high-level IL-10 production. The absence o f an 
enhancing transcription factor up-regulated in high-IL-10-producing CD4 T cell
HDAC HDAC
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populations (Th2 and IL-10-Treg) (GeneChip data, Figures 4.1 - 4.4) may be necessary to 
achieve high-level IL-10 production in addition to the GATA-3 over-expression (which 
induces chromatin accessibility at the 11-10 locus (Fig. 6.5)) in neutral and Thl culture 
conditions. An example of this may be, c-Maf, which is not up-regulated or 
quantitatively expressed in neutral or Thl conditions; however it is up-regulated in high 
IL-10-producing CD4 T cell populations (Th2 and IL-10-Treg) (Fig. 7.1a). Secondly, the 
accessibility for transcription factors at the 11-10 locus may be dependent on cell-specific 
cycling of acetylation/deacetylation of histones at site-specific locations throughout the 
potential regulatory regions on the 11-10 locus. Histone modifications represent another 
layer of chromatin-level regulation for cytokine gene expression (55), in addition to 
DNase I HSSs. DNase I HSSs within the 11-10 gene are defined in previous studies and 
outlined with respect to the highly sensitive chromatin accessibility (using ChART-PCR) 
in differential IL-10-producing CD4 T cell populations within this thesis (Fig. 5.3). 
However, the additional investigation of cell-specific, site-specific, activation-specific 
histone modifications within the 11-10 gene, supplemented with in silico and gene 
expression profiling may lead to identification of additional molecular mechanisms 
leading to increased 11-10 gene transcription. Lastly, the recruitment and presence of 
“repressor” transcription factors at the 11-10 locus are likely factors in determining 
optimal IL-10 production in CD4 T cells. The presence of repressors at regulatory 
regions is described for other genes to be influenced by “silencing” histone modification 
(55, 242). The mechanism that comes first; a “silencing” histone modification or 
presence of a repressing transcription factor, are presently understood to be dynamic 
processes and not sequential (55). Therefore, combining both an 11-10 gene site-specific
169
histone modification profile (ChIP) and site-specific repressor transcription factor 
analysis (ChIP) throughout the 11-10 locus in differential IL-10-producing CD4 T cell 
populations could lead to clues involved in an additional layer of 11-10 gene regulation. 
Together, enhancing factors, histone modifications, and repressor transcription factors 
represent independent molecular mechanisms for 11-10 gene regulation and they should 
be treated as separate in their initial investigation with regards to the collective molecular 
mechanisms at play in the 11-10 locus.
Does the 11-10 gene have an important regulatory region within intron 4? Three 
observations allude to a possible regulatory site within intron 4 of the 11-10 gene. First, 
the in silico analysis highlights a highly conserved (human) region (~500 bp) of putative 
transcription factor binding sites within intron 4 (Fig. 5.1b). The “predicted” 
transcription factor binding sites identifies two adjacent intronic TATA boxes located in 
the proximal 5’ position of exon 5 within the murine 11-10 gene (Fig. 5.1b). Putative 
binding sites for IL-10-associated transcription factors, Ets-1(72), GATA-3 (Figure 6.4) 
and NFATc2 (presence is also shown here (ChIP) (114)) are located in this regulatory 
region (murine). The combination of the significant homology within this location 
(intron 4), potential transcription factor binding sites (two of which are functionally 
shown (ChIP)) and dual conserved TATA boxes (located at the proximal 5’ edge of exon 
5) suggest strong potential for regulation at this site within the 11-10 locus (Fig. 5.1b). 
Secondly, DNase I digestion studies have described this region as a constitutive HSS in 
effector CD4 Th cells (ChART-PCR) (Fig. 5.3) (110, 114, 115). And further, histone 
modifications within the region vary between low-IL-10-producing populations (Thl)
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and high-IL-10 producing populations (Th2) (114). The fact that deacetylated histone 
modifications “silencing” are shown in Thl (D5 cell-line) chromatin at intron 4 
(unstimulated and stimulated conditions) (114); whereas acetylated histone modifications 
“active” are achieved in Th2 (DIO cell-line) chromatin at intron 4 (unstimulated and 
stimulated conditions) represents a histone modification profile usually reported at 
“highly” regulatory regions of DNA (114). Thirdly, the observation that the transfection 
of the IL-10 promoter (1.5 kbp 5’ proximal region of the 11-10 gene) and TCR activation 
does not enhance reporter assays with the minimal promoter in IL-10-producing cell-lines 
(DIO) (110), suggesting that other regions may provide enhancing features upon TCR 
activation. The idea that the murine 11-10 gene has a regulatory region located at intron 4 
is based on multiple assumptions; however given the recent reports that cytokine gene 
regulation can physically interact over long distances (52) suggests that scenarios such as 
the one presented here.
Ultimately the regulation of potential key non-coding regions of the 11-10 locus should be 
verified with coordinate-region deletion studies performed with in vivo animal models. 
These studies would allow for developmental study and various immunological 
challenges where the optimal production of the gene of interest would be necessary for 
control or clearance of a pathogen. In the case of IL-10 production, the balance of anti­
inflammatory and pro-inflammatory signals during the course of an infection could be 
tested. Careful design of these types of studies might lead to insight into the cell-specific 
mechanisms in which the 11-10 gene is regulated. For example, consider the investigation 
of the dysregulation of IL-10 production from modified animals with the deletion or
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mutation of the GATA binding motifs at either or both positions (-.865 (11-10 gene 5’ 
region) or +3.750 (intron 4)) within the 11-10 locus. Different immunological challenges 
of these animals with a priori essential IL-10-dependent mechanisms in immune cell- 
specific compartments would give investigators definitive in vivo proof for suggested 
potentially critical regulatory regions. Furthermore, different immune cell-types may 
produce normal amounts or significantly low amounts of IL-10 production based on the 
requirement for the modified regulatory region. In summary, a time-intensive, whole 
animal, gene modification study would serve as an in vivo “gold standard” to verify non- 
redundant 11-10 gene regulation at a specific-DNA regulatory region.
9.2 IL-10-Treg
IL-10-Treg are suggested to have potential for clinical applications (examples include: 
autoimmune disease (11) and immunotherapy (27)). In order to further explore the 
opportunity to use a homogeneous population of in vitro- or ex v/vo-generated antigen- 
specific IL-10-Treg, for therapeutic intervention there has to be, among numerous other 
things, a clear understanding for their specific molecular and cellular mechanisms. In 
this thesis I have outlined some principles for efficient 11-10 gene regulation in CD4 T 
cells (summarized in Fig. 9.1). The functional value for IL-10 in the course of an 
immune response or in regulating autoimmune and allergic/atopic pathology has been 
described by other groups (including the lab were this data was generated) and only 
reviewed here. Secondly, the functional value of CD4 Treg in the course of homeostasis 
and regulating inflammatory immune responses has been described by other groups 
(including the lab where this data was generated) and only reviewed here. Therefore, I
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propose that the generation of any CD4 “IL-10- Treg population, may need the following 
conditions for their differentiation or generation.
The molecular mechanisms that regulate both CD4 Treg (CD25+Treg and IL-10-Treg) 
populations seem to be similar with respect to the molecular targets de-activated during 
TCR activation. The molecular mechanism from the previously described naturally 
occurring CD25+Treg studies demonstrates an essential role for FoxP3 in its interactions 
with NF-kB and NFAT activity (137, 140). The interaction of FoxP3 with components 
of either NF-kB or NFAT proteins is likely a key element in the regulation of cytokine 
gene expression by CD25+Treg upon TCR activation (137,140). This translates into what 
was classically considered a suppressive or “anergic” (no IL-2 production) CD4 T cell. 
Now, IL-10-Treg do not produce IL-2 and produce little to no effector cytokines upon 
TCR activation, in the absence of FoxP3 (174). One conclusion that can be drawn from 
this comparison is, maybe IL-10- Treg express a functional equivalent to FoxP3? The 
GeneChip analysis and RV studies (GILZ) are not suggestive of a strong functional 
FoxP3 equivalent in IL-10-Treg. What seems to be occurring is IL-10- Treg down-regulate 
the transcripts of functional targets implicated in FoxP3 essential activity.
NF-kB family member, c-Rel plays a non-redundant role in enhancing IL-2 (96) and 
early IFN-y expression (98) upon TCR activation. Similarly, c-Fos is an essential 
molecule in the composition of competent AP-1 complexes, which target pro- 
inflammatory downstream gene activation (109). Furthermore, the inhibition of Fos:Jun 
dimers and subsequent skew in the AP-1 balance towards JunJun or Jun:Maf dimers has
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shown to induce anti-inflammatory gene expression profiles (109, 113). Both c-Rel and 
c-Fos transcripts are significantly quantitatively (qPCR) and differentially down- 
regulated (GeneChip) in IL-10- Treg and Th2 as compared to other CD4 T cell populations 
(including CD25+Treg) (Fig. 8.3 and 8.4). Finally, NFAT transcriptional activity is 
inhibited by either DEX and vitD3 and this direct effect is seen here with respect to target 
NFAT gene expression upon TCR activation (TNF) (226). Other studies, not shown 
here, demonstrate that DEX-treatment (20 hrs. before TCR activation) of effector Th2 
cells, that usually produce high amounts of TNF, are significantly impaired in TNF 
production (ICS FACS) upon TCR activation. This suggests that the NFAT target for 
gene activation, TNF (226), is directly inhibited by DEX upon TCR activation. 
Interestingly, DEX-induced GILZ did not effect TNF production (or any other cytokine) 
in RV studies. Therefore, a simplistic model for the IL-10- Treg population might be the 
down-regulation of key NF-kB and AP-1 transcripts as well as inhibition of NFAT 
transcriptional activity thereby compensating for necessary FoxP3 expression seen with 
CD25+Treg. Whether the same situation arises in soluble antigen induced IL-10- Treg in 
vivo remains to be seen, but regardless this offers a plausible mechanism for vitD3 and 
DEX action.
The repeated TCR triggering and differentiation of IL-10-Treg under the presence of DEX 
and vitD3 is a key component in the generation of homogeneous IL-10- Treg population 
from a naive CD4 T precursor cell. GILZ over-expression (RV data), without the 
influence of other DEX-induced properties, induces apoptosis in neutral or Thl driven 
culture conditions, but promotes expanded proliferation in Th2 driven culture conditions
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upon secondary TCR-activation. This is in agreement with the recently reported in vivo 
generated data from unmanipulated GILZ TG mice, where IFN-y production was down- 
regulated and Th2-associated cytokines were all up-regulated in comparison to WT ex 
vivo stimulated splenic CD4 T cells (ELISA) (209). In the context of an immune 
response, GILZ TG mice were significantly inhibited in a Thl immune response, as 
shown by their inhibition to respond to a delayed-type hypersensitivity model, which is 
driven by a Thl dependent response (209). Alternatively, in a Th2-driven immune 
response (bleomycin-induced pulmonary fibrosis) GILZ TG mice elicit a stronger 
immune response than WT mice and thereby induce severe pathology within the 
corresponding target organ (lungs) (209). GILZ is not a FoxP3 functional equivalent, 
shown by the fact transduction of GILZ does not affect the differential cytokine profile, 
as compared to control populations (neutral, Thl, Th2) revealed upon secondary TCR- 
activation (data not shown). The data in this thesis suggests that GILZ-expressing CD4 T 
cells prevent expansion of both IL-2-producing (neutral) and Thl populations after 
secondary TCR activation (Fig. 8.5). Alternatively, GILZ expression in Th2-driven 
culture conditions promotes increased expansion as compared to Th2 controls after 
secondary TCR activation (Fig. 8.5). The molecular mechanism for proliferation and 
survival of the IL-10-Treg population in the absence of cell-autonomous IL-2-production 
or effector cytokine intrinsic signaling is not clear. GILZ expression may play a central 
role as a “survival” factor in IL-10- Treg* which exhibit cytokine profiles outside of the 
typical IL-2 and key effector cytokine (IFN-y and IL-4) repertoire. In summary, the 
DEX-induced transcription factor, GILZ, is both complex and unique in terms of its 
functional role in CD4 T cells and our data suggests it may provide an essential but
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possibly indirect role in the survival of IL-10-Treg by inhibiting IL-2- and IFN-y- 
producing cell survival but with no direct effects on immediate cytokine expression.
Finally, the key question remains: what are the general molecular mechanisms that guide 
IL-10-Treg to produce IL-10 in the absence of other cytokines? These molecular 
mechanisms are not trivial, and definitely not likely to be completely described here, but 
there seem to be some clear themes. Firstly, NF-kB, NFAT, NFAT:AP-1 transcriptional 
activity are abrogated in IL-10-Treg. This is observed by the loss of non-redundant NF- 
kB- and NFAT- and NFAT:AP-1-target gene expression (described through the 
GeneChip data and validated via qPCR). The mechanism for this is likely from both 
physical, DEX- and vitD3 -induced factors and the down-regulation of key transcripts 
within these pathways (ex.: c-Rel, c-Fos, NFATcl). Secondly, IL-10 is a unique 
cytokine, which is described to be enhanced - at a regulatory site shown here to be 
universally re-modeled in Th cells - by Jun family members (110). Therefore, optimal 
IL-10 expression is likely dependent on the skewing of AP-1 signaling from their 
“strong” interacting partners, Jun:Fos to “weaker” interacting partners Jun:Jun or 
possibly Jun:Maf (which have been shown to dimerize in the absence of functional c-Fos) 
(59, 109). The AP-1 gene expression profiling in IL-10- Treg fits this scenario (down- 
regulated c-Fos and up-regulated JunB and c-Maf expression) (Fig. 8.3.). The presence 
of GATA-3 is essential for 11-10 gene regulation (induction of “active” acetylation of 
histone H3 and H4 along the 11-10 gene and re-modeling of the 11-10 gene especially seen 
with respect to “strong” re-modeling at the 5’ region which contains enhancing regulatory 
regions (Chapter 6)). In keeping with this it is shown here that IL-10-Treg up-regulate
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GATA-3 expression (Fig. 6.1a.). Together, these three components, along with GILZ- 
mediated protection from apoptosis during differentiation, provide the necessary cell- 
specific environment for the generation of a high-IL-10-producing CD4 Treg. This is 
summarized in Figure 9.2.
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Figure 9.2. Essential molecular properties at play in IL-10-Treg
A cartoon describing the mechanisms involved in IL-10-Treg upon TCR stimulus, as described from work in 
this thesis.
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10. Comparison of associated cellular markers for potential suppressor function in 
IL-lO-TYeg vs. CD25+Treg
The ability for CD4 Treg to regulate naive and effector CD4 T cell - proliferation and 
downstream pro-inflammatory cytokine production - is suggested to provide one 
perspective for clinical potential with CD4 Treg. However, the mechanism by which CD4 
Treg directly suppress the adaptive immune response is likely via multi-faceted 
mechanisms under condition-specific microenvironments and a clear understanding of 
differential CD4 Treg-mediated mechanisms is an ongoing area of research. One 
validated mechanism by which both of these profiled CD4 Treg populations (IL-10-Treg 
and CD25+Treg) can suppress CD4 T cell proliferation is via IL-10 production on APC 
(in vivo); however both CD4 Treg populations have been shown to suppress CD4 T cell 
proliferation independently of IL-10 expression (in vitro and in vivo) (8). Another clear 
mechanism of CD4 Treg suppression is via cell-cell contact achieved via expression of 
specific families of cellular receptors on CD4 Treg (127). In this Chapter I will begin by 
investigating the similarities between both CD4 Treg populations profiled here with a 
specific interest in the cellular receptor families implicated in cell-to-cell contact 
suppression, suggest leave out here and introduce later further down (127). GeneChip 
generated mRNA profiles and subsequent qPCR validation will serve as a basis for our 
comparison of differential suppressive mechanisms with an emphasis on the CD28 and 
TNF families of cellular receptors.
10.1.1 CD4 Treg-associated cellular receptors in CD4 T cell populations
The CD28 receptor family regulates both activation and inhibition within CD4 T cells 
(142). Ligation of the B7:CD28 pathway can serve as a required secondary signal to
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initiate and sustain T cell responses; however some CD28 family members serve as 
essential secondary signals to down-regulate T cell responses (142). Functional roles of 
CD28 family members are dependent on multiple variables including: the individual 
CD28 family member that is engaged, the state of differentiation of the engaged T cell, 
the signaling cell-type, and the location of the T cell during the engagement (thymus, 
lymph node, and periphery) (142). CD28 family members include CTLA-4, ICOS, Pcd-1 
(142). In this chapter, expression profiles generated between the CD4 T cell panel will 
allowed comparison of the these proposed cellular inhibitory receptors in CD25+ Treg 
versus IL-10-Treg and other effector populations.
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Figure 10.1 Profiling CD4 Treg-associated cellular markers
GeneChip profiles for CD4 Treg-associated cellular markers in CD4 T cells. The GeneChip image was 
compressed with the GC-RMA algorithm and normalized values (log2) are shown within each rectangle. 
More information is available in Materials and Methods for the computational details.
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CD4 Treg-associated cellular receptors in the CD28 family (Pcd-1, ICOS, CTLA-4) and 
TNFR family (0X40 and GITR) are up-regulated in unstimulated or stimulated 
conditions within CD4 Treg; however they are not exclusively up-regulated when 
compared to other CD4 populations (Fig. 10.1). Alternatively, both families are strongly 
down-regulated in naive CD4 T cells in both conditions (Fig. 10.1). CD28 family 
members, Pcd-1 and CTLA-4, are up-regulated in IL-10-Treg and in Th2 cells in both 
conditions, whereas ICOS is up-regulated in IL-10 ■Treg and Th2 cells in stimulated 
conditions (Fig. 10.1). CD25+Treg have a different profile in that they up-regulate CD28 
family members ICOS and CTLA-4 mainly under re-stimulated conditions (Fig. 10.1). 
Pcd-1 is not strongly up-regulated in either condition for the CD25+Treg population (Fig. 
10.1) but is up-regulated in other T cell populations upon re-stimulation through the 
TCR. Other populations up-regulate CD28 family members; for example, Pcd-1 in the 
stimulated neutral population, ICOS in both Th2 conditions, and CTLA-4 in the 
stimulated Th2 population (Fig. 10.1).
TNF receptors family members 0X40 and GITR are implicated to mediate CD4 Treg 
suppression (127). 0X40 is up-regulated in stimulated conditions for both CD4 Treg 
populations; however it is also up-regulated in both effector populations (Thl and Th2) 
within stimulated conditions (Fig. 10.1). GITR is expressed in both CD4 Treg populations 
in unstimulated conditions (Fig. 10.1). In stimulated conditions GITR is up-regulated 
exclusively in the CD25+Treg population (Fig. 10.1). Both GITR and 0X40 are up- 
regulated in unstimulated conditions in the Th2 population (Fig. 10.1). TNF receptor 
family members 0X40 and GITR are up-regulated in various conditions within CD4 Treg
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populations, although the up-regulated expression-signature within the Th2 population 
(and to a lesser degree Thl) provides evidence for up-regulation outside of CD4 Treg 
populations for the TNFR genes, 0X40 and GITR. (Fig. 10.1) Both CD28 and TNFR 
family members shown here were validated with qPCR across all CD4 populations and 
conditions under both stimuli (a-CD3/-CD28 and PMA/ionomycin) and all transcripts 
exhibit similar gene expression profiles as reported here with the GeneChip (data not 
shown).
We have not verified the expression by Flow cytometry of all these markers as yet, 
although our laboratory has previously shown that GITR and CTLA-4 are expressed on 
activated effector T cell populations as well as CD4+ Treg by Flow cytometry (data not 
shown). In summary, we report here that there is no clear correlation between the 
expression of these markers and the anergic phenotype and suppressive activity of the 
CD25+Treg or the IL-10-Treg, and that other additional properties (possibly functioning 
together with these molecules, contribute to the anergic and suppressive phenotype of 
CD4+ Treg.
10.1.2 CD4 Treg-associated cellular receptors induced by either vitD3 or DEX
CD4 Treg-associated cellular receptors were further investigated within respect to 
understanding their individual expression profiles under culture conditions with 
immunosuppressive drugs, vitD3 or DEX. IL-10- Treg were generated with both vitD3 and 
DEX, and DEX is prescribed for neutralizing pro-inflammatory clinical conditions in 
humans. Therefore, this suggested that individually, each immunosuppressive drug
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might induce expression of either CD28 or TNFR family member, with direct 
implications to the clinical setting. I have used qPCR to profile the CD4 Treg-associated 
cellular receptors with populations (vitD3, DEX, and IL-10-Treg) generated under in vitro 
culture conditions and the ex vivo isolated CD25+Treg. TCR activation was performed 
with a-CD3/-CD28 to represent stimulated conditions.
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Figure 10.2. qPCR of CD4 Treg-associated cellular markers in vitD3, DEX, IL-10-Treg, and CD25+Treg
Real-time reverse transcriptase PCR (qPCR) o f CD4 Treg-associated cellular markers in vitD3, DEX, IL-10- 
Treg and CD25+Treg (same transcripts as Figure 10.1). mRNA was isolated from unstimulated and 
stimulated cells (6 hr.) (a-CD3/CD28), converted to cDNA and qPCR was performed with primer/probes 
acquired from ABI (inventoried: assay-on-demand) and mastermix (ABGene) was used to measure relative 
expression o f  CD4 Treg-associated cellular markers on the ABI Prism 7900. Data shown is an accurate 
representation o f three experimental replicates.
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CD4 T cells generated under DEX culture conditions up-regulated CD4 Treg -associated 
cellular receptors when compared to vitD3, IL-10-Treg, and CD25+Treg (Fig. 10.2). Upon 
TCR activation, DEX populations expressed relative amounts of ICOS, CTLA-4, and 
GITR at levels equal to or higher than CD25+Treg (Fig. 10.2). DEX populations also 
expressed equal or higher-relative amounts of ICOS, CTLA-4, 0X40 and GITR as 
compared to vitD3 or IL-10-Treg generated conditions (Fig. 10.2). Interestingly, Pcd-1 
was the only CD4 Treg-associated cellular receptor up-regulated with the combination of 
vitD3 and DEX (IL-10-Treg) (Fig. 10.2). The expression profiles of CD4 Treg-associated 
cellular receptors (Fig. 10.2) demonstrates the ability of DEX to influence the expression 
of these gene in DEX generated CD4 T cells as well as suggest DEX is important in 
inducing expression of these cellular receptors within the IL-10-Treg population. Again, 
regardless of whether the effects that we report on the expression of particular cell 
surface molecules is achieved by an immunosuppressive drug mediated effect only, this 
is of importance with respect to their mechanism of action which thus far is unclear 
(127).
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10.2 Hierarchical clustering of cytokines and chemokines in CD4 T cells
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10.3 Hierarchical clustering of cytokine and chemokine receptors in CD4 T cells
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